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CHAPTER ONE
GENERAL INTRODUCTION
INTRODUCTION
Total hip arthroplasty (THA) is one of the most successful medical procedures. The clinical results 
are very satisfying, with restoration of hip function and relieve of pain symptoms that are as-
sociated with osteoarthritis of the hip. The success of THA in combination with the increasing 
possibilities in hip surgery have led to an extension of the indications for THA. Nowadays, also 
young patients with severe bone defects due to congenital hip disease or rheumatoid arthritis 
are indicated for THA. Unfortunately, the survival of hip prostheses is not unlimited. The main 
reason for loosening of hip implants is aseptic loosening.1 Aseptic loosening is a complex and 
multi-factorial event, however the underlying mechanism is still unknown. Although fluid flow 
and implant motion are associated with bone resorption, the importance of particles in aseptic 
loosening seems certain.2, 3 Wear particles that originate from the implant surfaces can induce 
an inflammatory reaction, resulting in peri-prosthetic bone loss and loosening of the implant. 
Other factors that may induce prosthetic loosening include infection, fractures or implant related 
problems.4-6 Loosening of hip implants necessitates revision surgery. Particularly more active 
younger patients may require two or more revisions during their lifetime. One of the major prob-
lems encountered in hip revision surgery is the loss of bone stock due to the loosening process 
itself and the removal of the failed implants. Several techniques are available for dealing with 
bone loss and bone defects in hip revision surgery.7-14 The type of technique used for recon-
struction depends on the type of bone defect present. The American Academy of Orthopaedic 
Surgeons (AAOS) classification for the acetabulum and proximal part of the femur is used most 
frequently and describes the type of defect adequately.15, 16 It distinguishes between segmental, 
cavitary, and combined segmental-cavitary defects as well as defects with a pelvic discontinuity 
and/or arthrodesis. Of the many methods of reconstruction available to the surgeon performing 
a revision, only two techniques have the aim to reconstitute the bone stock, i.e. bone impaction 
grafting and the use of structural allograft. The objective of bone impaction grafting is to achieve 
stability of an implant with the use of impacted, morselized bone graft and subsequently allow 
the restoration of living bone stock by bone ingrowth (Fig. 1 and 2).
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Bone impaction grafting has been used successfully as a reconstruction technique on both the 
acetabular and femoral side in revision total hip replacement. This technique is based on the 
pioneering work of the groups in Nijmegen,17 the Netherlands and Exeter,18 England, and its long 
term results have been favorable.19-22 However, there are numerous important issues related to 
the bone impaction grafting technique. A clear understanding of the mechanical and biological 
behavior of the morselized grafts in combination with an adequate surgical technique will opti-
mize the technique and improve the clinical outcome. The purpose of this chapter is to discuss 
the current scientific knowledge of biomechanical and biological characteristics of the bone 
impaction grafting technique and its future development.
Fig. 1 
Bone impaction grafting of the acetabulum. Segmental defects are reconstructed with a metal wire mesh to contain the defect. 
Trabecular bone grafts are inserted into the defect and firmly impacted using metal impactors and a hammer. A cemented cup is 
placed after reconstruction of the defect.
Fig. 2 
Bone impaction grafting of the femur. A bone plug is introduced into the femoral canal with a central rod attached to the plug. 
Trabecular bone grafts are introduced into the femoral canal and firmly impacted with metal impactors sliding of the central rod. 
Proximal impaction is done using a stem phantom. The canal is retrogradely filled with bone cement, followed by placement of 
the femoral stem.
Fig. 2Fig. 1
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GENERAL OVERVIEW OF GRAFT INCORPORATION
There is a complex and delicate balance between the mechanical demands of achieving initial 
stability and the biology of long term incorporation. Incorporation is clearly a biological proc-
ess, although it depends on a certain degree of mechanical stability. It is not known how much 
incorporation is needed for long-term success or how long the process of incorporation takes. 
Histological retrieval analysis has confirmed that remodeling does occur with gradual but vari-
able ingrowth. A goat model has been used to analyze the incorporation and remodeling process 
of impacted bone grafts histologically at different time points after acetabular impaction bone 
grafting.23 At three weeks, the first signs of revascularization and active bone remodeling were 
seen, progressing to the incorporation of two thirds of the graft at six weeks. The twelve week 
specimens showed almost total graft incorporation, with the graft mostly being replaced with 
normal viable bone in the revascularized areas. Complete consolidation and revascularization 
of the graft were observed in all specimens at 24 and 48 weeks. On the acetabular side, based 
on human biopsies taken between 1 and 72 months, histological data showed that impacted 
morselized graft completely transfers into a normal trabecular bony structure with time.24 A 
more extensive study of human samples taken after twenty-one revision arthroplasties with im-
paction bone grafting revealed in some cases a process of endochondral ossification in the graft 
bed.25 In another study, twenty-four acetabular bone biopsy specimens were obtained 3 months 
to 15 years after acetabular reconstruction in primary and revision total hip arthroplasties in 
combination with a cemented cup.26 Histological examination showed rapid revascularization of 
the graft, directly followed by osteoclastic resorption and woven bone formation directly on the 
graft remnants.
Studies using positron emission tomography have shown that the initial increase in blood flow 
and bone remodeling following surgery reduced to baseline levels by one year, indicating that 
the incorporation is complete by this stage.27 After 6 years, bone metabolism in most areas of 
the proximal femur was significantly reduced compared to the elevated activity during the first 
year after surgery, and also normalized compared to the contralateral healthy femur.28 The rate 
of incorporation may be related to the degree of impaction. A study comparing bone ingrowth 
into impacted and non-impacted graft in a bone chamber showed that increasing the degree of 
impaction reduces ingrowth.29 However, it is questionable if the used degree of impaction will be 
ever reached in clinical reconstructions. On the other hand, fibrous tissue ingrowth increases the 
stability, suggesting that complete osseous remodeling might not even be necessary for a good 
clinical result.30 This hypothesis has been supported by retrieval studies indicating that complete 
graft incorporation was not a prerequisite for clinical success if the resulting construct provided 
mechanical stability.31 An observational study of stable implants showed incomplete remodeling 
and graft incorporation, and the authors concluded that a stable construct could be provided by 
fibrous tissue ingrowth in areas of unincorporated graft.32 Clearly, there is still controversy about 
both the nature and the need for graft incorporation. It may be that fibrous tissue ingrowth can 
provide an acceptable degree of stability in the long term if full osseointegration does not occur. 
In the following part relevant items will be discussed in detail.
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MATERIALS
Autogenous bone graft is considered the gold standard material for bone grafting because it is 
osteoconductive, osteoinductive, and it provides osteogenic cells. In addition, there is no risk of 
infectious disease transmission and it is not accompanied by an immune response that often is 
present when allografts are used. However, donor site morbidity and lack of volume usually pre-
vents harvesting autograft from an individual at the same time as performing their revision hip 
surgery. The advantages of allograft bone include unlimited availability and the avoidance of the 
morbidity associated with harvesting autograft. The disadvantages of allograft bone grafts are 
immune response, lack of osteogenic cells, decreased activity of osteoinductive factors, and the 
risk of infectious disease transmission. Marrow elements within the cancellous bone are thought 
to be responsible for the majority of this immunogenic response. In the past, this has been recog-
nized only as a minor problem. However, there has been recent interest in the detrimental effect 
of this immunogenic response, with a number of authors reporting improved incorporation and 
biomechanical performance with histocompatibility-matched grafts.33, 34
The osteoarthritic femoral head harvested during hip replacement is the most common source 
of fresh frozen allografts for impaction bone grafting. It contains three types of tissues: cancel-
lous bone in its bulk, cortical bone (mainly from the neck) and remnants of articular cartilage 
or synovial lining. During the processing of these femoral heads into bone chips it is important 
that no cartilage is included, as this may influence mechanical stability and incorporation.26, 35 It 
was shown that the presence of cartilage prevented efficient impaction of the morselized grafts, 
probably due to its elastic nature.35 In addition, cortico-cancellous grafts without articular carti-
lage had stiffness values as good as in their control group. It seems unlikely that a few cortical 
bone fragments will significantly change the biological response of the graft. However, cancel-
lous bone usually is revascularized rapidly and replaced by new host bone. In contrast, cortical 
bone is revascularized slowly, requiring osteoclasts to resorb bone to provide channels for the 
invasion of vessel from the host. This osteoclastic activity weakens the graft compared with nor-
mal bone for a significant period depending on the size of the graft.36
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PREPARATION AND PROCESSING
MORSELIZATION
The size and grade of the bone particles are important for the initial mechanical stability of the 
impacted morselized graft. Particles should be as large as practical to ensure stability, i.e. they 
should be the largest size that can be fitted between the host cortical bone and the phantom 
prosthesis. That size is thought to be between 3 and 5 mm in diameter for femoral revisions.37, 38 
On the acetabular side, the ideal size is larger; research suggests 8 to 10 mm diameter chips 
provide the best initial stability.39-41 More proximal in the femur, these larger grafts are now also 
used to improve the initial stability of the stem. Another advantage of larger particles is that they 
result in a more porous and more permeable impacted graft. This is important because a higher 
degree of impaction may make it more difficult for new bone to grow into the impacted mass. 
A study comparing bone ingrowth into non-impacted and impacted bone showed that a higher 
degree of impaction reduces bone ingrowth.29 Also larger voids facilitate cement penetration, 
which may contribute to an improved initial stability. Implants supported by impacted morselized 
bone graft can migrate as a result of shear within the layers of the impacted graft. Shear strength 
of the graft layer is improved by using morselized grafts with a range of particle sizes.42 However, 
using a range of particle sizes reduces graft permeability, since the pores between the larger par-
ticles will be filled with smaller particles. A reduction in permeability may reduce bone ingrowth, 
but this can be offset by the improved mechanical resistance to shear. More work is needed to 
clarify the interaction between these mechanical and biological factors.
RINSING
Rinsing grafts has been shown to improve the shear strength of impacted allografts.42 The mech-
anisms for this are two fold. First, the removal of fat and marrow fluid reduces the lubrication of 
particles and thereby increasing frictional resistance. Secondly, removal of fat before impaction 
increases the compactability of the graft, allowing greater interdigitation between particles. 
These advantages have been borne out in a whole construct model of femoral impaction graft-
ing in bovine femora and during in vivo human studies.43 The authors reported a statistically 
significant reduction in subsidence using rinsed graft compared to using non-rinsed graft. Similar 
improvements in cup stability have also been demonstrated in an acetabular model.41 In this 
study, the force required to tilt the acetabular component by 16 degrees increased from 3450 N 
to 7000 N when the graft was rinsed with saline before impaction. Rinsing therefore certainly 
increases mechanical stability. However, the biological effects of rinsing are not as clear. On the 
one hand, freshly milled graft may contain growth factors and cytokines that stimulate the incor-
poration of the morselized graft bed by encouraging ingrowth and new bone formation. On the 
other hand, immunogenic factors present in the freshly frozen allograft bone may reduce bone 
ingrowth. Recently, a goat model was used to study the effect of rinsing on bone ingrowth into 
morselized impacted autograft and allograft bone.44 Without rinsing, the autograft bone showed 
more bone ingrowth than did the allograft bone. Rinsing prior to impaction reduced ingrowth 
into the autograft bone but increased ingrowth into the allograft bone.
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Similar results have been found with solvent defatted allograft in non-impacted bone chamber 
models in rabbits.45 It is not clear whether this increased ingrowth is secondary to the more 
porous nature of rinsed bone or whether there is some form of biological inhibition from the 
marrow. Allograft produces an immunogenic response to the graft and most antigenic cells are 
found in the marrow. Rinsing the graft removes most of the marrow, resulting in a reduction in 
the immunological load to the patient. Furthermore, the risk of disease transmission is reduced 
with removal of blood, marrow, cells and bacteria. Rinsing the bone bed also reduces throm-
boembolic extravasation of bone marrow during cement application. Sherman et al.46 compared 
hemodynamic and blood gas changes during THA in a dog model and suggested that thorough 
bone lavage before cementing had a highly effective prophylactic effect on cardiovascular com-
plications. Similarly, Byrick et al.47 found a significant reduction of fat emboli using high-volume 
pulsed lavage in comparison to low-volume lavage and no lavage during cemented arthroplasty 
in a dog model. The most effective method of rinsing grafts has not yet been determined.
IRRADIATION
Gamma radiation has been widely used for sterilization of bone allografts due to its efficacy 
against both bacterial and viral disease transmission. During gamma irradiation sterilization high-
ly reactive hydroxyl radicals are formed due to ionization of water molecules. It has been specu-
lated that these free radicals impair the integrity of collagen molecules.48 In addition, radiation 
may also denature bone morphogenetic proteins, thereby reducing the osteoinductive potential 
of the allograft. Due to changes in mechanical properties of bone by gamma irradiation it has 
been used with some cautiousness in clinical practice, especially in load bearing applications. 
Gamma irradiation at clinically relevant levels (at least 25 kGy) has no effect on the mechanical 
properties of frozen unprocessed human cancellous bone but irradiation at a higher dose of 60 
kGy was found to significantly reduce the compressive failure stress and the elastic modulus.49 
The effect of irradiation on freeze dried bone is different. A dose of 25 kGy in combination with 
freeze drying has been shown to reduce the ultimate strength by 42.5%.50 However, it was also 
shown that irradiated freeze-dried impacted grafts provide a more stable femoral reconstruc-
tion than fresh frozen grafts when tested in a hip simulator.51 On the other hand, the higher 
compactness caused by impaction of irradiated bone may reduce the speed of the incorporation 
process and reduce the cement penetration.
There are few clinical reports of impaction grafting with irradiated bone grafts in hip revision sur-
gery on both the femoral and acetabular side, using radiological and clinical scores as outcome 
measures. A study evaluating femoral impaction grafting with the Exeter hip using non-rinsed 
irradiated (25 kGy) bone grafts showed a lacking radiologic incorporation and trabecular remod-
eling.52 In contrast, in a 2 to 7 years follow up study using rinsed fresh and irradiated (25-30 kGy) 
allograft bone in 41 revision femoral athroplasties no significant difference was found in clinical 
or radiological outcome.53 Comparing fresh-frozen and irradiated allograft bone in impaction 
grafting of the acetabulum, no obvious difference in clinical performance with evidence of in-
corporation and remodeling after 6 months and 13 months for the irradiated graft, using two 
different radiologic criteria were found.54 Buckley et al.,55 using non washed irradiated (25 kGy) 
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bone for acetabular revision surgery, showed a 88% survival at a mean follow up of five years, 
which is comparable with that of studies using non irradiated bone. In addition, Hamer et al.56 
histologically examined five cases of rerevisions where irradiated cortical allograft had been 
used. All cases showed favorable histologic features, with soft tissue attachment by fibrous ad-
hesion, union of graft to host and osseous remodeling. In addition, irradiation of unprocessed 
femoral heads has also been shown to produce altered lipids from the marrow that are cytotoxic 
to osteoblast cultures, which may have an impact on bony ingrowth into a graft and long-term 
survival.57 
ETHYLENE OXIDE
One other common method of terminal sterilization, often used as alternative for gamma irradia-
tion, is ethylene oxide treatment. There is controversy regarding the suitability of ethylene oxide 
sterilization for bone grafts,58 with some authors arguing that it damages the osteoinductive 
potential of the graft,59, 60 while others state that it does not.61, 62
Ethylene oxide is also potentially carcinogenic and residual gas can cause inflammatory reaction 
in the recipient. A medium term follow up of ethylene oxide sterilized freeze-dried allograft in 
acetabular revision only reported one revision for aseptic loosening in 21 cases at a mean 5.8 
years, although 62% did show significant acetabular component migration.63 
FREEZE-DRYING 
Freeze-dried cancellous allograft is known to have inferior mechanical characteristics compared 
with fresh-frozen bone and is rarely used in bone impaction grafting. In vitro impaction studies 
comparing freeze-dried irradiated allograft with fresh-frozen, have shown that both types of 
graft reach the same maximal stiffness of 55 MPa, but the freeze-dried bone required three to 
four times fewer impactions to reach this level.51 In a separate study, the same authors showed 
less subsidence in a full hip simulator model with freeze-dried graft.64 Benefits may include a 
reduced risk of femoral fracture because of the lower impaction energy required and a reduced 
risk of disease transmission. However, caution is required when interpreting these studies, as 
the fresh frozen graft used as a control was not rinsed, a factor that can greatly influence the 
compactability and stability of the graft. Only few clinical studies have reported the results of 
this type of graft. A very short-term study, documented no failures at a mean follow-up of 14 
months in 40 femoral revisions.65 The authors used bone scintigraphy in nine patients and found 
high levels of new bone formation around the prosthesis. In addition, a medium term outcome 
study of both femoral and acetabular revisions in 32 patient showed a 91% survivorship with 
all failures on the acetabular side.66 Thien et al.67 reported an overall survival rate of 86% at an 
average follow-up of 7 years for 7 acetabular revisions using impacted freeze-dried cancellous 
bone chips.
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IMPACTION
Probably the most critical aspect of the bone impaction grafting technique is the graft impaction. 
During the process of graft impaction, plastic deformation of and intergranular motion occur, 
leading to denser packing of the graft and a permanent deformation with a reduced volume. 
Only after impaction the morselized graft is strong enough to carry the load imposed by the 
patient. In vitro studies have confirmed the importance of impaction: the migration of hip stems 
within a reconstruction with impacted grafts can be largely predicted from the density of the 
impacted graft. The degree of impaction is mainly influenced by the impaction force (the energy 
applied per impact) and the number of cycles. Gie et al.,18 in their original paper on impaction 
grafting in the femur, recommend “vigorous impaction” and commented on the impressive 
stability that can be achieved with such a technique. Although using more force creates a more 
impacted graft bed with improved resistance to mechanical loading, it also has a downside. 
Studies have shown intra-operative fracture of the femur to be the most common complication 
of the technique.68 As argued before, the higher compactness caused by impaction of bone 
may also reduce the speed of the incorporation process and reduce the cement penetration. An 
alternative technique to impact morselized bone grafts on the acetabular side with instruments 
available in every orthopaedic theatre is the so-called “reversed reaming technique”. In this 
technique, the acetabular reamer is used in a reversed direction in combination with manual 
compression on the reamer. However, it was found that reversed reaming (with small particles) 
led to an increase of migration of approximately 60% compared to the traditional technique us-
ing metal impactors, a hammer and large bone chips.40
The impaction energy required for the graft bed to achieve sufficient weight bearing capacity is 
determined not only by the impaction force and the number of cycles, but also by the material 
properties of the graft, the particle size and grading and the fat content. Using stronger and 
stiffer material, larger and better graded particles, and the removal of fat are all strategies that 
surgeons could employ to reduce the impaction effort and the probability of intraoperative 
fracture. 
CEMENTING
Modern cementing techniques have contributed to improved long-term results in total hip ar-
throplasty. Thorough cleaning of the bone bed, the use of a distal intramedullary plug, and 
a proximal seal (representing cement pressurizing techniques) reduce the risk for revision by 
approximately 20% for each.69 In addition, new implant designs improve cement penetration, 
increase the stability of the bone-cement interface and consequently lengthen the lifetime of 
femoral and, less evidently, acetabular components. Most basic research studies regarding ce-
menting technique are focused on the femur and the femoral component of THA. However, 
there have been few basic research studies addressing the effect of cementing technique on 
cement pressurization and penetration in the acetabulum.70, 71
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For primary total hip replacements, adequate bone cement intrusion into the cancellous bone 
bed has been shown to be important for success. With increased depth of cement penetra-
tion, the strength of the bone cement interface is enhanced.72, 73 Pressurization and lavage of 
cancellous bone have been identified to be significant factors with regard to improved cement 
penetration and consequently improved shear strength. Blood flow may obstruct cleaning and 
cement intrusion into trabecular bone, which could have a significant effect on results. The op-
timal amount of cement interdigitation in the revision of failed hip replacements with impaction 
allografting is not known. Excessive cement intrusion may prevent the remodeling of the bone 
graft or the cortex if the cement reaches the endosteal surface.74 On the other hand, insufficient 
cement interdigitation may lead to stem subsidence.75 The parameters that determine the ce-
ment intrusion into the cancellous bone bed are not well understood. 
ALTERNATIVE MATERIALS USED IN IMPACTION GRAFTING 
The concept of adding an alternative material to bone allograft is attractive because it reduces 
dependency on donor supply and raises the possibility of improving the biomechanics of the 
graft. The shear strength of impacted bone graft has been shown to increase with the addition 
of small bioglass particles.76 Other investigators have confirmed that adding stronger or stiffer 
particles (such as ceramic particles) to the morselized bone improves the mechanical stability. Us-
ing an in vitro acetabular model, a 27% reduction in migration of the acetabular component was 
found by adding a porous tricalciumphosphate (TCP) and hydroxyapatite (HA) mixture to human 
allografts, whereas a 55% reduction was found when a solid TCP/HA mixture was used.77 In vitro 
models using human cadaver femora have also shown increased mechanical stability with a TCP/
HA graft extender, but worryingly, also reported a higher risk of (iatrogenic) femoral fractures.78 
An animal model of femoral revision using supplementary TCP/HA mixtures showed no statisti-
cally significant differences in loosening or subsidence rates at 18 months.79 Graft incorporation 
of TCP/HA particles has been observed in a goat model of contained acetabular deficiencies 
reconstructed with a 50/50 mixtures of cancellous bone and TCP/HA granules.80 Although the 
mechanical stability may be improved with these extenders, the biological aspects of graft incor-
poration and remodeling have yet to be fully studied. A denser graft may reduce cement pen-
etration and also reduce ingrowth and lead to greater failure. A further concern is the possibility 
of third body wear of the articulating surface by the TCP/HA particles. Clinically, Oonishi et al. 81 
applied HA granules for acetabular reconstruction utilizing a double cementation technique for 
over a decade. They first used a cement layer in order to completely seal the ceramic materials 
in a reconstructed acetabulum. Then, they applied a second cement layer on top of the first one 
to fixate the acetabular cup. After performing an analysis of retrieved specimens, they reported 
that the HA granules evoked little foreign body reaction after 4-10 years follow-up. The main 
questions belonging to alternative materials are therefore not mechanical but biological. Clearly, 
before general clinical implementation of these alternative materials, more data are needed.
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GROWTH FACTORS AND ADDITIVES 
There has been considerable interest in graft additives to improve allograft incorporation. Growth 
factor enhanced allograft incorporation could improve clinical outcome after revision surgery by 
accelerating new bone formation and thereby improving implant stability. Particularly bone mor-
phogenetic protein-7 (BMP-7 or osteogenic protein-1 (OP-1)) has been studied extensively.
OP-1 has been shown to increase bone ingrowth in bone chamber models.82 However, the den-
sity of the new bone may be reduced because of an increased resorption. An animal study of 
femoral impaction grafting with additional OP-1 showed enhanced initial graft resorption and 
hastened graft incorporation and remodeling.83 However, there was one case of excessive stem 
subsidence in the OP-1 group, suggesting a relation between increased early graft resorption 
and reduced mechanical stability. No effects of OP-1 on the early and late incorporation of im-
pacted bone grafts were found using a realistic acetabular model in goats.84 A weight bearing 
animal model of impaction grafting showed that weight bearing increased graft remodeling but 
this was not further enhanced by additional OP-1.85
Accelerated resorption may have negative consequences for the outcome of bone impaction 
grafting, since resorption before the formation of bone may compromise implant fixation. A 
solution can be an osteoconductive material providing initial stability after reconstruction.86, 87 
The role of BMPs in hip revision surgery may then be to serve as a promotor of bone formation 
in combination with a slow resorbing or unresorbable graft materials.88, 89
The use of BMPs in hip reconstructive surgery is not without limitations and potential compli-
cations.90 A BMP cannot overcome a poor biologic or biomechanical environment. In order to 
induce bone formation and remodeling implant stability must be present if as well as a viable 
cell source, vascularity, and absence of infection. In addition, maintenance of the BMP at the 
implantation site and delivery of an appropriate dose by an appropriate carrier material are es-
sential for successful osteoinduction. 
Of unknown risk is the role of antibodies that develop in some patients after implantation. Little 
is known of the effects of these antibodies on bone induction and future healing particularly 
after repeat application of a BMP, which is not advised.91 However, BMPs likely play an important 
role in future hip reconstructive surgery where bone defects and deficits are present.
In addition, the action of bisphosphonates on impacted allograft has also been studied. Aspen-
berg and Astrand 89 showed in a bone chamber model that the addition of alendronate pre-
vented graft resorption but allowed bone ingrowth. Furthermore, the combination of OP-1 and 
bisphosphonate (clodronate) increased final graft density and bone ingrowth.92
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CONCLUSION 
Bone impaction grafting in combination with cemented implants for revision surgery of the 
hip has appeared to be a successful technique for dealing with bone loss. The success of this 
method depends on achieving adequate initial stability followed by a biological response of 
graft incorporation and remodeling. Manipulation of the graft to improve one of these factors 
(biomechanical vs biological) may be detrimental to the other. The ideal graft has not yet been 
defined. Fresh frozen femoral heads are the most frequently used, but concern remains over 
the potential for transmission of disease and the future ability to maintain an adequate supply 
of graft. The ideal size of bone chips for the acetabulum has been well defined but evidence 
on the femoral side is less certain. Rinsing grafts has been shown to be beneficial but the most 
efficient method has not been established. One of the greatest problems in assessing impaction 
bone grafting as a technique and interpreting the literature are the large number of variables 
and the diverse methods of outcome assessment. Radiologic follow-up needs better definition, 
specifically with regard to the early signs of failure and the correlation between radiologic and 
histological changes that may be relevant in clinical practice. Many authors have reported high 
rates of incorporation, but there are no accepted criteria for such incorporation, and radiograph-
ic appearances may well lag behind the clinical situation. Graft incorporation and remodeling 
has been demonstrated histologically but in vivo methods of monitoring these are limited to 
bone scintigraphy and positron emission tomography scanning. Less invasive and more sensi-
tive methods of monitoring remodeling would be useful. Impaction grafting is likely to remain 
one of the preferred options for revision hip surgery. The clinical results are good and support 
recommendations for the continued use and development of the technique. However, recently, 
a high risk of complications in revisions using bone impaction grafting in large acetabular bone 
defects and pelvic discontinuities was reported.93 Further work is needed on the most appropri-
ate production and processing techniques of the graft in order to generate mechanically stable 
constructs advantageous to biological incorporation and remodeling.
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STRUCTURE OF THIS THESIS 
The work in this thesis has evolved around the ongoing development of the bone impaction 
grafting technique. In this thesis is focused on how the incorporation of impacted morselized 
bone grafts and bone substitute materials can be influenced and optimized. Several factors play 
a role in the incorporation of bone grafts and bone substitutes into a new bony structure. To 
gain more insight in some of these factors, series of animal experiments were performed. 
Titanium chambers have been used for almost three decades for studies of bone regeneration 
in a separate environment without the direct effects of surrounding tissues. By isolating the 
chambers from surrounding soft tissues to prevent interference with the bone ingrowth proc-
ess, a standardization of the conditions for a regenerative response can be achieved. The effect 
of growth factors on bone conductive materials are usually seen at an early stage during bone 
ingrowth. It is then difficult to find the right time to measure these effects, if new ingrown bone 
rapidly fills the chamber. Therefore, we used the bone conduction chamber (BCC), a chamber 
which is never completely filled with bone. The final amount of ingrown bone in the chambers 
can be used as a marker for incorporation.
The BCC has several applications. Osteoconductive materials can be tested inside the chamber, 
and the local conditions for bone ingrowth may be manipulated by adding growth factors and 
drugs. 
Using the BCC various materials and factors have been tested for their effect on bone graft 
incorporation and bone healing. However, biomaterials often have to be crushed to fit in this 
small chamber. Since cellular responses to biomaterials are influenced by the size and shape of 
particles, research concerning the evaluation of biomaterials is limited by the dimensions of this 
bone chamber. In chapter 2 we developed and tested three new large titanium bone chambers, 
based on the bone conduction chamber, in order to be able to investigate the in vivo influences 
of bone processing, growth factors and biomaterials on tissue and bone ingrowth, biomaterial 
resorption and incorporation under reproducible, non-load bearing conditions.
A major point of discussion is the benefit of rinsing of bone grafts. Both rinsing before and 
before and after impaction are used clinically. However, rinsing before and before and after 
impaction might have quite different effects on the incorporation of grafts. It is not known how 
rinsing of morselized bone grafts again after impaction affects the incorporation process. By 
the impaction procedure many microfractures are created, and biologically active factors in the 
bone matrix consequently are released. Rinsing the grafts again after impaction might have a 
negative effect on bone induction if growth factors released by impaction are washed away. In 
chapter 3 we studied if growth factors are released in physiologically relevant concentrations from 
the mineralized matrix by firm impaction, and if these growth factors stimulate bone formation 
in vitro.
Gamma irradiation has been widely used for sterilization of bone allografts. However, gamma 
irradiation alters proteins. This is favorable when it reduces immunogenicity, but is undesirable 
when osteoinductive proteins are damaged. Although the effect of gamma irradiation on BMPs 
has been studied, effect of irradiation on the process of incorporation of morselized bone chips 
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remains unclear. In chapter 4 we studied the effects of sterilization by gamma irradiation on the 
incorporation of impacted morselized allografts.
The clinical application of osteogenic proteins offers solutions to many challenging problems in 
orthopaedics. Bone morphogenetic proteins have the potential to improve clinical outcome after 
revision surgery by improving graft incorporation and implant fixation. A major concern in using 
growth factor is the potential stimulation of the osteoclast lineage. A solution would be using an 
osteoconductive material resistant to resorption and providing initial stability after reconstruc-
tion. Growth factors may promote bone formation in combination with such graft materials. 
In chapters 5 and 6 we studied whether OP-1 promotes the incorporation of impacted morselized 
allografts and TCP/HA into host bone, if bone formation is preceded by an initial process of ac-
celerated resorption, and if a dose related bone graft remodeling response to OP-1 exists.
In addition, maintenance of the BMP at the implantation site and delivery of an appropriate dose 
by an appropriate carrier material are essential for successful osteoinduction. At locations with 
less favorable conditions the BMP clearance might be faster than the bone induction response 
of the host bone. In chapter 7 we developed a new carrier based delivery system with a localized 
sustained release. Heparin was covalenty attached to a collagen coated TCP/HA bone substitute 
and loaded with BMP-7. The location of the BMP on and its release from the coated granules 
was analyzed.
One of the more promising groups of synthetic graft materials for augmenting acute fracture 
healing are the calcium phosphate based cements. There has been a great interest in calcium 
phosphate cements as bone substitute materials because they can be molded to fill a void or 
defect and are osteoconductive. The suggestion has been made that they might also compete 
with the PMMA bone cements and apatite coatings for fixation of metal endoprostheses in 
orthopaedics and oral implantology. In chapter 8 we evaluated a new calcium phosphate cement 
and compared its crystallographic properties, biological activity, osteoconductive properties and 
resorption rate with two other commonly used calcium phosphate cements.
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CHAPTER TWO
DEVELOPMENT OF A LARGE 
BONE CHAMBER 
INTRODUCTION
Calcium phosphate-based materials, such as tricalcium phosphate and hydroxyapatite are popu-
lar bone graft substitutes in a wide range of applications.1-3 These materials have a proven os-
teocompatibility and can act as osteoconductive material. Promising is the combination of both 
biomaterials and bone inductive substances. There are in vivo models, e.g. critical size defects 
and titanium chambers,4-7 in which various materials and factors have been tested for their ca-
pacity in graft incorporation and bone healing. In the evaluation of osteoconductive materials, 
the defect created should be large enough to challenge the adjacent bone with a space that can 
hardly fill spontaneously. The effects of growth factors on bone conductive materials are usually 
seen at an early stage during bone ingrowth. It is then difficult to find the right time to measure 
these effects, if new ingrown bone rapidly fills the defect or chamber.
Particularly, the ‘bone conduction chamber’ (BCC) of Aspenberg has appeared to be a useful tool 
for quantifying bone regeneration under the most variable conditions in both rats and goats.8, 9 
This bone chamber is unlikely to be completely filled with bone, so that the effects of growth 
factors, processing of bone and biomaterials within these chambers can be evaluated as differing 
final amounts of formed bone. However, biomaterials often have to be crushed to fit in this small 
bone chamber. Although these materials are identical in composition, this process creates irregu-
larly shaped, sharp or jagged edged particles. When granules of these biomaterials are implanted 
into bone, bone growth behavior and cellular reactions are different due to the size and shape 
of the granules.10-14 Biological responses such as inflammation, bone bonding and resorption of 
bioactive ceramics are very important in clinical applications.15 Thus, the dimensions of this bone 
chamber limits research concerning the evaluation of biomaterials.
Therefore, we developed and tested three new large titanium bone chambers, based on the 
BCC, in order to be able to investigate the in vivo influences of biomaterials, growth factors and 
bone processing on tissue and bone ingrowth, biomaterial resorption and incorporation under 
reproducible, non-load bearing conditions.
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MATERIALS AND METHODS
BONE CONDUCTION CHAMBER
Our basic model is the BCC which is a model for membranous ossification (Fig. 1a).6 The BCC 
consists of a titanium screw with a cylindrical interior space. It is made up of two threaded half 
cylinders held together by a hexagonal closed screw cap. One end of the implant is screwed into 
the bone. The interior of the chamber has a diameter of 2 mm, and a length of 7.5 mm. There 
are two ingrowth openings for bone ingrowth located at the bone end of the chamber. Thus, the 
ingrowing tissues enter the cylindrical space from the bone compartment. The chamber extends 
far out into the subcutaneous region and the ingrown bone-derived tissue can fill the chamber 
without competing with other tissues. Thus, the tissue ingrowth distance from the holes towards 
the other end of the chamber can be used to estimate tissue regeneration. The geometry of the 
chamber makes it easy to distinguish areas for histomorphometry.6 Since the tibial cortex in rats 
is thinner than that in goats, we adjusted the BCC for use in goats. A 1 mm disk was placed in 
the cap of the BCC to provide for location of the ingrowth holes of the chamber to be deeper 
down, just at the level of the endosteum after the implant is screwed in.7
NEW CHAMBERS
All three new chambers are modifications of the BCC. Similar to the BCC, all new models were 
made of two threaded half-cylinders held together by a cylindrical closed screw cap and fab-
ricated of commercially pure titanium. The interior of the new chambers has a diameter of 6 
mm, and a length of 8.5 mm, so all chambers have the same large volume. The outer diameter 
is 8 mm, the overall length 13 mm. All ingrowth openings were located at the same height at 
endosteal level, only shape and size differed. The first model (BCC+) had two ingrowth openings, 
similar in shape and size to that of the BCC, which are located at the bottom of the chamber 
and are positioned subcortically when implanted into the bone (Fig. 1b). The second model (ROU) 
had two round ingrowth openings, each 1.5 mm in diameter (Fig. 1c). The third model (BOT) had 
no ingrowth openings present at the side of the cylinder but had an open bottom to allow bone 
and tissue ingrowth (Fig. 1d). All new chambers were designed for implantation in the proximal 
medial metaphysis of the goat tibia.
SURGICAL TECHNIQUE/ ANIMALS AND OPERATIONS
Seven mature Dutch milk goats (Capra Hircus Sana) (48–61 kg) were obtained from the Central 
Animal Laboratory, University of Nijmegen, the Netherlands. The goats received two empty bone 
chambers at each side in the cortical bone of the proximal medial tibia (Fig. 2). The position of 
implantation among the chambers and the side for each type of chamber were randomized. All 
procedures were approved by the Animal Ethics Committee of the University of Nijmegen, the 
Netherlands. 
Anaesthesia was accomplished by intravenous administration of pentobarbital (CEVA Santé Ani-
male, Maassluis, the Netherlands) (0.5 ml/kg) and maintained after intubation with nitrous oxide, 
oxygen and isoflurane (1.5-2%). Under aseptic conditions, a longitudinal incision was made in 
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the skin and fascia over the medial side of the proximal tibia. After raising the periosteum, a 
hole was drilled through the medial cortex at approximately 4 cm from the joint cleft using a 3.1 
mm drill for the BCC and a 7.3 mm watercooled hollow diamond tipped drill (Surgical Diamond 
Instruments, Scientific Developments GmbH, Munich, Germany) for the modified chambers. The 
hole was tapped and bone debris from drilling was removed. The bone chamber was screwed in 
manually. The second bone chamber was placed at a distance of 10 mm from the first one. This 
was repeated for the other side. The skin was sutured in two layers. All animals were allowed 
unrestricted movement in their cages and had free access to water and food after the opera-
tion. After the implantation procedure the animals received subcutaneous ampicillin (Albipen 
LA, Intervet International BV, Boxmeer, the Netherlands) (15 mg/kg/48 h) three times. The goats 
received intravital fluochromes (calcein green) (20 mg/kg) at 8 days and 1 day before killing.
After 12 weeks all goats were killed with an overdose of pentobarbital. Tibiae were removed, 
and the bone chambers with surrounding cortex were fixed in 4% buffered formalin. After 1 day 
the content was removed from the chambers and fixed additionally.
µCT
All specimens were scanned in a µCT (µCT20, Scanco Medical AG, Bassersdorf, Switzerland) with 
an isotropic spatial resolution of 9 µm to evaluate the distribution of ingrown bone within the 
chamber. Bone could be present around the ingrowth holes only and could therefore be missed 
during histological and histomorphometrical evaluation. In addition, the morphology of mineral-
ized trabecular microstructure was evaluated.
The scans were segmented into binary images. A local segmentation algorithm consisting of a 
standard edge-detection algorithm, extended to 3D, was used to find the location of the actual 
Fig. 1
The bone conduction chamber and the three modified models. All models are made of two threaded half-cylinders held together 
by a closed screw cap and fabricated of commercially pure titanium. A disk is placed in the cap of the BCC to lower the ingrowth 
holes to the level of the endosteum. All ingrowth openings are located at the same level in the bone. From left to right: BCC, 
BCC+, ROU and BOT. 
Fig. 2
Radiograph of implanted bone chambers in the proximal medial tibia of the goat.
Fig. 2Fig. 1
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surface of the bone. CT numbers at the position of the bone surface were used to construct a 
local threshold matrix, which was used to segment the data set. An option in the algorithm was 
used to accurately represent thin trabeculae that have a size close to resolution limits.16
From each specimen a 1x1x1 mm3 volume of interest was taken at the center of the bottom 
of the bone chamber. From the 3D-reconstructions we determined trabecular number (Th.N.), 
trabecular thickness (Tb.Th.) and structure model index (SMI). In all specimens the entire bone 
volume including bone marrow was measured using a (threshold-based) edge detection algo-
rithm. First, the original thresholded data set (XYZ) was resliced in order to have slices parallel to 
the longitudinal axis of the chamber (XZY; similar to the sections used for histology and histo-
morphometry). Subsequently, for each slice the edge detection algorithm was used to find the 
actual surface of the bone, column by column, from top down. Finally, a line was fitted/drawn 
through the detected surface points, by which, for each slice, a bone ingrowth area including 
bone marrow was created and a bone ingrowth volume could be calculated for the entire speci-
men.
HISTOLOGY
Following µCT scanning the specimens were dehydrated using ethanol and embedded in 
polymethylmetacrylate (PMMA). The specimens were cut with a microtome (Leica RM 2155, 
Leica Microsystems Nederland BV, Rijswijk, the Netherlands) parallel to the longitudinal axis of 
the chamber. Sections were taken at 0, 300 and 600 µm from the center of the BCC specimens, 
and at 0, 900 and 1800 µm from the center of the larger specimens, each section 5 µm thick. 
All sections within each experiment were investigated in random order. The tests were blinded, 
but it was possible to see whether or not a specimen originated from the BCC or BCC+, ROU 
and BOT. The sections were stained with haematoxylin and eosin, Goldner-Masson trichrome for 
routine histology or left unstained for fluorescence microscopy.
HISTOMORPHOMETRY
Histomorphometric analysis was performed by using interactive computer controlled image 
analysis (analySIS, Soft Imaging System GmbH, Münster, Germany). The bone ingrowth distance 
in each slide was calculated by dividing the new bone area by the width of the specimen.6 In 
all specimens marrow cavities surrounded by bone were included in the bone area. The mean 
of the three sections at 0, 300 and 600 µm from the center yielded a value for the BCC speci-
men. The mean of sections at 0, 900 and 1800 µm from the center yielded a value for the larger 
specimens. The total tissue ingrowth distance, which is the distance from the ingrowth end to 
the fibrous ingrowth frontier, was measured in the same way as bone ingrowth.
STATISTICS
Statistical analysis was performed using a univariate analysis of variance (SPSS Inc., Chicago, Il-
linois, USA) with factors goat, side, position and chamber type. To isolate the group or groups 
that differ from the others Tukey’s multiple comparison procedure was used. Normality and 
homogenity of variance were tested using Kolmogorov-Smirnov’s and Levene’s test.
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RESULTS
CLINICAL EVALUATION
No intra-operative complications occurred during surgery. All goats had good recovery after 
surgery, were standing within 1 day and had a normal gait pattern within 3 days after surgery. 
There were no signs of inflammation, skin ulceration, or wound healing problems. All bone 
chambers were strongly fixed into the tibia. In most cases the bone chambers were surrounded 
with a layer of callus and covered with fibrous tissue, irrespective of the contents of the cham-
ber. No new bone formation was seen at the endosteal surface of the tibial cortex.
HISTOLOGY
Histologic examination of the specimens revealed cancellous bone in all 28 chambers. In the 
top of the chamber, a zone containing vascularized fibrous tissue was observed, followed by a 
zone with woven-fibered bone. Near the bottom, there was a zone with more mature, remod-
eled cancellous bone. Qualitatively, all specimens were similar although differences in ingrowth 
distances were found. A thin cortical bone plate, sometimes completely, closed the bottom of 
BOT model chambers.
HISTOMORPHOMETRY
Neither side (p = 0.240 and p = 0.275) nor position (p = 0.628 and p = 0.512) of the chamber 
did affect bone or total tissue ingrowth, respectively. None of the factors interacted. The BCC 
and the ROU showed similar bone ingrowth distances. No difference in amount of fibrous tissue 
ingrowth between the chamber types was found (p = 0.362). Bone ingrowth was significantly 
higher in the ROU (p < 0.01 and p < 0.01) and BCC (p = 0.027 and p = 0.039) compared to the 
BCC+ and the BOT, respectively (Fig. 3).
µCT
µCT showed ingrown bone in all chambers (Fig. 4). The new formed bone was not solely present 
around the ingrowth holes, but covered the entire bottom of the chambers (Fig. 5). Bone in-
growth was significantly higher in the BCC (p = 0.009 and p = 0.036) compared to the BCC+ 
and the BOT, respectively (Fig. 6a). No significant difference in bone ingrowth between BCC and 
ROU was found (p = 0.529). Furthermore, no significant differences in Tb.Th. (p = 0.372) (Fig. 6b), 
Tb.N. (p = 0.503) (Fig. 6c) and SMI (p = 0.121) (Fig. 6d) between the chamber types were found.
Correlation indicated a good relationship between bone ingrowth measured using µCT and bone 
ingrowth measured using histomorphometry (r2 = 0.815) (Fig. 7). 
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Fig. 4
µCT 3D reconstruction of typical examples of ingrown bone in bone conduction chamber and the three modified models. 
(a) BCC, (b) BCC+, (c) ROU and (d) BOT.
Fig. 5
µCT 2D cross-sectional image of a typical large bone chamber sample taken at the level of the ingrowth openings. 
Arrows pointing at ingrown bone at the ingrowth openings. Ingrown bone (white) is surrounded by fibrous tissue (gray).
Fig. 3
Boxplot of histomorphometric results. Fibrous tissue and bone ingrowth distance in all chamber types. There are no statistical 
significant differences in fibrous tissue ingrowth between the chamber types. There is significantly more bone ingrowth in the 
ROU (p < 0.01 and p < 0.01) and BCC (p = 0.027 and p = 0.039) compared to the BCC+ and the BOT, respectively.
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Fig. 7
Correlation indicated a good relationship between bone 
ingrowth distance measured with µCT and histomorphometry 
(r2 = 0.815) for all samples.
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Fig. 6
Boxplots of µCT-parameters. (a) Trabecular thickness (Tb.Th.), (b) Trabecular number (Tb.N.), (c) Structure model index (SMI) 
and (d) Bone ingrowth distance. There are no statistically significant differences between the chamber types for µCT-parameters 
measured.
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DISCUSSION
We adapted the bone chamber model used in rodents for use in a larger vertebrate in order to 
optimize the research of in vivo influences of biomaterials and growth factors on tissue and bone 
ingrowth, resorption and incorporation under reproducible, non-load bearing conditions. Empty 
chambers were used as a test of the ability of these chambers to evaluate the in vivo tissue- and 
bone ingrowth. Bone ingrowth did not completely fill any of the chambers, so the final amount 
of bone in the chambers can be used for measuring the effect to various attempts to decrease or 
increase bone formation. This seems to provide a satisfactory model for investigating the speed, 
amount and quality of bone ingrowth in the goat.
Several factors, including the distance between the ingrowth holes, the mechanical loading 
situation and, particularly in this study, the geometry of the ingrowth holes, may influence the 
formation of new bone inside the chambers. First of all, by placing the chambers into the bone, 
the surrounding tissue is traumatized. This stimulates the production of local trauma factors, 
which spread in space and stimulate the bone ingrowth.17-20 Probably, the effect of these para-
crine factors can only reach a diffusion-limited distance into the chamber and consequently bone 
ingrowth will stop at a certain level. The inner diameter (6 mm for the BCC+ and ROU vs. 2 mm 
for the BCC) and thus the distance from one ingrowth hole to the other differ. This distance can 
be important in the bone formation process. Bone could be present around the ingrowth holes 
only and could therefore be missed during histological and histomorphometrical evaluation. 
Therefore, the distribution of ingrown bone within the chamber was evaluated using µCT. We 
showed that histology and µCT-data correlated well and thus µCT is not a prerequisite, merely 
additional for the evaluation of bone ingrowth in bone chambers.
Secondly, mechanical loading conditions are important in bone healing and remodeling, both in 
the bone chamber but also in the human skeleton.21, 22 Van der Donk et al.7 found considerable 
amounts of bone ingrowth in the BCC after both 6 and 12 weeks, where bone ingrowth in the 
repeated sampling bone chamber (RSBC) was low or even absent.23 Based on the differences in 
design and the differences in bone ingrowth between these bone chambers, Van der Donk et 
al.24 hypothesized that in the BCC the bone formation process may be influenced by mechanical 
stimuli outside the chamber, either by stress-shielding or by soft tissue movement. The stiff and 
compact outer housing of the RSBC might protect the surrounding bone and inner chamber 
against mechanical stimuli. In contrast, the BCC consists of two thin titanium walls (at the level 
of the cap) and possibly some mechanical factors are involved in the bone forming process in-
side this chamber. Caps were placed over the chambers to provide stress shielding of the BCC. 
A loose cap was made to rule out that the surrounding soft tissue would result in motion of 
the chamber. However, no differences were observed for bone and tissue ingrowth between 
chambers, with or without a cap, either loose or tight fit. If stress shielding is not the reason for 
the difference in bone ingrowth, then other factors are involved that govern bone and tissue 
ingrowth into these chambers.
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Finally, in the present study, the ROU model performed most similar to the BCC (gold standard) 
in both tissue and bone ingrowth. Bone ingrowth was less pronounced in the specimens from 
the BCC+. Remarkably, despite being subjected to the same cross-sectional area (2.25π), bone 
ingrowth was greater in the specimens from ROU having round, rather than the BCC+ with 
quarter of circle shaped holes. Moreover, the open bottom ‘hole’ in the BOT also provided a 
larger cross sectional area (6.25π), which might result in enhanced ingrowth of bone. However, 
a thin bone plate was formed, closing the ingrowth hole of the BOT, which seemed to inhibit the 
ingrowth of further bone into chamber. Only occasionally, tissue entered the chamber through 
a hole in this bone plate. Particularly the difference between the ROU and BCC+ was quite 
unexpected.
Previously, variable bone ingrowth was observed using different bone chamber designs (geom-
etry of ingrowth holes) in one species.24, 25 In a study using the micromotion chamber in rabbits, 
the chambers containing ingrowth cylinders with a round hole demonstrated less ingrowth as 
compared to cylinders with a square hole.25 This observation might have been due to the (21.5%) 
greater cross sectional area of the square versus the round hole in the cylinder and the enhanced 
congruity provided by the square outer and inner holes versus a round outer and a square inner 
hole. When placed in the goat, different bone ingrowth in the BCC and the RSBC was found.7, 
23, 24 However, in the study of Goodman et al.,25 the shape as well as the cross-sectional area of 
the ingrowth holes differed. Remarkably, the ingrowth holes of both the chamber types used in 
the study of Van der Donk et al.24 had the same cross-sectional area but differed in shape and 
length of the ingrowth canal. In the present study, the differences in bone ingrowth are probably 
(solely) caused by the differences in shape of the ingrowth holes.
In designing porous coatings and bone regeneration scaffolds for tissue engineering there are 
similar debates on bone ingrowth and pore size. The optimal pore size for bone ingrowth often 
has been reported to be in the range of 150–600 µm.26, 27 More recent, Hollister et al.28 exam-
ined pore size and geometry issues using designed HA scaffolds in a minipig mandibular defect 
model. A total of nine designs were created, consisting of three shapes (circular struts, circular 
pores and square pores) and three pore diameters for each shape. Pore diameters for the circular 
and square pores were 400, 600 and 900 µm and for the circular struts 600, 900 and 1200 µm. 
Their results suggested that there is no optimal pore size or shape for bone regeneration. All 
pore sizes and shapes were conductive to bone ingrowth. In contrast, McGlohorn et al.29 found 
that pore topography plays a critical role in the attachment of cells to a porous substrate. They 
concluded that changes in pore size and shape can radically affected the successful development 
of tissue. The optimal porosity or pore size for bone regeneration scaffolds and bone chambers 
remains an open question the answer to which may depend on the mechanical and vascular fac-
tors at the site of implantation.
The ROU model performed most similar to the BCC (gold standard) in both tissue and bone 
ingrowth. This new bone chamber offers new possibilities for studies of bone tissue reactions 
to various biomaterials (without crushing these biomaterials) and therefore is considered as a 
promising new tool in biomaterial research.
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CHAPTER THREE
RINSING BONE GRAFTS BEFORE 
AND AFTER IMPACTION 
INTRODUCTION
Bone impaction grafting with a cemented prostheses is a biologically attractive technique for 
treating bone stock defects around failed total hip prostheses, with long-term clinical survival 
data available both on the acetabular and the femoral sides.1, 2 Although the technique on the 
acetabular side has been well described by the original promoters,3 a dispute has been raised 
about the pros and cons of rinsing the allograft bone chips. Both rinsing once (before) and twice 
(before and after) impaction are used. However, rinsing before impaction or before and after 
impaction might have quite different effects on the incorporation of the grafts.
Rinsing before impaction enhances the stability of graft reconstructions by creating a higher 
interparticle shear resistance.4 Also, in more realistic acetabular testing models with bone impac-
tion grafting, rinsing had a positive effect on the initial stability of the cemented cups.5, 6 In ad-
dition, the use of allografts induces an immunogenic response to the graft. Since most antigenic 
cells are found in the marrow, rinsing the grafts to remove blood, marrow and fat have been 
shown to diminish this negative aspect.7 Bone grafts rinsed before impaction are better incorpo-
rated compared to unrinsed allografts.8
Rinsing again after impaction is performed, however, only on the acetabular side, in the expec-
tation of an additional effect on the initial mechanical stability through an increase in cement 
penetration. Although clinically practiced, there is no experimental data supporting the benefit 
of rinsing again after impaction. It is not known how the rinsing of morselized bone grafts again 
after impaction affects the incorporation process. Rinsing the grafts again after impaction might 
have a negative effect on bone induction if growth factors released by impaction are washed 
away.
By the impaction procedure, many microfractures are created, and biologically active factors in 
the bone matrix are, consequently, released. Recently, it was shown that a physiologically signifi-
cant amount of transforming growth factor-β (TGF-β) was released by the strong compression 
of rinsed cancellous bone blocks from femoral heads.9 Many contradictory reports have been 
published on the effects of TGF-βs on bone for mation,10, 11 however, the effects of TGF-βs on 
bone graft incorporation are unknown.
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Furthermore, it is not known if, other, more potent stimulators of bone induction, like bone 
morphogenetic proteins (BMPs), are released in physiologically relevant concentrations from the 
mineralized matrix during impaction. Therefore, we studied if TGF-βs and BMPs are released in 
physiologically relevant concentrations from the mineralized bone matrix by firm impaction, and 
if these released growth factors induce osteogenic differentiation in human mesenchymal stem 
cells (hMSCs).
MATERIALS AND METHODS
PRODUCTION OF “IMPACTION FLUID”
Cancellous allografts were collected from five human femoral heads obtained from the authors’ 
institutional bone bank. Swabs were taken and tested for bacterial contamination. All speci-
mens were clear of bacterial contamination. The allografts were cut to 5x5x5 mm pieces using 
a rongeur and were subsequently pooled. Blood and marrow were removed macroscopically by 
rinsing the grafts with saline for approximately 1 min, leaving only a white bone structure. Rins-
ing was done using a commercially available high-pressure pulsatile lavage system (SurgiLav Plus, 
Stryker Nederland BV, Waardenburg, the Netherlands). The grafts were in a sieve during rinsing. 
Allografts were dried overnight in a laminar flow cabinet (sterile airflow) at 4°C.
The bone grafts were inserted into a cylinder with a diameter of 30 mm. A piston, slightly smaller 
in diameter, was inserted into this cylinder. A rubber ring, sealing the piston, prevented the es-
cape of fluid between the piston and the wall of the cylinder. Using an MTS loading device (MTS 
Systems Corporation, Minneapolis, MN, USA), the allografts were impacted. Fluid was evacuated 
through a canal in the bottom of the cylinder and were collected sterile. The applied pressure 
was calculated to be 12.5 MPa. The gathered fluid was centrifuged for 10 min at 3,000 rpm 
at 4°C. Any cellular and fatty debris was separated from the supernatant. The supernatant was 
called “impaction fluid”.
ANALYSIS OF “IMPACTION FLUID”
TGF-β1 and TGF-β2 levels in the “impaction fluid” were measured by enzyme-linked immuno-
sorbent assay (ELISA; Quantikine, R&D Systems Europe Ltd., Abingdon, United Kingdom) accord-
ing to the manufacturer’s instructions. The plate was read in an ELISA reader at 450 nm (Sunrise, 
Tecan Group Ltd., Männedorf, Switzerland). Experiments were performed in triplicate.
The presence of BMPs was determined using a modified BMP-selective reporter bioassay (BRE-
luc) inducing luciferase expression.12 This assay is based on 3T3 fibroblasts stably transfected with 
the BRE-luc reporter construct. In short, 3T3 BRE-luc cells were seeded in a density of 20,000 
per well in microtiter plates in D-MEM (Gibco Invitrogen Corp., Grand Island, NY, USA) with 5% 
FCS. After 24 h, BMP-containing samples were added and the cells were incubated for a further 
20 h. Luciferase activity was quantified using the Bright-Glo Luciferase Assay System (Promega, 
Madison, WI, USA). Luminescence was measured using a plate luminometer according to the 
manufacturer’s protocol (POLARstar Galaxy, BMG Labtech GmbH, Offenburg, Germany). For the 
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standard curve, serial dilutions of rhBMP-2 (R&D Systems Europe Ltd., Abingdon, United King-
dom) to final concentrations of 0 to 100 ng BMP-2/ml were used. The lower detection limit of 
this assay is 1.6 ng/ml BMP-2. Experiments were performed in triplicate.
Almost all members of the TGF-β family, including BMPs, are secreted as latent complexes and 
need to be activated to exhibit their biological activity.13 Therefore, both active and total growth 
factor levels were measured in order to have an impression of latent growth factor levels. The 
total growth factor levels were measured by activating the growth factors in the samples using 
hydrochloric acid and, subsequently, neutralizing the samples by sodium hydroxide, according to 
the manufacturer’s instructions.
CULTURE STUDY
Human mesenchymal stem cells (Poietics hMSC, Cambrex Bio Science Verviers, S.p.r.l., Belgium) 
were cultured up to passage 7 on mesenchymal stem cell growth medium (MSCGM BulletKit 
(PT-3001), Cambrex Bio Science Verviers, S.p.r.l., Belgium). The cells were incubated in a humidi-
fied atmosphere of 92.5% air and 7.5% CO2 at 37°C. After primary culture, cells were detached 
using trypsin/ EDTA (Cambrex Bio Science Verviers, S.p.r.l., Belgium), and the cells were seeded 
in 96-well plates at a density of 20,000 cells/cm2. The cells were allowed to attach overnight. 
After cell attachment, the cells were cultured under static conditions for 7 days. Cells were 
cultured on osteogenic differentiation medium (hMSC Osteogenic Differentiation BulletKit (PT-
3002), Cambrex Bio Science Verviers, S.p.r.l., Belgium) with and without 10−7 M dexamethasone 
(Sigma, Chemical Co., St. Louis, MO, USA). The supernatant (“impaction fluid”) was lyophilized. 
Subsequently, the lyophilized “impaction fluid” was resuspended in osteogenic differentiation 
medium (without dexamethasone), equal to the original volume of the supernatant. The hMSCs 
were stimulated with 5 ng/ml TGF-β1 (rhTGF-β1, R&D Systems Europe Ltd., Abingdon, United 
Kingdom), 10−8 M vitamin D3 [1,25(OH)2D3], 100 ng/ml BMP-2 (rhBMP-2, R&D Systems Europe 
Ltd., Abingdon, United Kingdom) and 10%, 20%, 40% and 80% “impaction fluid”. The culture 
medium was changed every three days. Experiments were performed in triplicate. Osteogenic 
differentiation medium without dexamethasone was used as the negative control, whereas os-
teogenic differentiation medium supplemented with dexamethasone and vitamin D3 was used 
as the positive control.14
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ALKALINE PHOSPHATASE ASSAY
Alkaline phosphatase (ALP) activity was measured to obtain information about the osteogen-
ic differentiation of the cells. Medium was removed and the cell layers were washed twice 
with phosphate buffer solution (PBS). The cells were fixed with 4% buffered formaldehyde and 
washed twice with PBS again.
The substrate solution was made by adding 1 ml of 10 mM MgCl2 to 10 ml of 1 M di-ethanol-
amine (DEA) and dissolving 52.6 mg of para-nitrophenyl phosphate (PNPP) in 10 ml of this 
solution. Subsequently, 100 µl of substrate solution was added to each well and the plate was 
incubated for 15 min. The reaction was stopped by adding 100 µl of 0.5 M NaOH. The plate 
was read in an ELISA reader at 405 nm (Wallac VICTOR2 1420, PerkinElmer Life and Analytical 
Sciences, Inc., Boston, MA, USA).
NEUTRAL RED ASSAY
A neutral red (NR) assay was performed to obtain an indication of the number of viable cells 
(proliferation). A 1:1 solution of neutral red stock (1 mg/ml milliQ water) and 1.8% NaCl solution 
was made and filtered. One hundred microliters (100 µl) of this solution was added to each well 
and the plate was incubated for 90 min at 37°C. Neutral red solution was removed and the cell 
layers were washed twice with PBS. Subsequently, 100 µl of elution buffer (0.05 M NaH2PO4/50% 
EtOH) was added to each well. The plate was read in an ELISA reader at 550 nm (Wallac VICTOR2 
1420, PerkinElmer Life and Analytical Sciences Inc., Boston, MA, USA). The neutral red assay was 
used to correct the alkaline phosphatase assay for the number of viable cells.
RESULTS
ANALYSIS OF “IMPACTION FLUID”
Analysis of the “impaction fluid” revealed that TGF-β was abundant. Both TGF-β1 and TGF-β 2 
were present in the “impaction fluid” in physiologically significant amounts. The total levels of 
TGF-β1 and TGF-β 2 present after activation were 5.39±1.12 ng/g bone and 1.20±0.12 ng/g 
bone, respectively. Before the samples were activated, an already active amount of 0.43±0.05 
ng TGF-β1/g bone and 0.13±0.11 ng TGF-β 2/g bone was measured (Fig. 1). No BMPs could be 
detected using the BMP-selective reporter bioassay. Luciferase expression did not exceed the 
detection limit of 1.6 ng BMP-2/ml.
CELL CULTURE STUDY
Adding dexamethasone to the osteogenic differentiation medium caused an approximately 
three-fold increase in ALP activity. Vitamin D3 added to osteogenic differentiation medium sup-
plemented with dexamethasone showed the highest induction of ALP activity, whereas the addi-
tion of 5 ng/ml TGF-β1 strongly suppressed the induction of ALP activity. The “impaction fluid” 
dose-dependently suppressed the ALP activity induced by dexamethasone (Fig. 2). Both 40% and 
80% “impaction fluid” showed similar suppression to 5 ng/ml TGF-β1.
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Fig. 1
Levels of transforming growth factor-β1 and -β 2 (TGF-β1 and TGF-β 2) measured in the “impaction fluid”. Both total and already 
active growth factor levels are shown. Data are mean±standard deviation of experiments performed in triplo.
Fig. 2
Data from cell culture. Human mesenchymal stem cells (hMSCs) were cultured with and without dexamethasone. As a measure 
for osteogenic differentiation, alkaline phosphatase activity (ALP) was corrected for the number of viable cells (NR). Data are 
mean±standard deviation of experiments performed in triplo.
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DISCUSSION
The fracture surface created by impaction could have a growth promoting effect by enabling 
the release of growth factors. Rinsing morselized bone grafts again after impaction, therefore, 
might have a negative effect on bone induction if growth factors released during impaction are 
washed out. In our study, we examined if TGF-β and BMPs are released from the mineralized 
matrix by impaction, and whether these released growth factors induce osteogenic differentia-
tion in hMSCs.
Both TGF-β1 and TGF-β 2 were abundantly present in “impaction fluid”. Corresponding to what 
is seen in demineralized bone, in our study, most TGF-β was present in a latent form. Bone grafts 
from five femoral heads were pooled to minimize variation to overcome possible bias. However, 
it should be noticed that a large variation of TGF-β exists in human bone tissue both in tissue 
location and between individuals.15 Our results are in accordance with the results of Fyhrie et 
al.9 who recently showed that strong mechanical compression of cancellous bone blocks from 
femoral heads accelerates the release of TGF-β2. In addition, they and others suggested that 
mechanical loading also might accelerate the release of other growth factors, like BMPs, from 
mineralized bone matrix.9, 16 In our study, however, no BMPs could be detected. In the light of 
the overwhelming literature on BMPs in bone,17, 18 we have to conclude from this experiment 
that BMPs cannot be released from the mineralized matrix by impaction. The BMPs in bone are 
considered to be activated by demineralization;19 however, as described in Burwell’s classical 
work on bone grafting, some new bone formation may be induced also from non-demineralized 
allografts.20 If all BMPs are retained in the bone, this might explain the coupling of resorption 
and new bone formation during the incorporation of morselized cancellous bone in bone impac-
tion grafting.21
Since TGF-β is abundantly present in the “impaction fluid”, it is not surprising to see a suppres-
sion of osteogenic differentiation with an increasing concentration of “impaction fluid” in our 
culture experiment. TGF-β is known to inhibit the ALP expression of mesenchymal stem cells 
(MSCs), even when these cells are stimulated with BMPs.11, 22 In contrast to BMPs, TGF-β is unable 
to induce osteogenesis in mesenchymal pluripotent cells.11, 23 From this perspective, it seems that 
rinsing bone grafts again after impaction might even be beneficial if TGF-β is washed away.
Data from numerous in vitro experiments have demonstrated the role of TGF-β in every stage of 
bone formation.11, 24 Despite conflicting results, most data support the following model:11 TGF-β 
increases bone formation in vitro mainly by recruiting osteoblast progenitors and stimulating 
their proliferation, thus, expanding the pool of committed osteoblasts, in addition to promoting 
the early stages of differentiation (bone matrix production). On the other hand, it blocks later 
phases of differentiation and mineralization. These later stages are regulated by other growth 
factors, like BMPs. In other words, TGF-β generally inhibits the mineralization of the matrix it 
helps to produce.
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However, TGF-β not only modulates bone formation, but it can also stimulate osteoclast re-
cruitment, formation and function.25, 26 Bone resorption is more detrimental for the outcome 
of impaction grafting than just suppression or lack of bone formation, because resorption may 
compromise implant fixation.27, 28 In addition, little or no BMPs from bone can be released prior 
to demineralization. Only biological remodeling might free these factors (BMPs) to stimulate 
bone formation. Therefore, removing the excess of TGF-β from bone grafts might be a useful 
procedure.
On the contrary, TGF-β released after impaction might, indeed, be beneficial at an early stage 
postoperatively when chemotactic and proliferative signals might be needed. Furthermore, 
TGF-β promotes the early stages of osteoblast differentiation. However, the fluid released by the 
impaction procedure in clinical surgery will, probably, only be in situ for a short period of time at 
the very early postoperative stage, when osteoblast differentiation is not relevant.
It should be noticed that results obtained in vitro are often not in line or even contradictory to in 
vivo observations. In vivo, the presence of other growth factors, cytokines and hormones in the 
bone environment and the environment itself determine the exact outcome of TGF-β function.
In summary, by rinsing morselized bone grafts again after impaction, growth factors (TGF-βs) 
released during impaction are washed out. Although TGF-β appears to be a potent stimulator 
of chemotaxis and the proliferation of osteoblasts, but also of osteoclast recruitment, formation 
and bone resorption, more potent stimulators of bone formation (BMPs) are not released from a 
mineralized matrix during impaction. To our knowledge, there is only one study reporting in vivo 
data on the effects of rinsing and the impaction of morselized bone grafts on bone ingrowth.8 
Rinsing before impaction increased bone ingrowth in the allograft group to approach that of 
autografts. However, rinsing after impaction did not additionally alter bone ingrowth. The results 
from our study, and the dual effects of TGF-β reported in the literature, leave us only able to 
speculate whether rinsing grafts again after impaction has a beneficial effect on the incorpora-
tion process.
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CHAPTER FOUR
NO EFFECT OF IRRADIATION ON 
THE INCORPORATION PROCESS 
INTRODUCTION
Impacted morselized bone grafts are used successfully to restore bony defects in revision hip sur-
gery in both the acetabulum and the femur.1-3 Despite promising clinical results with allografts, 
bone autografts remain the gold standard. However, the use of autografts is limited by the 
amount of graft available and additional donor site morbidity created by the harvest procedure. 
In order to obtain results that are more comparable with those of autografts, osteoconductivity 
is often promoted by rinsing allografts before impaction, thereby improving the incorporation 
process.4, 5 However, one remaining major disadvantage of using allografts is the potential risk 
of disease transmission.
Gamma irradiation has been widely used for (terminal) sterilization of bone allografts due to its 
efficacy in preventing transmission of both bacteria and viruses.6-9 Due to changes in mechanical 
properties of bone by gamma irradiation, it has been used with some caution in clinical practice, 
especially in load-bearing applications. Irradiated morselized bone was found to be less strong, 
less stiff and significantly more brittle than fresh-frozen control bone when tested in compres-
sion models.10 However, it has been shown that irradiated freeze-dried impacted grafts provide 
a more stable femoral reconstruction than fresh-frozen grafts when tested in a hip simulator.11 
On the other hand, the higher degree of compactness caused by impaction of irradiated bone 
may reduce the speed of the incorporation process.12
Irradiation has also been found to alter proteins. This is favorable when it reduces immuno-
genicity, but appears to be undesirable when osteoinductive proteins are altered or damaged. 
Osteoinductive proteins within the graft may be important in the process of incorporation. These 
proteins may be released during the resorptive phase of bone graft incorporation, and can have 
a profound effect on bone cell physiology. Although studies have been performed to determine 
the effect of irradiation on bone morphogenetic proteins (BMPs),13-19 the effect of irradiation on 
the incorporation process of morselized bone chips remains unclear. We studied the effects of 
sterilization by gamma irradiation on the incorporation of impacted morselized allografts. Using 
a bone chamber model in goats, the process of bone incorporation was studied in fresh-frozen 
bone grafts, rinsed bone grafts, and bone grafts that had been both rinsed and irradiated, at 12 
weeks after surgery.
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MATERIAL AND METHODS
ANIMALS
12 mature female Dutch milk goats (Capra Hircus Sana) (45–56 kg) were obtained from the 
Central Animal Laboratory, Radboud University Nijmegen, the Netherlands. The goats received 
two bone chambers at each side in the cortical bone of the proximal medial tibia. We implanted 
an empty chamber, a chamber containing fresh-frozen impacted allograft, a chamber contain-
ing rinsed impacted allograft, and a chamber containing allograft that had been rinsed and 
subsequently irradiated. The position of implantation among the chambers and the side for each 
chamber were randomized. All procedures were approved by the Animal Ethics Committee of 
the Radboud University Nijmegen.
PREPARATION OF GRAFTS
Cancellous allografts were obtained from the sternum of 6 donor goats. Familial bonds between 
donor and recipient goats were excluded. To prevent bias in terms of different immunological 
reactions, the allografts were pooled.
One-third of the pooled allograft was used as fresh-frozen allograft. Blood and marrow of the 
remaining two-thirds were removed macroscopically by rinsing the grafts with saline for approxi-
mately 1 min, leaving only a white bone structure. Rinsing was done using a high-pressure pul-
satile lavage system (SurgiLav Plus, Stryker Nederland BV, Waardenburg, the Netherlands). Grafts 
were located in a sieve during rinsing. Half of the rinsed cancellous allograft was subsequently 
irradiated with a minimal dose of 25 kGy using a 60Co gamma-ray source (Isotron BV, Ede, the 
Netherlands) at a temperature of -78.5 °C (on dry ice). Bacterial cultures from all three types of 
grafts were negative. The grafts were stored at -80 °C until use. Before implantation, they were 
thawed at room temperature and cut into pieces of 2x2x1 mm using a rongeur.
BONE CHAMBER
The bone ingrowth chamber used in this study was a modification of a large bone chamber 
(ROU),20 which was in turn based on the bone conduction chamber.21 The chamber consisted of 
two threaded half-cylinders held together by a cylindrical closed screw cap, and was made of 
commercially pure titanium (Fig. 1). The interior of the chamber had a diameter of 6 mm and a 
length of 8.5 mm. The outer diameter was 8 mm, and the overall length 13 mm. Two additional 
ingrowth openings were added to the orginal model,20 resulting in a total of 4 round ingrowth 
openings, each 1.5 mm in diameter. All ingrowth openings were located at the same height, at 
endosteal level.
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Fig. 1
The bone ingrowth chamber. The chamber consists of two 
threaded half-cylinders held together by a cylindrical closed 
screw cap. 4 round ingrowth openings are located at the 
endosteal level.
IMPACTION PROCEDURE
Impaction was performed by gradually filling the chamber with the allograft bone. A piston, 
slightly smaller in diameter, was used for impaction. The piston was guided by low-friction 
bearings, strictly limiting it to vertical movement. The chamber was clamped into a cylindrical 
holder. A constant force of 680 N was kept on the free end of the piston for 2 min. During this 
time, fluid could escape between the piston and the wall of the bone chamber and the ingrowth 
openings. The pressure applied was calculated to be 25 MPa. With this method of impaction, the 
mean volume fraction rises from about 35% in unimpacted grafts to about 65% in the impacted 
ones.12 After impaction, the closed screw cap was screwed on.
SURGICAL TECHNIQUE
The goats were anesthetized by intravenous administration of sodium pentobarbital (0.5 ml/kg) 
and maintained after intubation with nitrous oxide, oxygen and isoflurane (1.5-2%). Under asep-
tic conditions, a longitudinal incision was made in the skin and fascia over the medial side of 
the proximal tibia. After raising the periosteum, a hole was drilled through the medial cortex 
at approximately 4 cm from the joint cleft using a 7.3 mm watercooled hollow diamond-tipped 
drill (Surgical Diamond Instruments, Scientific Developments GmbH, Munich, Germany). The 
hole was tapped, and bone debris from drilling was removed. The bone chamber was screwed 
in manually. The second bone chamber was placed at a distance of 10 mm distally from the first 
one. This was repeated for the other side. The subcutaneous layer and the skin were sutured. All 
animals were allowed unrestricted movement in their cages and had free access to water and 
food after the operation. After the implantation procedure, the animals received subcutaneous 
ampicillin (15 mg/kg/48 h) 3 times.
After 12 weeks, all goats were killed with an overdose of sodium pentobarbital (1 ml/kg). The 
tibiae were removed, and the bone chambers with surrounding cortex were fixed in 4% buffered 
formalin. After 1 day, the content was removed from the chambers and fixed additionally.
Fig. 1
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EVALUATION
All specimens were scanned in a µCT (µCT20, Scanco Medical AG, Bassersdorf, Switzerland.) 
with an isotropic spatial resolution of 9 µm to evaluate the bone volume fraction of the impacted 
graft remnants at the top of the chambers. Impacted irradiated bone could have a higher com-
pactness, thereby influencing the incorporation process.
The scans were segmented into binary images. We used a local segmentation algorithm consist-
ing of a standard edge-detection algorithm, extended to 3D, to find the location of the actual 
surface of the bone.22 From each specimen, a 4x4x2 mm volume of interest was taken at the 
center of the top of the bone chamber. From the 3D-reconstructions, we determined the bone 
volume fraction (BV/TV) of the graft remnant.
Following µCT scanning, the specimens were dehydrated using ethanol and embedded in 
polymethylmetacrylate. The specimens were cut with a microtome (Leica RM 2155, Leica Mi-
crosystems Nederland BV, Rijswijk, the Netherlands) parallel to the longitudinal axis of the cham-
ber. 5 µm thick sections taken at 0, 600, 1200, 1800 and 2400 µm from the center of each speci-
men, were used for histology and histomorphometry. All sections within each experiment were 
investigated in random order. All the tests were done blinded. The sections were stained with 
hematoxylin and eosin, and Goldner-Masson trichrome for routine histology. Histomorphomet-
ric analysis was performed using interactive computer-controlled image analysis (analySIS, Soft 
Imaging System GmbH, Münster, Germany). The bone ingrowth distance in each slide was calcu-
lated by dividing the area of new bone by the width of the specimen.21 In all specimens, marrow 
cavities surrounded by bone were included in the bone area. The total tissue ingrowth distance, 
which is the distance from the ingrowth end to the fibrous ingrowth frontier, was measured in 
the same way as bone ingrowth. The mean of 5 sections yielded a value for each specimen.
STATISTICS
Statistical analysis was performed using a univariate analysis of variance (SPSS software) with 
the factors goat, side, position and chamber type. To isolate the group or groups differing from 
the others, Tukey’s multiple comparison procedure was used. Normality and homogenity of vari-
ance were tested using the tests of Kolmogorov-Smirnov and Levene. When the assumption of 
normality or homogenity of variance was not met, a Friedman repeated-measures ANOVA on 
ranks was performed. P-values less than 0.05 were considered to be significant. The study was 
designed to have 80% power in detecting a difference of 0.5 mm between the means of all 
groups.
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RESULTS
CINICAL EVALUATION
No intraoperative complications occurred. All goats recovered well after surgery. There were 
no signs of inflammation, skin ulceration or wound healing problems. All bone chambers were 
strongly fixed into the tibia. In most cases the bone chambers were surrounded by a layer of 
callus and covered with fibrous tissue, irrespective of the contents of the chamber. No new bone 
formation was seen at the endosteal surface of the tibial cortex.
HISTOLOGY
A layer of necrotic, nonvascularized graft remnant was present at the top of the chamber, ei-
ther with fibrous tissue infiltration or only graft material as when inserted. Fibrous tissue was 
present between the new bone at the bottom of the chamber and the graft remnant at the top 
of the chamber. This fibrous tissue preceded the bone ingrowth front (Fig. 2a). The graft material 
was penetrated by a loose mesenchymal-like tissue with blood sinusoids and capillaries. In the 
fresh-frozen allografts, a denser fibrous tissue was observed. This group showed a more sharply 
defined ingrowth frontier, where the fibrous tissue was organized more loosely at the transition 
with the graft remnants in the rinsed allografts and those that were both rinsed and irradiated. 
No difference in amount of vascularization was seen. Newly formed bone was present in all bone 
chambers. New bone was formed by intramembranous ossification, growing upward into the 
chamber. The amount and appearance of the new bone varied between specimens, from young, 
woven bone surrounded by active osteoblasts to more mature lamellar bone with fatty marrow 
and trabeculae. If the resorption of the graft remnant was not complete, new bone was appos-
ited on these remnants (Fig. 2b and 2c). This apposition of new bone was only observed in allografts 
that had been rinsed and those that had been both rinsed and irradiated.
HISTOMORPHOMETRY
Neither side (p = 0.7, p = 0.5, and p = 0.4) nor position (p = 1.0, p = 1.0, and p = 0.7) of the 
chamber affected bone ingrowth or total tissue ingrowth or amount of remaining graft, respec-
tively. None of the factors interacted. Rinsing of allografts and subsequent irradiation had no 
added effect on total tissue ingrowth or bone ingrowth distance relative to rinsing only (p = 1.0 
and p = 1.0) or no processing (p = 0.7 and p = 0.2), respectively (Fig. 3). However, no processing 
of allografts resulted in more graft remnant in the top of the chamber compared to rinsing (p < 
0.001) and both rinsing and irradiation (p < 0.001) (Table 1). Irradiation after rinsing had no effect 
on the amount of graft remnant (resorption process) compared to rinsing alone (p = 1.0) (Fig. 3). 
Ingrowth of fibrous tissue in the empty chamber was significantly less than in the other groups 
(p < 0.001). However, there was significantly more ingrowth of bone in the empty chamber than 
in the unprocessed allograft group (p = 0.01), but this was no different from bone ingrowth in 
the group with rinsed allograft (p = 0.4) and in the group with allograft that was rinsed and 
subsequently irradiated (p = 0.5). Furthermore, no difference in bone volume fraction (BV/TV) of 
the graft remnants between the groups was found using µCT (p = 0.6) (Table 2).
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Fig. 3
Boxplot of histomorphometrical results. Rinsing and subsequent irradiation had no effect on total tissue ingrowth or bone 
ingrowth compared to rinsing and no rinsing of allografts. No rinsing resulted in more graft remnant at the top of the bone 
ingrowth chamber.
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Fig. 2
Hematoxylin and eosin (H&E) stained sections. (a) Typical example of bone chamber content. Graft remnants (GR) are still present 
in the top of the specimen. New bone (NB) formation takes place from the ingrowth openings up to the top of the chamber. 
Fibrous tissue (FT) precedes the bone ingrowth front. 12.5x magnification (b) Overview of a rinsed and irradiated specimen. 
Unincorporated graft remnants (GR) are present at the top of the chamber. Incorporated graft remnants are present below the 
front of bone ingrowth. 12.5x magnification (c) Detail showing the area of new bone formation. Within this area, new bone (NB) 
is apposited on graft remnants (GR) at the bottom of the chamber and a marrow cavity (M) has formed. 50x magnification.
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Histomorphometric results
  Implants Empty Allograft Rinsed allograft Rinsed & 
      irradiated 
      allograft
  (n) (mm) (mm) (mm) (mm)
Bone ingrowth  12 2.08±0.62 1.32±0.71 1.74±0.66 1.78±0.63
Soft tissue ingrowth 12 3.51±1.21 6.32±0.50 5.96±0.66 5.95±0.62
Graft remnant  12 - 3.99±0.74 2.79±0.49 2.77±0.70
Values are mean ± standard deviation
Table 1
Bone volume fraction of graft remnants
  Implants Empty Allograft Rinsed allograft Rinsed & 
      irradiated 
      allograft
  (n) (%) (%) (%) (%)
BV/TV   12 - 65.6±13.7 69.4±13.3 68.7±13.4
Values are mean ± standard deviation
Table 2
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DISCUSSION
During sterilization by gamma irradiation, highly reactive hydroxyl radicals are formed due to 
ionization of water molecules. These free radicals have been speculated to impair the integrity 
of collagen molecules.23 In addition, radiation may also denature bone morphogenetic proteins, 
thereby reducing the osteoinductive potential of the allograft.
Controversial results concerning the effect of radiation sterilization on the osteoinductive poten-
tial of both bone and BMPs have been published. In some studies, irradiation has been found 
to inhibit or only partially destroy the osteoinductive capacity.13, 16, 24-26 In others, no effect of 
irradiation on the osteoinductive capacity has been found.14, 17-19
There have been few clinical reports of impaction grafting with irradiated bone grafts in hip revi-
sion surgery on both the femoral and acetabular side,27-30 using radiological and clinical scores as 
outcome measures. In one study evaluating femoral impaction grafting with the Exeter hip and 
unwashed irradiated (25 kGy) bone grafts, a lack of radiological incorporation and trabecular 
remodeling was found.27 In contrast, in a 2-7 year follow-up study using rinsed fresh irradiated 
(25-30 kGy) allograft bone in 41 revision femoral arthroplasties, Bankes et al.28 found no sig-
nificant difference in clinical or radiographical outcome. Comparing fresh-frozen and irradiated 
allograft bone in impaction grafting of the acetabulum, Holt et al.29 found no obvious difference 
in clinical performance with evidence of incorporation and remodeling after 6 months and 13 
months for the irradiated graft, using 2 different radiographical criteria. Buckley et al.,30 using 
unwashed irradiated (25 kGy) bone for acetabular revision surgery, showed an 88% survival rate 
at a mean follow-up time of 5 years, which is comparable with that of studies using unirradiated 
bone. In addition, Hamer et al.31 histologically examined 5 cases of re-revision where irradiated 
cortical allograft had been used. All cases showed favorable histological features, with soft tissue 
attachment by fibrous adhesion, union of graft to host, and osseous remodeling.
One explanation for the good performance of the rinsed and subsequently irradiated allografts 
in our study may be that the allograft was irradiated on dry ice and not at room temperature. 
Recently, Hamer et al.23 reported that irradiation of cortical bone at dry ice temperature gave 
partial protection against embrittlement compared to the more common practice of irradiating 
bone at room temperature. Freezing reduces the mobility of water molecules, and may therefore 
decrease the production of free radicals. Protection of the osteoinductive properties of bone al-
lografts has been observed when irradiation was performed at low temperatures.15 Furthermore, 
the removal of marrow by rinsing the allografts before irradiation may have been favorable, 
since gamma irradiation of human bone allografts alters medullary lipids and releases toxic com-
pounds from osteoblastlike cells.32 Another explanation may be that the osteoinductive capacity 
of bone allografts in impaction grafting may be less important than when implanted in a healthy 
bone bed. Observations on retrieved human allografts suggest that large frozen allografts in 
humans are osteoconductive rather than osteoinductive.33
In summary, we have found no negative effect on graft incorporation after impaction of rinsed 
and subsequently irradiated bone in an unloaded model. Further clinical studies are warranted.
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CHAPTER FIVE
HIGH DOSES OF OP-1 INHIBIT 
FIBROUS TISSUE INGROWTH 
INTRODUCTION
Aseptic loosening is the main reason for total hip arthroplasty (THA) component failure.1 The 
loosening process often is accompanied by progressive bone stock loss around the prosthesis. 
Several reconstruction techniques to deal with this problem have been suggested.2, 3 One of 
these techniques, bone impaction grafting, has become a popular method to restore bone stock 
deficiencies. The intent of this technique is to obtain stable implant fixation, to restore normal 
hip biomechanics, and in the long term, to revitalize bone with restoration of normal bone anat-
omy. Several authors report satisfactory clinical results on the acetabular and femoral sides.4-7
The chance of a reconstruction failure is greatest immediately after the reconstruction when 
the bone graft is not yet incorporated. If the incorporation of bone grafts can be facilitated by 
growth factors, the critical period after a reconstruction with impacted bone grafts might be 
shortened.8-10
Growth factors, such as bone morphogenetic protein-2 (BMP-2), platelet derived growth fac-
tor (PDGF), and osteogenic protein-1 (OP-1 or BMP-7) are well known stimulators of bone 
formation.11-13 However, BMP-2 and OP-1 also stimulate osteoclasts in vitro and PDGF has been 
associated with aseptic loosening of prostheses.14-18 The role of OP-1 in stimulation of osteoclasts 
has not been studied in vivo. Preliminary results of a trial in humans with unstable thoracolum-
bar spine fractures, treated with transpedicular OP-1 transplantation, suggest increased bone 
resorption as a primary event.19 Salkeld et al.,20 using autograft and allograft with OP-1, found 
an accelerated resorption of the graft material but also substantial formation of new bone. 
Moreover, a study by Jensen et al.,21 using impacted mixtures of allograft and OP-1 in a gap 
model around implants in dogs, showed an extensive effect on new bone formation by OP-1, but 
also accelerated graft resorption. The results from these studies suggest OP-1 initially enhances 
osteoclast activity.
Impacted morselized allografts around prostheses serve not only as a bone conductor, but also as 
a mechanical support for the prostheses. Accelerated bone graft resorption before the formation 
of bone may cause loss of stability of the prostheses, resulting in micromotion and ultimately fail-
ure. An often suggested solution would be an osteoconductive material providing initial stability 
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after reconstruction.22-27 Synthetic ceramic calcium phosphate-based materials such as tricalcium 
phosphate (TCP), hydroxyapatite (HA), and biphasic mixtures of these two components are con-
sidered promising materials. TCP and HA are incorporated in a way similar to human bone grafts. 
However, the remodeling process, as being part of the incorporation process, generally takes 
place much slower in TCP/HA.28 The role of BMPs in hip revision surgery then may be to serve as 
a promoter of bone formation when used in combination with slow resorbing or unresorbable 
graft materials, such as TCP/HA particles or bone grafts pretreated with bisphosphonates.29, 30
We attempted to determine if OP-1 promotes the incorporation of impacted morselized allo-
grafts and TCP/HA into host bone, if bone formation is preceded by an initial process of acceler-
ated resorption, and if a dose-related bone graft remodeling response to OP-1 exists.
MATERIALS AND METHODS
We performed two experiments, an allograft experiment and a TCP/HA experiment (Table 1). In 
both experiments, we tested three doses of OP-1 combined with allograft or TCP/HA. In each 
experiment an allograft control was included. For each experiment, 12 mature Dutch milk goats 
(Capra Hircus Sana) (range, 46-55 kg) were obtained from the Central Animal Laboratory, Uni-
versity of Nijmegen, the Netherlands. The goats received three bone chambers at each side in 
the cortical bone of the proximal medial tibia (Fig. 1). The position of implantation among the six 
chambers and the side for each type of chamber were randomized. We observed the animals 
for 4 weeks. All procedures were approved by the Animal Ethics Committee of the University of 
Nijmegen, the Netherlands. In the TCP/HA experiment, one of the groups was used for testing 
another osteoconductive material. Because the outcome was outside the scope of our hypoth-
esis and the outcome of the other groups was not influenced by this particular group, it was 
excluded from the statistical analysis.
We used the bone conduction chamber (BCC), which is a model for membranous ossification 
(Fig. 2).31 The BCC consists of a titanium screw with a cylindrical interior space. It is made up of 
two threaded half-cylinders held together by a hexagonal closed screw cap. The interior of the 
chamber has a diameter of 2 mm, and a length of 7.5 mm. There are two ingrowth openings for 
bone ingrowth located at the bone end of the chamber. Therefore, the ingrowing tissues enter 
the cylindrical space from the bone compartment. The chamber extends far out into the sub-
cutaneous region and the ingrown bone-derived tissue can fill the chamber without competing 
with other tissues. Thus, the tissue ingrowth distance from the holes toward the other end of the 
chamber can be used to estimate tissue regeneration. The shape of the chamber makes it easy to 
distinguish areas for histomorphometry.32 The tissue ingrowth distance can be increased by plac-
ing an osteoconductive material, such as a bone graft, in the chamber. Originally developed as a 
rat model, the BCC was adjusted for use in goats.33 The threaded end of the implant is screwed 
into the bone, so that the ingrowth openings are in direct contact with the endosteal transition 
from marrow into bone. To accomplish this in goats, a 1 mm thick disk was inserted into the cap 
to lower the ingrowth openings through the cortex.
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Fig. 1
A radiograph shows implanted bone chambers in the proximal medial tibia of the goat.
Fig. 2
A schematic drawing shows the bone conduction chamber. A 1 mm thick disk was inserted into the cap to lower the ingrowth 
openings through the cortex. New bone and fibrous tissue are shown growing into the graft. Unremodeled graft is seen at the 
top of the chamber. 
Fig. 1 Fig. 2
Overview of experimental design
Experiment    Group OP-1 Collagen carrier 
     (µg)  (mg) 
“Allograft experiment”   Allograft - -
    Allograft + OP-1 [1] 0.83 0.24
  Allograft + collagen carrier [1] 0 0.24
    Allograft + OP-1 [2] 2.5 0.72
    Allograft + OP-1 [3] 25 7.2
  Allograft + collagen carrier [3] 0 7.2
“TCP/HA experiment”   Allograft - -
    TCP/HA - -
    TCP/HA + OP-1 [1] 0.83 0.24
    TCP/HA + OP-1 [2] 2.5 0.72
    TCP/HA + OP-1 [3] 25 7.2
Table 1
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We obtained cancellous allografts from the sternum of six donor goats. Familial bands between 
donor and recipient goats were excluded. To prevent bias from different immunologic reactions, 
the allografts were pooled. Most blood and marrow were removed by rinsing the grafts with 
saline for approximately 1 min, leaving only a white bone structure. Rinsing was done using a 
high-pressure pulsatile lavage system (SurgiLav Plus, Stryker Nederland BV, Waardenburg, the 
Netherlands). The grafts were in a sieve during rinsing, and then were stored at -80 °C until use. 
Cultures from the grafts were negative. Before implantation, the grafts were thawed at room 
temperature and cut in 2x2x1 mm pieces by using a rongeur.
The TCP/HA particles were composed of 20% HA [Ca10(PO4)6(OH)2] and 80% TCP [Ca3(PO4)2] 
(BoneSave, Stryker Howmedica Osteonics, Limerick, Ireland). We used granules with a diameter 
of 2 to 4 mm. The TCP/HA granules have a 50% non-interconnected macroporosity (range, 
300-600 µm), which is produced by burning sacrificial carbonaceous filler during sintering. The 
granules are also microporous (range, 5-80 µm) (porosity values derived from Stryker Orthopaed-
ics). Before use, the TCP/HA particles were crushed to fit in the BCC and subsequently soaked 
in saline for 30 min.
The recombinant human osteogenic protein-1 (rhOP-1) device (Stryker Biotech, Hopkinton, MA, 
USA) was supplied sterile for implantation and consisted of 3.5 mg rhOP-1 combined with 1000 
mg highly purified bovine bone-derived type I collagen. Immediately after warming to room 
temperature, the rhOP-1 device was mixed with a preweighed amount of allograft chips before 
impaction. The BCC volume was 23.56 mm3, which allowed 0.0325 g of allograft chips and 
0.0163 g of TCP/HA particles to be impacted in each implant.
We tested three doses of the rhOP-1 device, a low-dose OP-1 (0.83 µg/implant), a medium-dose 
OP-1 (2.5 µg/implant), and a high-dose OP-1 (25 µg/ implant). The medium dose (2.5 µg/ im-
plant) would correspond to approximately one OP-1 device combined with one ordinary femoral 
head. According to the instructions of the manufacturer, this is the intended dose for bone im-
paction grafting. We tested two doses of collagen carrier, a low-dose collagen carrier (0.24 mg/
implant) and a high-dose collagen carrier (7.22 mg/implant), which equals the amount of carrier 
used in the low-dose OP-1 and high-dose OP-1 groups described above.
We performed impaction in the chambers by gradually filling the BCC with the allograft bone/
OP-1 mixes or TCP/HA particles/OP-1 mixes. We used a piston, slightly in smaller diameter, for 
impaction. The piston was guided by low-friction bearings, strictly limiting it to vertical move-
ment.32 The BCC was clamped into a cylindrical holder. A constant force of 40 N was kept on the 
free end of the piston for 2 min. During this time, fluid could escape between the piston and the 
wall of the bone chamber and the ingrowth openings. The applied pressure was calculated to be 
12.5 MPa. The plate was placed in the hexagonal closed screw cap and the cap was screwed on 
the two threaded half-cylinders.
The goats were anesthetized by intravenous administration of sodium pentobarbital (Nembutal, 
CEVA Santé Animale, Maassluis, the Netherlands) (0.5 ml/kg) and maintained after intubation 
with nitrous oxide, oxygen, and isoflurane (1.5-2%). Under aseptic conditions, a longitudinal 
incision was made in the skin and fascia over the medial side of the proximal tibia. After raising 
the periosteum, a hole was drilled through the medial cortex approximately 4 cm from the joint 
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cleft using a 3.1 mm drill. The hole was tapped and bone debris from drilling was removed. The 
bone chamber was screwed in manually. The other bone chambers were placed 10 mm from the 
others. This was repeated for the other side.
The subcutaneous layer and the skin were sutured. All animals were allowed unrestricted movement 
in their cages and had free access to water and food after the operation. After the implantation 
procedure the animals received subcutaneous ampicillin (Albipen LA, Intervet International BV, 
Boxmeer, the Netherlands) (15 mg/kg/48 hours) three times.
After 4 weeks all goats were sacrificed with an overdose of sodium pentobarbital (Nembutal, 
1 ml/kg). Tibiae were removed, and the bone chambers with surrounding cortex were fixed in 
4% buffered formalin. After one day, the contents were removed from the chambers and fixed 
in 4% buffered formaldehyde, dehydrated using ethanol, and embedded in polymethylmeth-
acrylate (PMMA). Specimens from the TCP/HA experiment were decalcified using 25% ethyl-
enedinitrilo tetraacetic acid (EDTA) in 0.1 mol/l phosphate buffer (pH 7.4) before dehydration. 
The specimens were cut with a microtome (Leica RM 2155, Leica Microsystems Nederland BV, 
Rijswijk, the Netherlands) parallel to the longitudinal axis of the chamber. Sections were taken 
at 0, 300, and 600 µm from the center of the BCC specimens,31 each section 5 µm thick. All 
sections in each experimental group were investigated in random order. The tests were blinded, 
but it was possible to see whether a specimen contained allograft or TCP/HA. The sections were 
stained with hematoxylin and eosin, Goldner-Masson trichrome, and tartrate resistant acid phos-
phatase (TRAP) for routine histology.
Histomorphometric analysis was performed by using interactive computer-controlled image 
analysis (analySIS, Soft Imaging System GmbH, Münster, Germany). The bone ingrowth distance 
in each slide was calculated by dividing the new bone area by the width of the specimen. In all 
specimens, marrow cavities surrounded by bone were included in the bone area. The mean of 
the three sections at 0, 300, and 600 µm from the center yielded a value for each specimen. 
The total tissue ingrowth distance, which is the distance from the ingrowth end to the fibrous 
ingrowth frontier, was measured in the same way as bone ingrowth.31
Statistical analysis was performed using a univariate analysis of variance (SPSS Inc, Chicago, IL, 
USA) with the factors goat, side, position, and graft type. To isolate the different groups, we used 
Tukey’s multiple comparison procedure. Normality and homogeneity of variance were tested us-
ing Kolmogorov-Smirnov’s and Levene’s tests. When the assumption of normality or homogene-
ity of variance was not met, a Friedman Repeated Measures ANOVA on Ranks (nonparametric 
test) was performed. In both experiments an allograft control was included. Therefore, we were 
able to compare the difference in bone and fibrous tissue ingrowth between equal OP-1-dosed 
groups by comparing the differences between the OP-1 groups and their allograft controls.
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RESULTS
No intraoperative complications occurred during surgery. All goats recovered fully after surgery, 
were standing within 1 day, and had a normal gait pattern within 3 days after surgery. There 
were no signs of inflammation, skin ulceration, or wound healing problems. All bone chambers 
were strongly fixed into the tibia. In most cases, the bone chambers were surrounded with a 
layer of callus and covered with fibrous tissue, regardless of the contents of the chamber. No 
new bone formation was seen at the endosteal surface of the tibial cortex.
The incorporation process of impacted morselized allografts and TCP/HA was not promoted by 
OP-1. A layer of necrotic, nonvascularized graft remnants or TCP/HA granules were present in 
the top of the chamber, with fibrous tissue infiltration or only graft material as was inserted. In 
the allograft and TCP/HA groups, a well vascularized loose mesenchymal-like tissue with numer-
ous blood sinusoids and capillaries penetrated the graft material. In the OP-1 and carrier (col-
lagen particles) groups, a denser fibrous tissue was observed. These groups showed a sharply 
defined ingrowth frontier, where the fibrous tissue was organized more loosely at the transition 
with the allograft and TCP/HA remnants. However, in general, no accumulation of plasma cells, 
lymphocytes, or polymorphonuclear cells was seen in OP-1 and non-OP-1 groups. After 4 weeks, 
newly formed bone was present in part of the bone chambers (Table 2). New bone was formed by 
intramembranous ossification, mainly at the level of the ingrowth openings, sometimes growing 
upward halfway into the chamber. If the resorption of the graft remnant was not complete (as 
seen with the TCP/HA cases), new bone was deposited on these remnants (Fig. 3). Active osteob-
lasts and osteoid were seen. No cartilage was seen. Regardless of group or OP-1 dose, in some 
sparse cases, we found a direct contact between newly formed bone and collagen particles. In 
the allograft experiment, bone ingrowth was higher in the allograft with low-dose OP-1 (p = 
0.019) and the allograft with medium-dose OP-1 (p = 0.038) compared with the allograft with 
high-dose collagen carrier (Table 3, Fig. 4). However, we observed no difference in bone ingrowth 
between the groups tested in the TCP/HA experiment (Table 3, Fig. 5).
Bone formation was not preceded by an initial process of accelerated resorption. At the ingrowth 
front mainly osteoclasts were present as indicated by the TRAP staining. Thus, osteoclasts invad-
ed the grafts clearly ahead of bone ingrowth. After the passage of the ingrowth front, resorbing 
cells disappeared from the stroma. Multinucleated giant cells were seen only occasionally, close 
to the resorption front, in the fibrous tissue. In the OP-1 and collagen carrier groups, the osteo-
clasts were aligning the sharp defined ingrowth front, where in the non-OP-1 groups (controls) 
the osteoclasts were distributed over the more loosely organized ingrowth front (Fig. 6). However, 
the number of osteoclasts per bone-resorbing surface seemed similar. In most cases, allografts 
totally resorbed behind the ingrowth front. In some sparse cases, regardless of group or OP-1 
dose, allograft was not totally resorbed and new bone was deposited on the graft remnants. The 
TCP/HA granules showed no signs of resorption in the form of presence of resorption pits. How-
ever, TCP/HA granules/particles were surrounded by TRAP-positive cells (osteoclasts and multi-
nucleated giant cells) (Fig. 6). In addition, very small TCP/HA particles (< 1 mm) were engulfed in 
mononuclear macrophage-like cells. 
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Number of bone chambers showing bone formation after 4 weeks
Experiment   Group Total  Bone No bone 
     formation  formation
    (n) (n) (n) 
“Allograft    Allograft 12 10 2
experiment”   Allograft + OP-1 [1] 12 9 3
  Allograft + collagen carrier [1] 12 9 3
   Allograft + OP-1 [2] 12 9 3
   Allograft + OP-1 [3] 12 5 7
  Allograft + collagen carrier [3] 12 5 7
“TCP/HA experiment”  Allograft 12 9 3
   TCP/HA 12 8 4
   TCP/HA + OP-1 [1] 12 11 1
   TCP/HA + OP-1 [2] 12 9 3
   TCP/HA + OP-1 [3] 12 5 7
Table 2
Histomorphometric results
Experiment    Group Fibrous tissue Bone  
      (mm) (mm)
“Allograft experiment”   Allograft 3.02±0.83 0.20±0.25
    Allograft + OP-1 [1] 2.89±0.94 0.59±0.78
  Allograft + collagen carrier [1] 2.81±0.82 0.20±0.29
    Allograft + OP-1 [2] 2.17±0.86 0.44±0.42
    Allograft + OP-1 [3] 1.30±0.66 0.26±0.49
  Allograft + collagen carrier [3] 1.68±0.66 0.06±0.11
“TCP/HA experiment”   Allograft 4.43±1.10 0.46±0.74
    TCP/HA 4.75±1.36 0.56±0.59
    TCP/HA + OP-1 [1] 3.82±0.83 0.66±0.42
    TCP/HA + OP-1 [2] 2.47±0.80 0.42±0.41
    TCP/HA + OP-1 [3] 1.50±0.42 0.24±0.41
Values are mean ± standard deviation
Table 3
bone_impaction_grafting_02.indd   71 21.04.2008   13:04:26 Uhr
72
Treatment type
In
g
ro
w
th
 d
is
ta
n
ce
 (
m
m
)
Fig. 4
Fibrous tissue Bone
Treatment type
In
g
ro
w
th
 d
is
ta
n
ce
 (
m
m
)
Fig. 5
Fibrous tissue Bone
Fig. 3
A typical example of remodeling and 
incorporation of TCP/HA granules is 
shown. Newly formed bone (NB) was 
deposited on TCP/HA granules (TCP/HA) 
(Stain, hematoxylin and eosin; original 
magnification, x100). 
FT = fibrous tissue.
Fig. 3
Fig. 4
Boxplot showing the histomorphometric 
results of the allograft experiment 
including the ingrowth distances 
of fibrous tissue and bone for each 
treatment group. The OP-1 device doses 
included: [1] 0.83 µg OP-1 combined 
with 0.24 mg collagen carrier per 
implant; [2] 2.5 µg OP-1 combined with 
0.72 mg collagen carrier per implant; 
and [3] 25 µg OP-1 combined with 7.2 
mg collagen carrier per implant. 
The collagen carrier doses included: 
[1] 0.24 mg collagen carrier per 
implant; and [3] 7.2 mg collagen carrier 
per implant.
Fig. 5
Boxplot showing the histomorphometric 
results of the TCP/HA experiment 
including the ingrowth distances 
of fibrous tissue and bone for each 
treatment group. The OP-1 device doses 
included: [1] 0.83 µg OP-1 combined 
with 0.24 mg collagen carrier per 
implant; [2] 2.5 µg OP-1 combined with 
0.72 mg collagen carrier per implant; 
and [3] 25 µg OP-1 combined with 7.2 
mg collagen carrier per implant.
TCP/HA
NB
FT
FT
TCP/HA
NB
TCP/HA
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Fig. 6
Typical examples of bone chamber 
content after 4 weeks are shown 
(a,c,e). The details show the presence 
and position of TRAP-positive cells 
(b,d,f). (a) Loosely organized fibrous 
tissue (FT) can be seen penetrating 
the graft material (GR) in the allograft 
groups. (b) Osteoclasts (arrows) were 
distributed over the loosely organized 
ingrowth front. (c) In contrast, a sharply 
defined ingrowth front was shown in 
the OP-1 and carrier groups in allograft 
and TCP/HA groups. (d) Osteoclasts 
(arrows) aligned the sharply defined 
ingrowth front. (e) Loosely organized 
fibrous tissue penetrated the TCP/
HA control group granules (TCP). 
(f) The TCP/HA granules (TCP) were 
surrounded by TRAP-positive cells 
(arrows) (Stain, hematoxylin and eosin; 
original magnification, x12.5 (a,c,e); 
Stain, TRAP; original magnification, 
x100 (b,d,f)).
Fig. 6a
Fig. 6c
Fig. 6e
Fig. 6b
Fig. 6d
Fig. 6f
GR
FT
GR
FT
TCP
FT
GR
GR
GR
FT
GR
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At the level of the ingrowth front, we found resorption of the collagen particles as indicated 
by the presence of osteoclasts adjacent to the particles. The collagen particles did not seem to 
behave different than the bone grafts.
We observed a dose-related remodeling response to OP-1. An increase in OP-1 dose resulted in 
an inhibition of fibrous tissue formation. Fibrous tissue penetration into the graft decreased with 
an increase in OP-1 or carrier concentration. Depending on the OP-1 dose tested, more or less 
collagen carrier particles were entrapped in the spaces between the impacted grafts or TCP/HA 
particles (Fig. 7). Fibrous tissue penetration into the graft seemed to be the highest in the allograft 
and TCP/HA groups without OP-1 added. This was confirmed by our histomorphometric data. 
The TCP/HA with the high-dose OP-1 (25 µg) showed less (p < 0.001) fibrous tissue ingrowth 
compared with the TCP/HA with the medium-dose OP-1 (2.5 µg). The TCP/HA with the medium-
dose OP-1 showed less (p = 0.003) fibrous tissue ingrowth than the TCP/HA with the low-dose 
OP-1 (0.833 µg). The allograft, TCP/HA, and TCP/HA with the low-dose OP-1 (0.833 µg) showed 
similar fibrous tissue ingrowth (Table 3, Fig. 4). Similar results were found in the allograft experi-
ment. Fibrous tissue ingrowth in the allograft with medium-dose OP-1 did not differ from the 
allograft with low-dose OP-1 (p = 0.176), whereas the allograft with the high-dose OP-1 showed 
less (p < 0.001) fibrous tissue ingrowth compared with the allograft with low-dose OP-1. The 
OP-1 carrier groups and their OP-1–supplemented counterparts were similar, as was the fibrous 
tissue ingrowth between allograft, allograft with low- and medium-dose OP-1, and allograft 
with low-dose collagen carrier (Table 3, Fig. 5). We observed no differences in bone and fibrous 
tissue ingrowth for allograft and TCP/HA with equal OP-1 doses.
Fig. 7
A dose-dependent response to OP-1 on the incorporation process was found. Depending on the OP-1 dose tested, more or less 
collagen carrier was entrapped in the spaces between the impacted graft. Type I collagen carrier particles (CC) are shown trapped 
between the impacted allografts. Typical examples of (a) low-dose OP-1 and (b) high-dose OP-1 are shown (Stain, Goldner-
Masson trichrome; original magnification, x50).
Fig. 7a Fig. 7b
CC
CC
CC
CC
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DISCUSSION
The addition of OP-1 to allograft bone may hasten incorporation and remodeling, including an 
initial process of accelerated resorption. Accelerated resorption before the formation of bone 
may have negative consequences for bone impaction grafting because this may compromise 
implant fixation. An osteoconductive material, resistant to resorption and able to provide initial 
stability after reconstruction combined with growth factors would be a solution. We investigated 
the early effect of an OP-1 device on the incorporation process of impacted morselized allografts 
and TCP/HA. Because BMP-7 is combined with a collagen carrier in the OP-1 device, we also 
studied the effects of the carrier on the incorporation process.
The effect of growth factors on bone conductive materials usually is seen at an early stage dur-
ing bone ingrowth. It is difficult to find the right time to measure these effects, if new ingrown 
bone rapidly fills the defect. Therefore, we used the bone conduction chamber, a bone chamber 
model that is never completely filled with ingrown bone.31, 33, 34 The final amount of ingrown 
bone in the chambers can be used to measure the effects of growth factors on bone formation. 
Extrapolation of results of studies with bone conduction chambers to clinical recommendations 
should be made carefully, because factors like vascularity and composition of the host bone bed, 
its interaction with the bone graft, loading conditions, and surrounding tissue are not included 
in this study. However, the chamber with its limitations has been used extensively, therefore we 
think it is valid for detecting the effects of bone substitutes and signaling molecules that arise 
under unloaded conditions. It has been suggested that the BCC can be regarded as a bone tissue 
culture in vivo.35, 36 In our opinion, the BCC should be interpreted at that level in the hierarchy 
of experimental models.
Osteogenic proteins require a viable cell source, vascularity, and mechanical stability to induce 
bone formation and remodeling.37 In several studies with positive results from BMP-2 and BMP-7, 
considerable surgical trauma was present before the introduction of the BMP.20, 38-42 Trauma 
such as a fracture or an osteotomy will release endogenous factors that activate migration of 
inflammatory cells and cells of mesenchymal origin, which can respond to the applied BMP and 
stimulate bone formation.43 Our approach involved minimal surgical trauma which may explain 
the absence of this effect. This explanation also was suggested by Jeppsson and Aspenberg,44 
and Franke Stenport et al.45 in similar studies using titanium implants. In addition, Bostrom et 
al.,46 showed trauma (micromotion) switched the response to BMP-2 from inhibition toward 
stimulation of bone formation.
The migration of cells into the impacted allograft is compromised and vascularization is delayed 
for several weeks.3 This delayed ingrowth after impaction may be related to physical factors, 
such as the size and numbers of pores for tissue intrusion into the material.47 The available 
volume for tissue ingrowth might have been decreased by the impaction of TCP/HA particles, 
creating small TCP/HA particles between the larger ones.48 Furthermore, by using higher doses 
of the OP-1 device, more collagen carrier material was impacted between the graft material, also 
filling up the space and thereby delaying tissue ingrowth and remodeling.
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If the collagen carrier needs extensive exposure to macrophages and other cells to release the 
active substance in a proper way,45 the compromised migration of cells into the impacted al-
lograft and the delayed vascularization might have delayed the release of OP-1 from the carrier. 
This might explain the lack of difference in bone and tissue ingrowth between the bovine type I 
collagen carrier groups without OP-1 and their OP-1 added counterparts. An alternative explana-
tion could be that a considerable amount of OP-1 was released from the carrier by the process 
of impaction. The amount of early release may be dependent on the carrier system used.49 This 
makes it interesting to compare the results of this study with results of studies in which OP-1 
was combined with graft without a carrier system. In a similar bone chamber model in rats, using 
a dose similar to our lowest dose without a collagen carrier (OP-1 solution) in impaction graft-
ing, Tägil et al.34 found an increase in bone formation. In contrast, studies using an OP-1 device 
(with collagen carrier) in combination with impaction grafting showed no or a very moderate 
effect on bone ingrowth.50, 51 Moreover, using an OP-1 solution in a weightbearing rabbit knee 
impaction grafting model, Tägil et al.26 showed no augmentation of morselized impacted bone 
graft. In addition, the influence of OP-1 on impacted allograft implants recently was investigated 
experimentally in loaded, primary, and impaired revision settings.10 Under primary conditions, 
using OP-1 solution decreased mean implant fixation; in contrast, under the impaired healing 
conditions of the revision setting, OP-1 increased incorporation and fixation of the implants. In 
addition to the dose and carrier system, setting and/or application seems to be important.
In the impaction grafting setting, grafts also seem able to withstand the forces acting on them 
during revascularization and remodeling. Histologic studies show that full replacement of the 
grafts by new bone does not always take place.52-53 Instead, a mixed pattern of living bone and 
areas of dead graft in a fibrous tissue stroma often is seen. The addition of ingrowing fibrous 
tissue, with collagen fibers winding between the graft chips might lead to a higher resistance 
to shear and affect the rate of prosthetic migration. It seems the delayed or reduced new bone 
ingrowth seen in experiments with impaction therefore, is less important and even may be ben-
eficial, as long as the graft/fibrous tissue composite remains strong enough to withstand forces 
acting on it during remodeling.54 In our case, using an OP-1 device also delayed the fibrous tissue 
ingrowth. Our data suggest the observed early failures in impaction grafting in combination with 
high doses of OP-1 device could be attributable to the lack of reinforcement by fibrous tissue and 
not necessarily because of an increase in resorption and remodeling.
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CHAPTER SIX
EFFECTS OF OP-1 DEVICE ON THE 
INCORPORATION PROCESS
INTRODUCTION
Growth factor-enhanced allograft incorporation could improve clinical outcome after hip revi-
sion surgery by accelerating new bone formation and thereby improving implant stability.1 Bone 
morphogenetic proteins (BMPs) provide an opportunity to achieve faster and more extensive 
remodeling.2 They stimulate bone formation and graft remodeling.3, 4 However, also BMP stimu-
lated bone resorption has been observed both in vitro and in vivo.5-9 Accelerated resorption may 
have negative consequences for bone impaction grafting, since resorption before the formation 
of bone may compromise implant fixation. One solution would be an osteoconductive material 
providing initial stability after reconstruction.10-12 The role of BMPs in hip revision surgery might 
then be to serve as a promotor of bone formation in combination with a slow resorbing or un-
resorbable graft material.13, 14
In a previous study, we investigated the early effects of osteogenic protein-1 (OP-1) device on the 
incorporation of impacted morselized cancellous bone and tricalcium phosphate/hydroxyapatite 
(TCP/HA) in an unloaded bone chamber in goats.15 After 4 weeks, new bone formation was not 
promoted by the OP-1 device, and there were also no signs of accelerated resorption. However, 
a dose-related inhibition of vascularization and fibrous tissue ingrowth was found. In general, in 
impacted bone grafts, the migration of cells within the allograft is compromized and vasculariza-
tion is delayed for several weeks.16-18 In an unloaded bone chamber in rats, at 6 weeks the bone 
ingrowth into densely impacted allografts was delayed relative to bone ingrowth in allografts 
that had not been impacted.19 By adding OP-1 solution to the impacted bone grafts in the same 
unloaded model, bone ingrowth increased dramatically.4 In contrast, in our previous study the 
collagen carrier might initially have further delayed bone and fibrous tissue ingrowth into the 
impacted graft material by filling up the space between the impacted graft material.15
Thus, although the collagen type I carrier may not be optimal for use in bone impaction grafting, 
in clinical cases better late ingrowth may appear despite an early delay.20 The present study was 
designed to determine whether the decrease in ingrowth represented a final loss or was just a 
delay. If the latter, could the OP-1 device overcome this initial delay and did this ultimately result 
in a better late ingrowth?
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ANIMALS AND METHODS
EXPERIMENTAL DESIGN
12 mature Dutch milk goats (Capra Hircus Sana) (range, 40–56 kg) were obtained from the 
Central Animal Laboratory, Radboud University Nijmegen, the Netherlands. The goats received 
3 bone chambers on each side in the cortical bone of the proximal medial tibia. The side and 
position of implantation of the 6 chambers were randomized. Two concentrations of OP-1 device 
were tested in combination with allografts and TCP/HA. Allografts not treated with OP-1 and 
TCP/HA served as controls (Table 1). The observation time was 8 weeks. All procedures were ap-
proved by the Animal Ethics Committee of the Radboud University Nijmegen.
BONE CONDUCTION CHAMBER
The bone conduction chamber (BCC) consists of a threaded titanium cylinder, formed from 
two half-cylinders held together by a hexagonal closed screw cap.21 One end of the implant is 
screwed into the bone. The interior of the chamber has a diameter of 2 mm and a length of 
7.5 mm. There are two ingrowth openings for bone ingrowth located at the bone-end of the 
chamber.
Thus, the ingrowing tissues enter the cylindrical space from the bone compartment. Originally 
developed as a rat model, the BCC was adjusted for use in goats.22 Since the tibial cortex in rats 
is thinner than that in goats, a 1 mm disk was placed in the cap of the BCC to provide for loca-
tion of the ingrowth holes of the chamber to be deeper down, just at the level of the endosteum 
after the implant is screwed in (Fig. 1).
Overview of experimental design
Treatment groups     Dose OP-1 device Implants
   (µg OP-1/mg collagen) (n)
Allograft     -/- 12
Allograft+OP-1[1]     0.83/0.24 12
Allograft+OP-1[2]     2.5/0.72 12
TCP/HA     -/- 12
TCP/HA+OP-1[1]     0.83/0.24 12
TCP/HA+OP-1[2]     2.5/0.72 12
Table 1
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IMPLANT MATERIALS
Cancellous allografts were obtained from the sternum of six donor goats. Familial bands be-
tween donor and recipient goats were excluded. To prevent bias because of different immuno-
logic reactions, the allografts were pooled.
Most blood and marrow was removed by rinsing the grafts with saline for approximately 1 min, 
leaving only a white bone structure. Rinsing was done using a high-pressure pulsatile lavage 
system (SurgiLav Plus, Stryker Nederland BV, Waardenburg, the Netherlands). The grafts were 
in a sieve during rinsing. They were stored at -80 °C until use. Bacterial cultures from the grafts 
were negative. Before implantation, the grafts were thawed at room temperature and cut into 
pieces by using a rongeur.
The TCP/HA particles were composed of 20% HA (Ca10(PO4)6(OH)2) and 80% TCP (Ca3(PO4)2) 
(BoneSave, Stryker Howmedica Osteonics, Limerick, Ireland). We used granules with a diam-
eter of 2-4 mm. The TCP-HA granules have a 50% non-interconnected macroporosity (range, 
300-600 µm), which is produced by burning sacrificial carbonaceous filler during sintering. The 
granules are also microporous (range, 5–80 µm) (porosity values obtained from Stryker Ortho-
paedics). Before use, the TCP/HA particles were crushed to fit into the BCC and subsequently 
soaked in saline for 30 min.
GRAFT PREPARATION
The rhOP-1 device (Stryker Biotech, Hopkinton, MA, USA) was supplied sterile for implantation 
and consisted of 3.5 mg recombinant human osteogenic protein-1 (rhOP-1) combined with 1 g 
of highly purified bovine bone-derived type I collagen.
Immediately after warming to room temperature, the rhOP-1 device was mixed with a pre-
weighed quantity of allograft chips before impaction. The BCC volume is 23.56 mm3, which 
allowed 0.0325 g of allograft chips and 0.0163 g of TCP/HA particles to be impacted in each 
implant. Two doses of rhOP-1 device were tested, a low-dose OP-1 (0.83 µg/implant) and a 
high-dose OP-1 (2.5 µg/implant). The high dose (2.5 µg/implant) would correspond to about 
one OP-1 device combined with one ordinary femoral head. According to the instructions of the 
manufacturer, this was the intended dose for bone impaction grafting.
Fig. 1
The bone conduction chamber. The chamber consists of two 
threaded half-cylinders held together by a cylindrical closed 
screw cap. There are ingrowth openings at the endosteal level. 
A 1 mm thick disk was inserted into the cap to lower the 
ingrowth openings through the cortex. New bone and fibrous 
tissue are shown growing into the graft. Unremodeled graft 
can be seen at the top of the chamber. 
Fig. 1
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IMPACTION PROCEDURE
Impaction was performed by gradually filling the BCC with the allograft bone/OP-1 mixtures or 
TCP/HA particles/OP-1 mixtures. A piston of a slightly smaller diameter was used for impaction.23 
The piston was guided by low-friction bearings, strictly limiting it to vertical movement. The 
BCC was clamped into a cylindrical holder. A constant force of 40 N was kept on the free end 
of the piston for 2 min. During this time, fluid could escape between the piston and the wall of 
the bone chamber, and the ingrowth openings. The pressure applied was calculated to be 12.5 
MPa. The disk was placed on the two threaded half-cylinders and the hexagonal closed screw 
cap was screwed on.
SURGICAL TECHNIQUE
The goats were anesthetized by intravenous administration of sodium pentobarbital (0.5 ml/kg) 
and maintained after intubation with nitrous oxide, oxygen and isoflurane (1.5-2%). Under asep-
tic conditions, a longitudinal incision was made in the skin and fascia over the medial side of 
the proximal tibia. After raising the periosteum, the cortical bone was observed and a hole was 
drilled through the medial cortex at approximately 4 cm from the joint cleft using a 3.1 mm 
drill. The hole was tapped and bone debris from drilling was removed. The bone chamber was 
screwed in manually. The other bone chambers were placed 10 mm from the others. This was 
repeated for the other side. The subcutaneous layer and the skin were sutured. All animals 
were allowed unrestricted movement in their cages and had free access to water and food after 
the operation. After the implantation procedure, the animals received subcutaneous ampicillin 
(15 mg/kg/48 h) three times. After 8 weeks, all goats were killed with an overdose of sodium 
pentobarbital. 
EVALUATION
All specimens were fixed in 4% buffered formaldehyde, dehydrated using ethanol, and embed-
ded in polymethylmetacrylate (PMMA). They were decalcified using 25% EDTA in 0.1 mol/l phos-
phate buffer (pH 7.4) before dehydration. The specimens were cut with a microtome (Leica RM 
2155, Leica Microsystems Nederland BV, Rijswijk, the Netherlands) parallel to the longitudinal 
axis of the chamber. From each specimen, a total of 5 sections were taken at 0, 300 and 600 
µm from the center of the specimen, each section being 5 µm thick. All sections within each ex-
perimental group were investigated in random order. The tests were done blind, but it was pos-
sible to see whether a specimen contained allograft or TCP/HA. The sections were stained with 
hematoxylin and eosin (HE), Goldner-Masson trichrome, and tartrate-resistant acid phosphatase 
(TRAP) for routine histology. Histomorphometric analysis was performed by using interactive 
computer-controlled image analysis (analySIS, Soft Imaging System GmbH, Münster, Germany). 
The bone ingrowth distance in each slide was calculated by dividing the new bone area by the 
width of the specimen.21 In all specimens, marrow cavities surrounded by bone were included in 
the bone area. The total tissue ingrowth distance, which is the distance from the ingrowth end 
to the fibrous ingrowth frontier, was measured in the same way as bone ingrowth. The mean of 
5 sections yielded a value for each specimen.
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STATISTICS
Statistical analysis was performed using a univariate analysis of variance (SPSS Inc., Chicago, IL, 
USA) with factors goat, side, position and graft type. To identify the group or groups that dif-
fered from the others, Tukey’s multiple comparison procedure was used. Normality and homog-
enity of variance were tested using the Kolmogorov-Smirnov test and the Levene test. When the 
assumption of normality or homogenity of variance was not met, a Friedman repeated measures 
ANOVA on ranks (non-parametric test) was performed. This study was designed to have 80% 
power of detecting a difference of 0.5 mm between the means of all groups.
RESULTS
CLINICAL
No intraoperative complications occurred during surgery. All goats recovered fully after surgery, 
were standing within one day, and had a normal gait pattern within three days after surgery. 
There were no signs of inflammation, skin ulceration, or wound-healing problems. All bone 
chambers were strongly fixed into the tibia. In most cases the bone chambers were surrounded 
by a layer of callus and covered with fibrous tissue, irrespective of the contents of the chamber. 
No new bone formation was seen at the endosteal surface of the tibial cortex.
HISTOLOGY
A layer of necrotic, non-vascularized graft remnant was present at the top of the chamber, either 
with fibrous tissue infiltration or only graft material as it was inserted. Fibrous tissue was present 
between the new bone at the bottom of the chamber and the graft remnant at the top of the 
chamber (Fig. 2a). This fibrous tissue preceded the front of bone ingrowth. A loose mesenchymal-
like tissue with blood sinusoids and capillaries penetrated the graft material.
Newly formed bone was present in all bone chambers. New bone was formed by intramembra-
nous ossification, with growth upward into the chamber. The amount and appearance of the 
new bone varied between specimens—from young, woven bone surrounded by active osteo-
clasts to more mature lamellar bone with fatty marrow and trabeculae (Fig. 2b). No resorption of 
the graft material was observed in the TCP/HA-filled chambers (Fig. 2c). Apposition of new bone 
on the TCP/HA was observed in all TCP/HA-filled chambers (Fig. 2d). No collagen carrier material 
could be seen filling up the spaces between the impacted graft materials.
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Fig. 2
(a) Typical examples of the bone chamber content of allograft control (left) and allograft with high-dose OP-1 (right). Graft 
remnants (GR) are still present in the top of the specimen. New bone (NB) formation takes place from the ingrowth openings 
upward to the top of the chamber. Fibrous tissue (FT) precedes the front of bone ingrowth. Hematoxylin-eosin stained section. 
Magnification: x12.5. (b) Detail of allograft with high-dose OP-1 specimen showing newly formed bone at the bottom of the 
chamber. There were no differences in appearance of newly formed bone between the controls and either low-dose or high-dose 
OP-1 specimens. Hematoxylin-eosin stained section. Magnification: x100. (c) Typical examples of the bone chamber content of 
TCP/HA control (left) and TCP/HA (TCP) with high-dose OP-1 (right). There are TCP/HA granules throughout the entire specimen. 
New bone (NB) formation takes place from the ingrowth openings upward to the top of the chamber. Fibrous tissue precedes the 
front of bone ingrowth. New bone is apposited on the TCP/HA granules at the bottom of the chamber. Hematoxylin-eosin stained 
section. Magnification: x12.5. (d) Detail of TCP/HA specimen with high-dose OP-1 showing new bone (NB) apposited on the TCP/
HA granules at the bottom of the chamber. There were no differences in appearance of newly formed bone between the controls 
and either low-dose or high-dose OP-1 specimens. Hematoxylin-eosin stained section. Magnification: x100.
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Fig. 3
Ingrowth distances of fibrous tissue and bone for each treatment group, depicted in a boxplot. The doses of OP-1 device 
included: [1] 0.83 µg OP-1 combined with 0.24 mg collagen carrier per implant, and [2] 2.5 µg OP-1 combined with 0.72 mg 
collagen carrier per implant. 
HISTOMORPHOMETRY
Neither side (p = 0.6 and p = 0.1) nor position (p = 0.9 and p = 0.2) of the chamber affected 
bone or total tissue ingrowth, respectively. There was no interaction between factors. The ad-
dition of OP-1 device to allografts at either low dose (p = 0.04) or high dose (p = 0.02) gave 
increased total tissue ingrowth distances compared to the allograft control. The use of TCP/HA 
either with or without the addition of OP-1 device did not result in any differences in total tissue 
ingrowth. However, total tissue ingrowth distance was significantly less in the allograft control 
than in the TCP/HA control (p = 0.02). OP-1 had no effect on bone ingrowth distance relative 
to the controls for both allografts and TCP/HA (Fig. 3). However, high-dose OP-1 mixed with al-
lograft gave significantly more bone ingrowth than the TCP/HA control (p = 0.004).
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DISCUSSION
Within impacted bone chips, the migration of cells into the impacted allograft is compromised 
and vascularization is delayed for several weeks. It seems, however, that delayed or reduced new 
bone ingrowth seen in experiments with impaction is less important and may even be beneficial, 
as long as the graft/fibrous tissue composite remains strong enough to withstand forces acting 
on it during remodeling.24 In a previous study, impaction of cancellous bone grafts and a TCP/
HA bone substitute mixed with OP-1 device led to reduced fibrous tissue ingrowth as seen after 
4 weeks.15 Using higher doses of the OP-1 device, more collagen carrier material was impacted 
between the graft material, filling up the space between the impacted material and thereby de-
laying tissue ingrowth and remodeling. Similar observations, although not in the context of the 
impaction grafting setting, have been described previously by Franke Stenport and coworkers.25 
In addition, the volume available for tissue ingrowth was reduced by the impaction of TCP/HA 
particles, creating small TCP/HA particles between the larger ones.
From our present findings, the previously observed lack of ingrowth after 4 weeks appears to 
have been a delay rather than an inhibition. After 8 weeks, however, the delay was only par-
tially overcome. Similarly to our results after 4 weeks, no differences in bone ingrowth between 
OP-1 device groups and their controls were observed. However, after 8 weeks significantly more 
fibrous tissue ingrowth was measured in allografts mixed with OP-1 device compared to the 
allograft control. In contrast, after 4 weeks significantly less fibrous tissue was measured when 
comparing the allografts mixed with OP-1 to the allograft control.15 In the TCP/HA groups, no 
differences in fibrous tissue ingrowth between OP-1 device groups and their controls were ob-
served, where there was a highly significant dose-dependent decrease in fibrous tissue ingrowth 
after 4 weeks. An observation time of 8 weeks might still be too short; however, no remnants of 
collagen carrier could be seen between the impacted allografts or TCP/HA granules, suggesting 
that all the OP-1 had been released from the carrier, thus no effect of the growth factor could 
be expected.
The data from both our previous study and the present work demonstrate the difficulty of using 
a biological enhancer of bone healing, such as an osteoinductive growth factor, in a situation 
where access to the blood supply and stem cells is limited and where bone healing is not opti-
mal. Recently, Kärrholm et al.26 showed that mixing of OP-1 with morselized allograft did not 
improve early fixation of either the acetabular or femoral component in revision surgery of the 
hip. In contrast, the influence of OP-1 on impacted allograft implants was recently investigated 
experimentally in loaded, primary, and impaired revision settings.27 Under primary conditions, 
OP-1 reduced mean implant fixation; in contrast, under the impaired healing conditions of the 
revision setting, OP-1 increased incorporation and fixation of the implants. However, an OP-1 
solution (without the collagen carrier) was used in that study.
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The collagenous extracellular matrix of bone is considered an optimal delivery system for osteo-
genic proteins.28 However, probably the collagen type I carrier is not the optimal carrier to use 
in impaction grafting. Ideally, a carrier should perform several important functions in addition to 
binding the protein;29 it should not, however, obstruct the migration of cells into the impacted 
graft or vascularization. This makes it interesting to compare the results of the present study 
with the results of studies in which OP-1 was combined with graft without a carrier system. In a 
similar bone chamber model in rats, using a dose similar to our lowest dose without a collagen 
carrier (OP-1 solution) in impaction grafting, Tägil et al.4 found an increase in bone formation. 
In contrast, a study using an OP-1 device (with collagen carrier) in combination with impaction 
grafting showed only very moderate effects on bone ingrowth.1 Moreover, using an OP-1 solu-
tion in a weight-bearing rabbit knee impaction grafting model, Tägil et al.12 showed no augmen-
tation of morselized impacted bone graft incorporation.
The effects of BMPs have been shown to be concentration-dependent. The local concentration 
will be greatly determined by the release kinematics of the carrier.30 The collagen carriers that 
have been used in clinical studies effect an initial bulk release. Such a release may result in ex-
cessive bone formation at locations with favorable conditions. At locations with less favorable 
conditions, however, such as within impacted bone grafts, the BMP clearance might be faster 
than the bone induction response of the host.31
Our data again indicate that the lack of effect when OP-1 is used in different clinical situations 
could be related to the problem that different biological environments require different dosages 
of growth factors and carriers for optimal stimulation. The challenge is to find ways to apply 
these drugs with consistent success in various applications in humans.
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CHAPTER SEVEN
COLLAGEN AND HEPARIN COATED 
TCP/HA AS A CARRIER 
FOR BMP-7
INTRODUCTION
Bone defects caused by congenital defects, malignancies, trauma, removal of failed implants, 
and orthognatic and preposthetic surgery require reconstruction for functional and aesthetic 
purposes. There are various ways to reconstitute these bone defects, each with its particular 
advantages and disadvantages. Although autografts show a considerable success rate because 
of their marked osteogenic potential, problems such as the limited availability of donor tissue 
and donor site morbidity exist for this type of graft. On the other hand, allografts are attractive 
alternative sources, however, there are also several problems encountered in using them, includ-
ing the risk of disease transmission, immunogenicity, loss of biologic and mechanical properties 
secondary to its processing, increased cost, and non-availability world-wide due to financial and 
religious concerns.1-4 Despite the benefits of both autografts and allografts, the relative concerns 
over the use of either autograft or allograft have led to the development of numerous synthetic 
and tissue engineered bone graft substitutes.
Calcium phosphate ceramics such as hydroxyapatite (HA) and tricalcium phosphate (TCP) have 
been investigated extensively because they are composed of materials similar to natural bone 
tissue.5-8 Both TCP and HA are osteoconductive and biocompatible, however to achieve osteo-
conduction close proximity to the host bone is essential. However, these biomaterials are not 
osteoinductive. Therefore, their clinical application is limited to small bony defects or the areas 
of the defect directly facing the host bone.
To overcome these problems, a number of carrier systems have been designed and evaluated 
for the delivery of bone morphogenetic proteins (BMPs), such as collagen gel,9 poly-L-lactic 
acid scaffolds,10 hyaluronic acid,11 fibrin gel,11 porous HA,12 and TCPs.13 Although these delivery 
systems enhanced bone repair and accelerated fracture healing, there are still some problems in 
controlling release rate, often resulting in a high initial burst release.9, 10, 13 Particularly in large 
voluminous defects where the repair might take considerable time, a controlled sustained re-
lease could prolong the action of BMPs to allow regenerative tissue forming cells to migrate to 
the area of injury and to proliferate and differentiate. Therefore, it would be ideal to develop a 
system for the sustained delivery of BMPs over an extended time period.
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The attachment of heparin, a polysaccharide macromolecule associated with the cell surface 
and the extracellular matrix, to biomaterials may result in an appropriate matrix for the binding, 
modulation, and sustained release of biologically active BMPs.14 Heparin avidly binds to a variety 
of bioactive components. These include basement membrane components, such as fibronectin, 
laminin and collagens, but also extracellular matrix proteins, proteases, cytokines, and growth 
factors.15-18 Binding of growth factors to heparin stabilizes these growth factors and protects 
them from proteolytic degradation.17, 19, 20 Furthermore, in the presence of heparin the half-life 
of BMPs in culture media is prolonged 20-fold.21 In addition, sulfated polysaccharides including 
heparin, heparan sulfate, and dextransulfate have been shown to enhance the osteoblast dif-
ferentiation induced by BMPs.22 Recently, it has been shown that heparin sulfate-like molecules 
aid bone formation in-vivo.15, 21, 23
In order to create a carrier based delivery system with a localized sustained release, heparin was 
covalently attached to a cross-linked collagen type I coated TCP/HA bone substitute and sub-
sequently loaded with BMP-7. The purpose of this study was to introduce and evaluate a new 
carrier system for BMP-7.
MATERIALS AND METHODS
PREPARATION OF GRANULES
Six different granules were prepared:
TCP/HA:  TCP/HA granules
TCP/HA+BMP-7:  TCP/HA granules with BMP-7
TCP/HA-COL:   TCP/HA granules coated with type I collagen
TCP/HA-COL+BMP-7:   TCP/HA granules coated with type I collagen and BMP-7
TCP/HA-COL-HEP:  TCP/HA granules coated with type I collagen and heparin
TCP/HA-COL-HEP+BMP-7: TCP/HA granules coated with type I collagen, heparin and BMP-7
TYPE I COLLAGEN COATING
The TCP/HA granules were composed of 20% HA [Ca10(PO4)6(OH)2] and 80% TCP [Ca3(PO4)2] 
(BoneSave, Stryker Osteosynthesis, Limerick, Ireland). We used granules with a diameter of 2 to 
4 mm. The TCP/HA granules have a 50% non-interconnected macroporosity (range, 300-600 
µm), which is produced by burning sacrificial carbonaceous filler during sintering. The granules 
are also microporous (range, 5-80 µm; porosity values derived from Stryker Osteosynthesis, Lim-
erick, Ireland). 
Insoluble type I collagen was isolated and purified from bovine achilles tendon as described 
previously.24 A homogenous 0.5% (w/v) type I collagen suspension was made and swollen o/n at 
4°C. The suspensions were homogenized using the Potter-Elvehjem on ice. The TCP/HA granules 
were put in the type I collagen suspension and frozen individually in liquid nitrogen. The granules 
were dried o/n in a Sublimator 500 II freeze dryer (Zirbus Technology, Bad Grund, Germany).
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HEPARIN COUPLING
Cross-linking of type I collagen coated TCP/HA granules in the presence and absence of heparin 
(Sigma Chemicals Co., St. Louis, MO, USA) was performed using 1-ethyl-3-(3-dimethyl amino-
propyl)carbodiimide (ECD, Fluka Chemica, Buchs, Switzerland) and N-hydroxysuccinimide (NHS, 
Fluka Chemica, Buchs, Switzerland).24, 25 Briefly, type I collagen coated TCP/HA granules were 
incubated in 40% (v/v) ethanol containing 50 mM 2-morpholinoethane sulfonic acid (pH 5.5) 
(MES, Fluka Chemica, Buchs, Switzerland) for 30 min at 20°C. Subsequently, the coated type 
I collagen was cross-linked by immersion in 40% (v/v) ethanol containing 50 mM 2-morpholi-
noethane sulfonic acid (pH 5.5), 66 mM ECD, and 6 mM NHS, with and without 0.5% (w/v) 
heparin for 4 h at 20°C. To stop the cross-link reaction, the granules were incubated twice for 
60 min in 0.1 M Na2HPO4 and were washed twice with 1 M NaCl and six times with 2 M NaCl for 
2 h. Finally, the granules were washed six times with demineralized water, frozen in -20 °C and 
dried overnight in a Sublimator 500 II freeze dryer.
BMP-7 LOADING ON COATED GRANULES
Granules were loaded with Chinese hamster ovary-derived recombinant human BMP-7 (R&D 
Systems, Minneapolis, MN, USA) by immerging the granules in 100 µl 1 µg BMP-7/ml phosphate 
buffered saline (PBS) solution for 2 h. As controls, granules were mixed with 100 µl PBS alone.
CHARACTERIZATION OF COATED GRANULES SCANNING ELECTRON MICROSCOPY (SEM)
To analyze the morphology, the granules were fixed on a stub with double-sided carbon tape. 
Granules were sputtered with an ultra thin layer of gold in a Polaron E5100 SEM coating system. 
Specimens were studied with a JEOL JSM-6310 scanning electron microscope (JEOL, Tokyo, Ja-
pan) with an accelerating voltage of 15 kV. The samples were examined using 1000x and 5000x 
magnifications.
IMMUNOFLUORESCENT ASSAY (IFA)
To determine the distribution of heparin and BMP-7, the granules were blocked for 20 min 
with 1% (w/v) bovine serum albumin (BSA) in PBS, washed 3 times with PBST and stained using 
specific antibodies. In case of heparin, the granules were incubated with anti-heparin antibodies 
(HS4C3 periplasmic fraction, monoclonal anti VSV glycoprotein clone P5D4 conjugate (Sigma 
Chemicals Co., St. Louis, MO, USA) and Alexa 594 labeled goat anti-mouse IgG (Invitrogen, 
Leiden, the Netherlands)) and washed with PBST. In case of BMP-7, the granules were incubated 
with rhBMP-7 antibodies (rhBMP-7 monoclonal antibody (MAB3541, R&D Systems Europe Ltd., 
Abingdon, United Kingdom) and Alexa 488 labeled goat anti-human IgG (Invitrogen, Leiden, the 
Netherlands)). Omission of the primary antibody was taken as a negative control.
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TYPE I COLLAGEN CONTENT
To determine the amount of coated type I collagen, the collagen was isolated from the granules 
by using a 30 min 6 M HCl decalcification step at 21 °C. After six washings with milliQ wa-
ter, the collagen remnants were freeze dried and weighted using a semi-microbalans (Simadzu 
AUW220D, Kyoto, Japan).
AMINO GROUP CONTENT
During cross-linking, an amine group reacts with a carboxylic group. Therefore, the extent of 
cross-linking was evaluated by analyzing the remaining free amine groups after a reaction with 
2,4,6-trinitrobenzene sulfonic acid.24
HEPARINE CONTENT
The heparin content was determined by hexosamine assay using p-dimethylaminobenzalde-
hyde.24
BMP-7 BINDING AND ITS RELEASE
After loading the granules with 1 µg BMP-7/ml PBS for 2 h, the granules were withdrawn and 
the supernatant was analyzed with ELISA (Human BMP-7 Duoset, R&D Systems, Minneapolis, 
MN, USA).
The release from the granules was determined by immerging the granules in 2 ml microcentri-
fuge tubes containing 1.5 ml PBS and 0.05% (w/v) sodium azide. The tubes were incubated at 
37 °C with continuous agitation. At various time points, the supernatant was withdrawn and the 
tubes were replenished with fresh buffer. The amounts of BMP-7 in the supernatant were deter-
mined using sodium dodecyl sulfate polyacrylamide gel electrophoresis and subsequent staining 
with 0.2% AgNO3 (Drijfhout, Amsterdam, the Netherlands), 0.2% NH4NO3 (Sigma Chemicals 
Co., St. Louis, MO, USA), 5% Na2CO3 (Fluka Chemica, AG, Buchs, Switzerland) and 1% tungsten 
acid (Fluka Chemica, AG, Buchs, Switzerland).26 Gene Tools (Syngene, Cambridge, United King-
dom) was used to analyse the intensity of the bands with a standard curve of 0-100 ng BMP-7. 
TCP/HA, TCP/HA-COL, and TCP/HA-COL-HEP granules were taken as controls.
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RESULTS
CHARACTERIZATION OF GRANULES
Type I collagen was coated on TCP/HA granules and subsequently cross-linked in the presence 
and absence of heparin. To determine the total amount of coated type I collagen on the surface 
of the granules, the collagen was isolated and weighted. The amount of coated collagen was 
8.3±1.1 mg collagen/g granule (Table 1). The thickness of the type I collagen coating was meas-
ured by SEM and was approximately 100 µm (Fig. 1). The morphology consisted of a highly porous 
interconnecting network with a pore size of approximately 5 µm (Fig. 2a). The collagen was chem-
ically cross-linked with EDC and NHS to covalently bind heparin. The addition of heparin did not 
change the porous structure (Fig. 2b). During cross-linking, an amine group reacts with a carboxy-
lic group and hence the extent of cross-linking was evaluated by analyzing the remaining free 
amine groups. About 50-60% (167.7±10.6 from 331.4±22.2 nmol/mg collagen) of the amine 
groups were used for cross-linking (Table 1). The amount of heparin covalently bound to the scaf-
fold was 193.5±51.1 µg heparin/mg collagen, as determined by hexosamine assay (Table 1).
The distribution of the different components on the granules was visualized using immunofluo-
rescence, which revealed that collagen, heparin, and BMP-7 were present on and were evenly 
distributed over the granules (Fig. 4). The heparin staining confirmed the highly incorporated 
heparin in the TCP/HA-COL-HEP granules (Fig. 3). These heparin incorporated granules showed 
also a higher rhBMP-7 signal compared with the TCP/HA-COL granules (Fig. 4).
BMP-7 BINDING IN TIME
Immersion of the granules in BMP-7 solution to load BMP-7, resulted in the binding of 54±3% 
(62.9±5.4 ng BMP-7/mg granule) to the TCP/HA granule, 64±8% (69.0±9.6 ng BMP-7/mg gran-
ule) to the TCP/HA-COL granules, and 78±1% (92.9±4.8 ng BMP-7/mg granule) to the TCP/HA-
COL-HEP granules (Table 1). TCP/HA granules showed a burst release of BMP-7 within the first 4 h. 
After an initial burst, the TCP/HA-COL granules showed a more gradual release of BMP-7. In con-
trast, BMP-7 release from the TCP/HA-COL-HEP granules was sustained up to 21 days (Fig. 5). 
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Fig. 1
Scanning electron microscopy picture 
of a cross-sectioned type I collagen 
coated TCP/HA granule. The highly 
porous interconnective type I collagen 
(C) network is clearly visible on top 
of the TCP/HA granule (TCP). Original 
magnification 150x.
Fig. 2
Scanning electron microscopy picture 
of the highly porous interconnecting 
network of type I collagen cross-linked 
in the absence (ac) and presence (bd) 
of heparin. Original magnifications (ab) 
1000x; (cd) 5000x.
Fig. 1
Biochemical properties of granules
Granule Cross-linked Collagen content  Amino group  Heparin content  BMP content
 with ECD/NHS (mg/mg granule) content (µg/mg collagen) (ng/mg granule)
TCP/HA -    
TCP/HA with BMP -    62.9±5.4
TCP/HA-COL + 8.3±1.1 331.4±22.2 25.4±10.1 
TCP/HA-COL with BMP + 8.3±1.1 331.4±22.2 25.4±10.1 69.0±9.6
TCP/HA-COL-HEP + 10.5±0.7 167.7±10.6 193.5±51.1 
TCP/HA-COL-HEP with BMP + 10.5±0.7 167.7±10.6 193.5±51.1 92.9±4.8
Values are mean ± standard deviation
Table 1
Fig. 2a Fig. 2b
Fig. 2c Fig. 2d
C
TCP
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Fig. 3
Immunolocalization of heparin on the 
type I collagen coated TCP/HA granules 
cross-linked without (a) and with (b) 
heparin.
Fig. 4
Immunolocalization of BMP-7 on 
TCP/HA (ad), TCP/HA-COL (be) and 
TCP/HA-COL-HEP granules (cf). (abc) 
Control granules, (def) Granules loaded 
with BMP-7.
Fig. 3a Fig. 3b
Fig. 4a
Fig. 4b
Fig. 4c
Fig. 4d
Fig. 4e
Fig. 4f
0 hours 4 hours 1day 3days 7days 14days 21days
Fig. 5
The amounts of BMP-7 in the supernatant at different time points were determined 
using SDS-PAGE. TCP/HA granules showed a burst release of BMP-7 within the first 
4 h. After that only very little BMP-7 was released. TCP/HA-COL granules showed an 
initial burst release, followed by a more gradual release. In contrast, BMP-7 release 
from the TCP/HA-COL-HEP granules was sustained up to 21 days.
TCP/HA
TCP/HA-COL
TCP/HA-COL-HEP
Fig. 5
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DISCUSSION
Many systems have been designed and evaluated for the delivery of BMPs.9-13 Although these 
delivery systems enhanced bone repair and accelerated fracture healing, there are still some 
problems in controlling release rate, often resulting in a high initial burst release.9, 10, 13 Therefore, 
it would be ideal to develop a system for the sustained delivery of BMPs over an extended time 
period. In order to create a suitable carrier based delivery system with a localized sustained re-
lease, heparin was covalently attached to a cross-linked collagen coated TCP/HA bone substitute 
and loaded with BMP-7.
The sustained delivery system in the present study is based on the inherent capacity of heparin 
to bind various growth factors, such as BMPs, basic fibroblast growth factor (bFGF), vascular en-
dothelial growth factor (VEGF), platelet derived growth factor (PDGF), and transforming growth 
factor beta (TGF-β), via electrostatic interactions between heparin’s negatively charged sulfate 
groups and the proteins positively charged amino acid residues.14, 21, 27, 28 It is well established 
that BMP-2, BMP-4 and BMP-7 bind to heparin.16, 22, 29-31 However, the location of the heparin 
binding site within BMP-7 remains to be established, as do the consequences of such GAG inter-
actions. In addition, different types of receptors have been identified for the BMP-2 and BMP-7 
subgroups.21
In the present study, the attachment of heparin to type I collagen coated granules amounted the 
binding of BMP-7 for up to 92.9±4.8 BMP-7/mg granule, whereas the TCP/HA and TCP/HA-COL 
granules bound 62.9±5.4 ng and 69.0±9.6 ng BMP-7/mg granule, respectively. The amounts of 
BMP-7 in the supernatant at different time points were determined using SDS-PAGE. TCP/HA 
granules showed a burst release of BMP-7 within the first 4 h. After that only very little BMP-7 
was released. TCP/HA-COL granules showed an initial burst release, followed by a more gradual 
release. In contrast, BMP-7 release from the TCP/HA-COL-HEP granules was sustained up to 21 
days. Recently, the BMP-2 release from a heparin conjugated PLGA scaffold was compared to 
that of an unmodified PLGA scaffold.14 The delivery system of the heparin conjugated PLGA 
exhibited a sustained release of BMP-2, while BMP-2 was rapidly released from the unmodified 
PLGA scaffold. The slow BMP release can be attributed to the specific interactions between the 
immobilized heparin and the BMP. Similar release patterns were observed for various heparin 
conjugated hydrogel systems, such as, hyaluronic acid, fibrin gel, and alginate.32-34
The discrepancy in results between these studies may be due to differences in carrier materials, 
or in BMP subgroups (BMP-2 versus BMP-7). However, in-vivo release kinetics and drug diffu-
sion will depend on a multitude of factors including materials permeability, shape, surface area, 
surface roughness, thickness, and other external modifications.35
For BMPs, it has been shown that these proteins exhibit a sustained release from both bovine type I 
collagen and heparin,14 however, there is a strong binding affinity to hydroxyapatite mineral.5, 36 
Winn et al.37 showed that after ectopic implantation in rats a hydroxyapatite based material 
initially had a burst release at the first collection interval, but thereafter, BMPs appeared to bind 
irreversibly to the hydroxyapatite. Since the hydroxyapatite carrier did not resorb, they suggested 
that the lack of BMP released from the carrier implies a strong affinity to the hydroxyapatite. In 
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contrast, a study evaluating five different ratios of hydroxyapatite to tricalciumphosphate as car-
riers for BMP-2, showed that more new bone was formed using ceramic with high HA ratio.38
Even though quite a large number of biomaterials based approaches have been developed for 
bone defect repair, none of them proved ideal. One major advantage of the carrier system 
presented in this study is that it might be used in load bearing applications. In early attemps, 
synthetic materials, such as HA and TCP, were only conformable to fill non-load bearing bone 
cavities. However, improved processing techniques have allowed the production of biologically 
and mechanically stronger ceramics that can withstand loading conditions of weight-bearing 
bones.39-41 In addition, it was found that the presence of a collagen coating on TCP/HA ceramics 
increased the biocompatibility of the TCP/HA, increasing osteoblast infiltration and prolifera-
tion.42 This may indicate that collagen coating of calcium phosphate ceramics may also increase 
their compatibility and osseointegration in-vivo. In addition, cross-linking of collagen decreased 
the biodegradability, and increased retention of BMP at the implant site.43 An additional benefit 
to using heparin in the protein delivery system is its ability to enhance growth factor stability.21 
Furthermore, heparin may potentiate the BMP bioactivity.22
The delivery system developed in the present study could probably be applied to deliver dual or 
multiple growth factors that have affinities for heparin such as VEGF, BMPs and PDGF, which 
could synergistically enhance osteogenesis by increasing vascularity. The delivery system pre-
sented in this study may provide a powerful tool for bone regeneration.
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CHAPTER EIGHT
BEHAVIOR OF A NOVEL 
INJECTABLE CALCIUM PHOSPHATE 
CEMENT
INTRODUCTION
More than 500,000 bone grafting procedures are performed annually in the United States and 
2.2 million worldwide to repair bone defects in orthopedics, neurosurgery, craniofacial surgery, 
and dentistry.1 Bone grafts are often used to provide support, enhance biologic repair of skeletal 
defects and fill voids. Although autograft bone is the gold standard that alternatives must try to 
meet or even exceed, autograft has some serious disadvantages, including the limited quantity 
and associated donor site morbidity.2, 3 Though successful clinical results have been reported us-
ing allografts, there are also several problems encountered in using them, including the risk of 
disease transmission, immunogenicity, loss of biologic and mechanical properties by its process-
ing, increased cost, and limited availability worldwide.4 In addition, some religions do not allow 
the use of allograft materials. Despite the benefits of both autografts and allografts, the relative 
concerns over the use of either autograft or allograft have led to the development of numerous 
synthetic bone graft substitutes.
One of the more promising groups of synthetic graft materials for augmenting acute fracture 
healing are the calcium phosphate based cements (CPCs).5 There has been great interest in 
CPCs as bone substitute materials because they can be molded to fill a void or defect and are 
osteoconductive. Most of the research performed on CPCs has dealt with the improvement of 
bone cement formulations. Additives, such as accelerants, cohesion promoters, and fluidificants 
have been used to improve workability, and setting and hardening properties.6-8 In particular, the 
development of injectable bone cements is still of great interest.
Injectable CPCs can be used in treating distal radius fractures, femoral neck fractures, vertebral 
body compression fractures, and reinforcement of pedicle screw fixation.9 Recently, the sugges-
tion has been made that they might also compete with the polymethylmethacrylate (PMMA) 
bone cements and the apatite coatings for fixation of metal endoprostheses in orthopedics and 
oral implantology.10-12 In addition, the possibility to use CPCs not only as bone substitutes, but 
also as carriers for local and controlled supply of drugs, such as antibiotics, anti-inflammatory 
drugs, and growth factors, is very attractive and can be useful in treatments of different skeletal 
diseases, as well as for accelerating the rate of bone fracture healing.13
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Commonly utilized calcium phosphate cements currently available for use in the United States 
are BoneSource (Stryker Osteosynthesis, Freiburg, Germany) and Norian SRS (Synthes, Monu-
ment, CO, USA).14-16 Calcium phosphate transformations in vitro have been well described for 
both BoneSource and Norian SRS. However, only limited in vivo data are available.17, 18 Recently, 
a novel calcium phosphate cement, HydroSet (Stryker Osteosynthesis, Freiburg, Germany), was 
developed to have improved (intrinsic) qualities as workability, injectability and cohesion. To 
date, no study has evaluated this new synthetic material and compared its crystallographic prop-
erties, biological activity, osteoconductive properties, and resorption rate with other commonly 
used CPCs. 
MATERIALS AND METHODS
ANIMAL MODEL/EXPERIMENTAL DESIGN
The three bone cements were tested in a modified version of an established rabbit distal femoral 
defect model (Fig. 1).19-22 Thirty-six adult female New Zealand White rabbits were operated bi-
laterally. The CPCs were randomly assigned to the right or left limb. All animals were skeletally 
mature and weighed between 3200 and 4900 g (mean 3770±403 g). The rabbits were accli-
matized to their environment for 4 weeks prior to surgery and housed in groups of maximal six 
animals in a controlled environment with a normal light-dark cycle and a temperature between 
23 and 26°C. The rabbits had access to water and rabbit chow ad libitum. All procedures were 
approved by the Animal Ethics Committee of the Radboud University Nijmegen, Nijmegen, the 
Netherlands. The biological activity, osteoconductive properties, and the resorption rate of the 
CPCs were evaluated using histology, histomorphometry, X-Ray Diffraction (XRD), and Fourier 
Transform Infrared Spectrometry (FTIR) at three different time points (Table 1).
Fig. 1
Schematic drawing showing the location of the implantation 
site in the medial aspect of the medial femoral condyle (left), 
and an overview of experimental defect with CPC implant 
(right). The defect is closed with a press-fit plastic plug.
Fig. 1
plastic plug
bone cement
patella
patellar 
ligament
site of implantion
medical 
collateral 
ligament
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FILLING MATERIALS
HydroSet powder consists of three powder components: dicalcium phosphate dihydrate 
(DCPD) [CaHPO4·2H2O], tetracalcium phosphate (TTCP) [Ca4(PO4)2O], and tri-sodium citrate 
[C6H5Na3O7·2H2O]. The liquid used for HydroSet is water based with polyvinylpyrrolidone (PVP) 
[C6H9NO]x, and sodium phosphate [Na2HPO4] added (cement formulations obtained from Stryker 
Osteosynthesis, Freiburg, Germany).
Norian Skeletal Repair System (SRS) powder consists of three powder components: monocalcium 
phosphate monohydrate (MCPM) [Ca(H2PO4)2·H2O], α-tricalcium phosphate (α-TCP) [Ca3(PO4)2], 
and calcium carbonate (CC) [CaCO3]. The liquid used for Norian SRS is a sodium phosphate 
solution.9, 23
BoneSource powder consists of two powder components: tetracalcium phosphate (TTCP) and 
dicalcium phosphate anhydrous (DCPA) [CaHPO4]. The liquid used for BoneSource is water based 
with 0.25 mol/l sodium phosphate solution added.24
SURGICAL PROCEDURE
Preoperatively, all animals received antibiotics (15 mg/kg) (Excenel, Pharmacia & Upjohn Animal 
Health BV, Woerden, the Netherlands) and analgetics (1.1 mg/kg) (Fynadine, Schering Plough 
Animal Health Benelux, Utrecht, the Netherlands). All animals were anesthetized by intravenous 
administration of 0.2 ml/kg medetomidine (Dormitor, Pfizer Animal Health BV, Capelle a/d IJs-
sel, the Netherlands) and maintained after intubation with nitrous oxide, oxygen, and isoflurane 
(2%). Under aseptic conditions, a 2-3 cm longitudinal skin incision was made and the distal 
medial femur was exposed. A 2 mm diameter hole was drilled in the medial aspect of the medial 
femoral condyle. A guide pin was inserted and, using a custom made drill, a final drill hole with 
a diameter of 5.5 mm and a depth of 10 mm was created. The defect was cleaned from bone 
debris using a sharp spoon and saline. All CPCs were prepared according to the manufactur-
ers instructions. The defect was filled with cement and a 2 mm thick polyethylene plug with a 
diameter of 5.55 mm was press-fitted on top of the implanted material to seal the defect. The 
area surrounding the defect was cleaned using saline to remove any remaining bone and cement 
debris. Soft tissues were closed in layers and the procedure was repeated on the other side.
Overview of experimental design
Histology & histomorphometry
Observation time  Animals (n)
-  -
6 weeks  9
26 weeks  9
52 weeks  9
XRD & FTIR
Observation time  Animals (n)
powder -
24 hours 3
26 weeks 3
52 weeks 3
Table 1
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After the implantation procedure the animals received subcutaneous injections of antibiotics 
(15 mg/kg) (Excenel, Pharmacia & Upjohn Animal Health BV, Woerden, the Netherlands) and 
analgetics (1.1 mg/kg) (Fynadine, Schering Plough Animal Health Benelux, Utrecht, the Nether-
lands) two times. Post operative X-rays were made to ensure proper placement and filling of the 
implant locations and to exclude fractures. The animals were allowed to walk freely. At the set 
time points, the rabbits were killed with an overdose of sodium pentobarbital (1 ml/kg) (Nem-
butal, CEVA Santé Animale, Maassluis, the Netherlands). The distal femora were immediately 
harvested, cleaned of soft tissue, and fixed in 4% buffered formaldehyde.
HISTOLOGY AND HISTOMORPHOMETRY
After localizing the PE plug, the defect with surrounding tissue was dissected from the host bone 
with a diamond coated saw. All sections were cut in a plane perpendicular to the long axis of the 
specimen. The specimen was split 4 mm underneath the plug, also perpendicular to the long axis 
of the specimen. All specimens were dehydrated using ethanol, and subsequently embedded in 
PMMA. Specimens from the lower part of specimen were decalcified using 25% ethylenedinitrilo 
tetraacetic acid (EDTA) in 0.1 mol/l phosphate buffer (pH 7.4) before dehydration. These speci-
mens were cut with a microtome (Leica RM 2155, Leica Microsystems Nederland BV, Rijswijk, 
the Netherlands) perpendicular to the longitudinal axis of the specimen, each section 5 µm thick. 
These sections were stained with hematoxylin and eosin (HE), Goldner-Masson trichrome, and 
tartrate resistant acid phosphatase (TRAP) for routine histology. The superior part, directly un-
derneath the plug, was used for undecalcified histology. Serial slices of 20 µm were made using 
a saw-microtome (Leica SP 1600, Leica Microsystems Nederland BV, Rijswijk, the Netherlands). 
These sections were stained with HE for routine histology (and histomorphometry). All sections 
were investigated blinded and in random order.
Histomorphometric analysis was performed by using interactive computer-controlled image 
analysis (analySIS, Soft Imaging System GmbH, Münster, Germany) and consisted of the fol-
lowing two measurements:25, 26 (1) Percentage of bone contact at the interface. The amount of 
interfacial bone contact was defined as the percentage of cement perimeter at which there is 
direct bone to cement contact without intervening soft tissue layers. The total perimeter and the 
total length of sites with direct bone-to-cement contact were measured in the sections at 2.5x 
magnification. (2) Cement area. The total area of cement present in the transversal sections was 
determined and compared between the different implantation periods to determine the rate of 
cement resorption.
All quantitative measurements were performed for three different sections per specimen. The 
three sections were equally distributed over each specimen, each at a distance of ~1200 µm 
from the next. The presented data are based on the average of these three measurements.
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X-RAY DIFFRACTION
Crystallographic analyses were made with powder XRD after the samples were ground to a fine 
powder in an agate mortar and pestle. CuKα X-rays (λ = 0.154 nm) were diffracted off the sample 
plane and intensities recorded in steps of 0.02° from 20° to 40° 2θ (40 kV; 40 mA) (PW3710, 
PANalytical BV, Almelo, the Netherlands). The resultant XRD patterns were compared to the In-
ternational Center for Diffraction Data standards for phase identifications. (HydroSet JCPDS file 
9-432, 25-1137, and 2-85 for HA, TTCP and DCPD, respectively; Norian SRS JCPDS file 9-432, 
9-348, and 5-586 for HA, α-TCP, and CaCO3, respectively; BoneSource JCPDS file 9-432, 25-
1137, and 9-80 for HA, TTCP, and DCPA, respectively.)
The relative proportions of the phases in the products were semiquantitatively determined with 
the use of the following relation:27-29
where Ii is the phase of concern, i = 1, 2, 3,
I1 corresponds to the intensity of the HA (211)-peak at 2θ = 31.8° for all three CPCs, 
I2 corresponds to the intensity of the TTCP (013)-peak at 2θ = 29.2° for HydroSet and Bone-
Source, and corresponds to the intensity of the α-TCP (034)-peak at 2θ = 30.8° for Norian SRS, 
and 
I3 corresponds to the intensity of the DCPD (021)-peak at 2θ = 20.9° for HydroSet, the CaCO3 
(306)-peak at 2θ = 29.4° for Norian SRS, and the DCPA (110)-peak at 2θ = 26.6° for Bone-
Source
These peaks were selected because they occur at 2θ values, which do not overlap with other 
peaks of the various phases present.
FOURIER TRANSFORM INFRARED SPECTROMETRY
To characterize the molecular structure of the cements, infrared spectra of the cement powders 
were obtained from 4000 to 450 cm-1 by FTIR (Spectrum One, Perkin Elmer, Groningen, the 
Netherlands) with a resolution of 4.00 cm-1.
STATISTICAL ANALYSIS
Statistical analysis was performed using a two-way ANOVA. To isolate the different groups, we 
used Tukey’s multiple comparison procedure.
Ii
I1 + I2 + I3
% Ii = 
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RESULTS
CLINICAL
No intraoperative complications occurred during surgery. All animals were able to walk within 
48 h after surgery. There were no signs of inflammation, skin ulceration, or wound healing prob-
lems. All X-rays showed closed implant sites without plug displacement or plug loosening. No 
femoral fractures or fractures at the implant site were found.
HISTOLOGY
The CPCs were clearly visible in the created bone defects (Fig. 2). A very uniform bone reaction for 
all implantation times and CPC materials was observed. No clear differences in healing response 
to the three CPCs could be observed. Differences in morphological appearance were only found 
between the various implantation times. However, a large variation in remodeling was observed 
between animals. Bilateral a similar response was observed. Penetration of the CPCs into inter-
trabecular voids was seen, causing irregular contours of the cement plugs.
Fig. 2
Norian SRS in defect after 6 weeks of implantation. 
The CPC (C) is almost totally covered with new formed bone 
(NB). HE stained section; original magnification x12.5.
IMPLANTATION TIME 6 WEEKS
After 6 weeks, the CPC surfaces were almost completely covered by newly formed bone. The 
remodeling process of this newly formed bone had already started (Fig. 3ab). A tight contact 
existed between the new bone and the cement surface, without signs of an intervening fibrous 
tissue layer. At locations where no bone was formed, fibrous cell dense tissue was formed with 
vascular invasion and osteoclastic resorption of the cements. Resorbed cement was replaced by 
new bone or by normal looking medullar tissue. No inflammatory cells were seen. The surface of 
the CPCs had a granular appearance. The surface zone of the CPCs had a less dense appearance 
compared with the central part. Occasionally, pores and/or cracks were seen in the CPCs. When 
the pores and/or cracks had an opening to the outer environment, the surface inside the pores 
and/or cracks was completely covered with a thin layer of bone.
Fig. 2
NB
C
bone_impaction_grafting_02.indd   110 21.04.2008   13:04:37 Uhr
111
IMPLANTATION TIME 26 WEEKS
After 26 weeks, an ongoing remodeling of the CPCs into (new) bone was seen. Remodeling 
activity in the interface, characterized by the presence of remodeling lacunae and osteoclast-like 
cells, was still seen (Fig. 4ab). Numerous remodeling lacunae could be seen close to the cements. 
Frequently, the cutting cone of these remodeling lacunae was directional and penetrated into 
the cement. In these situations, osteoclast-like cells were present at the cement outside, whereas 
bone apposition occurred at the other side of the lacunae. The bone was mature and could 
not be discerned from original trabecular bone. The major part of the CPCs was still present in 
the produced bone defects. Only occasionally larger parts of the cements had disappeared and 
became subsequently completely replaced by bone. Sometimes, cement remnants were inter-
twined within new bone.
IMPLANTATION TIME 52 WEEKS
An ongoing remodeling of the CPCs into (new) bone was still seen (Fig. 5a). More often, larger 
parts of the cements had disappeared and were replaced by bone or marrow. Cement remnants 
intertwined within new bone were still seen (Fig. 5b).
HISTOMORPHOMETRY
PERCENTAGE OF BONE CONTACT AT THE INTERFACE
After 6 weeks of implantation, the CPC surfaces were almost completely covered by newly 
formed bone. No significant differences in percentage of bone contact existed between the 
three CPCs and their respective implantation times were found (Fig. 6a).
Fig. 3
(a) Detail of BoneSource after 6 weeks of implantation. Intense remodeling with active osteoclastic resorption (arrows). HE stained 
section; original magnification x200. (b) Adjacent section showing acid phosphatase positive cells (osteoclast-like cells) resorbing 
BoneSource after 6 weeks of implantation. TRAP stained section; original magnification x200. NB = new bone; C = cement; 
M = marrow.
Fig. 3a Fig. 3b
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Fig. 4
(a) Continued remodeling of HydroSet after 26 weeks of implantation. HE stained section; original magnification x100. 
(b) Adjacent section showing acid phosphatase positive cells (osteoclast-like cells; arrows) resorbing HydroSet after 26 weeks of 
implantation. TRAP stained section; original magnification x100. NB = new bone; C = cement; M = marrow.
Fig. 5
(a) Ongoing remodeling of HydroSet after 52 weeks of implantation. The CPC is totally covered with bone (NB). Remodeling 
lacunae with cutting cone (arrows) headed towards CPC (C). Osteoclast-like cells (arrows) resorbing the cement. (b) Incorporation 
of HydroSet remnants (C) into lamellar bone (LB) after 52 weeks of implantation. HE stained sections; original magnification x200.
Fig. 4a Fig. 4b
Fig. 5a Fig. 5b
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CEMENT AREA
A large variation in CPC cement areas between animals was measured. The CPCs had penetrated 
into intertrabecular voids, causing a larger surface area than the area of the drill hole. The meas-
urements suggest a decrease in CPC surface area at 52 weeks compared with the CPC surface 
area at 6 and 26 weeks (Fig. 6b). However, this could not be confirmed by statistical analysis (p 
> 0.05). Also, no significant difference existed between the three CPCs within an implantation 
period (p > 0.05).
X-RAY DIFFRACTION
Diminution of base peak intensities was observed and accompanied by a continuous increase 
in the HA peak intensity. All three CPCs converted towards HA with time (Fig. 7abc). Conversion 
towards HA was visible at 24 h. After 26 weeks no further changes were observed. The relative 
proportions of these phases over the time of this study are shown in (Figure 8abc). These observa-
tions are consistent with the formation of HA during this period.
FOURIER TRANSFORM INFRARED SPECTROMETRY
The FTIR spectra demonstrated the transformation to carbonated hydroxyapatite over time. FTIR 
measurements showed for all three CPCs two clusters of peaks, that is, from 900 to 1150 and 
from 550 to 600 cm-1. These peaks could be attributed to the major absorption modes associ-
ated with the presence of phosphate (PO4
3-).30 Also, carbonate groups were observed at 1416, 
1460, and 1540 cm-1, indicating transformation of the CPCs into carbonated hydroxyapatite (Fig. 
9abc).31, 32 The spectra have the characteristic features of carbonated hydroxyapatite and show 
that the CPCs appear similar to bone apatite.17, 32
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Fig. 7
XRD patterns of (a) HydroSet, (b) Norian SRS, and (c) BoneSource after different evaluation periods. All CPCs converted towards 
HA with time. The positions of peaks I1-I3 are marked with a dotted line. An XRD pattern of rabbit cortical bone is added on top 
of each plot for comparison.
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Fig. 8
Relative proportions of different phases present in the products. (a) HydroSet. Percentage of HA, TTCP and DCPD phases present 
as a function of time. (b) Norian SRS. Percentage of HA, α -TCP and CaCO3 phases present as a function of time. (c) BoneSource. 
Percentage of HA, TTCP and DCPA phases present as a function of time.
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Fig. 9
FTIR patterns of (a) HydroSet, (b) Norian SRS, and (c) BoneSource after different evaluation periods. The FTIR patterns shows the 
absorption bands of the hydroxyl (OH), carbonate (CO3
2-), and phosphate (PO4
3-) groups. The FTIR patterns of these CPCs change 
with time to have the characteristic features of carbonated hydroxyapatite. The characteristic CO3
2- bands are marked with arrows. 
FTIR patterns of rabbit bone and synthetic hydroxyapatite are added on top of each plot for comparison.
Wavenumber (cm-1)
Tr
a
n
sm
it
ta
n
ce
 (
1
)
Fig. 9b
- synthetic hydroxyapatite
- 52 weeks
- 26 weeks
- 24 hours
- cement powder
- rabbit cortical bone
CO3
2-
CO3
2-
Wavenumber (cm-1)
Tr
a
n
sm
it
ta
n
ce
 (
1
)
Fig. 9a
- synthetic hydroxyapatite
- 52 weeks
- 26 weeks
- 24 hours
- cement powder
- rabbit cortical bone
CO3
2-
CO3
2-
Wavenumber (cm-1)
Tr
a
n
sm
it
ta
n
ce
 (
1
)
Fig. 9c
- synthetic hydroxyapatite
- 52 weeks
- 26 weeks
- 24 hours
- cement powder
- rabbit cortical bone
CO3
2-
CO3
2-
bone_impaction_grafting_02.indd   116 21.04.2008   13:04:41 Uhr
117
DISCUSSION
HydroSet is a novel, injectable, calcium phosphate cement that hardens to form hydroxyapatite 
and remodels to natural bone through osteoclastic resorption and new bone formation. It is a 
fast-setting cement indicated to fill bony voids or gaps that are not intrinsic to the stability of 
the bony structure.
Calcium phosphate transformations in vitro have been well described.32, 33 However, most of 
this work has been carried out in vitro under standard laboratory conditions. More recently, the 
phase and morphological properties of CPC samples that were placed in living tissue for various 
periods were studied to evaluate whether the conversion and rate of transformation of CPCs 
in vitro is similar to that in vivo.17, 18 It is important to know how these CPCs change chemically 
when implanted, as this will affect their resorption rate, osteoconductivity, and biocompatibility. 
The results from the present study showed that under in vivo conditions all three CPCs largely 
converted to carbonated HA after 24 h, and remained stable over time. XRD analyses showed 
that the carbonated HA formed in vivo from the present CPCs were comparable in crystallinity to 
that of the cement products reported by Constantz et al.,17 and Takagi et al.18
The histological and histomorphometrical results confirmed the excellent bone biocompatibility 
of all three CPCs used. None of the materials evoked any inflammatory response. Excellent os-
teoconduction was observed in all three materials. Already after 6 weeks, the cement surface 
was almost completely covered with new deposited bone. These findings correspond with many 
other studies dealing with CPCs.26, 34, 35 However, occasionally unfavorable bone healing of CPCs 
is reported, as characterized by the presence of inflammatory cells and fibrous encapsulation.36, 
37 Such a reaction is supposed to be due to the use of acidic cements or to the use of additives 
to improve the handling properties of the cement.
The CPCs were applied into the created bone defects by using a syringe. Injection of the CPCs 
offers the opportunity to fill defects in a retrograde way, which can prevent (significant) air en-
trapment. Furthermore, pressure can be generated during the injection.26 This provides a good 
cement fill of the bone bed and a tight initial contact with the defect walls.6, 9 Our histological 
results confirmed these advantages of the injection technique. However, as it is injected the 
CPCs interdigitated with the adjacent trabecular bone, causing an irregularity in the contour of 
the cement plugs, which may explain the large surface areas measured.
Although, an ongoing remodeling was observed, none of the materials did resorb significantly 
over the time of this study as shown from histology and histomorphometry. After 52 weeks, 
most of the cement material was still present in the bone defects. The kind of cells involved in 
the degradation/resorption of CPCs differs between the variously studied cements. Generally, 
for fast degrading cements, macrophages, and giant cells are the cell types involved in the re-
sorption process.38 This is in contrast to very slow degrading cements (months to years). Then 
osteoclast-like cells are held responsible for the degradation.26, 34, 35 Evidently, this is true for CPCs 
tested in the present study. Eventually, the cements will completely disappear and be replaced by 
bone. However, this will take considerable time. The rate at which the material finally degrades 
varies between weeks to years.35, 39 More than one year postoperatively, BoneSource still was 
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visible on radiographs of feline cranial defects.24 Norian SRS was still present in the center of the 
metaphysis on 3 and 4 year follow-up radiographs.5 However, complete degradation of CPCs 
is not only dependent on physicochemical properties, like crystallinity, density and porosity, but 
also on animal model and implantation site.17, 35, 40, 41 Although we do not feel that it is a clinical 
problem to have the HA cements remaining, this still may be a concern at longer follow-up for 
certain surgical defects/locations.5, 39
Most CPCs, when implanted as a paste which is just starting to set, tend to disintegrate upon 
early contact with blood or other fluids. For this reason cohesion promoters must be added.6 
Some authors improved the cohesion of a cement consisting of tetracalcium phosphate and dical-
cium phosphate by dissolving sodium alginate in the cement liquid.42, 43 Recently, hydroxypropyl 
methylcellulose, carboxymethylcellulose, chitosan acetate, and chitosan lactate have been tried 
for the same type CPC cement.44 All of these additives improved the handling properties with 
respect to the cohesion of the cement paste, whereas the setting was retarded by the cellulose 
derivatives and the mechanical strength was reduced by the chitosan derivatives. Furthermore, 
the disintegration of CPCs in circulating blood does not only compromise the mechanical proper-
ties, but also represents a risk of cardiovascular complications.45-47 Therefore, a reliable cohesion 
of CPCs in an aqueous environment is essential for clinical applications. Unlike BoneSource, 
Norian SRS can set in the presence of fluid.5, 48 HydroSet was specifically formulated to provide 
exceptional wet-field environment characteristics. As a cohesion promotor, PVP was added.
These wet-field environment characteristics were designed to make HydroSet particularly useful 
to stabilize fractures that communicate with the joint space, although it should be demonstrated 
first that HydroSet does not have any negative effects on articular cartilage if introduced in the 
joint space. Clinical application of CPCs in comminuted fractures revealed penetration of the 
viscous paste into the joint space.49-51 Recently, Braun et al.52 investigated the potential hazard of 
the presence of cement particles intra-articularly with observation periods from 1 week up to 24 
months. Norian SRS cement was injected into one knee joint, the contra-lateral side received the 
same volume of Ringers’ solution. No signs of pronounced acute or chronic inflammation were 
visible. Injected cement became surrounded by synovial tissue and there were signs of superficial 
resorption. In some cases, bone formation was seen around the cement. Degeneration of the 
articular surface showed no differences between experimental and control side, and no changes 
over time became present. Prolonged presence of cement still seems to make it advisable to 
remove radiologically visible amounts from the joint space.
HydroSet has been developed to set fast. Surgeons should be aware that for cements with a 
short setting time, this might result in application problems. The combination of a short setting 
time and a complicated surgical technique might affect a proper delivery of the CPC.
Although a large variation was observed between animals, HydroSet has been shown to be both 
biologically safe and effective as bone void filler. In this experimental model, no differences in 
biological activity, osteoconductive properties, and resorption rate compared with other com-
monly used calcium phosphate cements were found.
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CHAPTER NINE 
SUMMARY, CLOSING REMARKS 
AND FUTURE PERSPECTIVES 
CHAPTER ONE
Total hip arthroplasty (THA) is one of the most successful medical procedures. The success of 
THA in combination with the increasing possibilities in hip surgery has led to extension of in-
dications for THA. Unfortunately, the survival of hip prostheses is not unlimited. The main rea-
son for loosening of hip implants is aseptic loosening. Loosening of hip implants necessitates 
revision surgery. One of the major problems encountered in hip revision surgery is the loss of 
bone stock due to the loosening process and the removal of failed implants. Bone impaction 
grafting in combination with cemented implants for revision surgery of the hip has appeared to 
be a successful technique for dealing with bone loss. The clinical results are good and support 
recommendations for the continued use and development of the technique. The success of this 
method depends on achieving adequate initial stability followed by a biological response of 
graft incorporation and remodeling. Manipulation of the graft to improve one of these factors 
(biomechanical versus biological) may be detrimental to the other. The most appropriate produc-
tion and processing techniques of the graft in order to generate a mechanical stable construct 
advantageous to biological incorporation and remodeling still has to be unraveled. In chapter 1, 
an overview is presented on the basic science of the bone impaction grafting technique. In this 
chapter relevant items, like materials, preparation and processing, impaction, cementing, alter-
native materials and growth factors, are discussed.
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CHAPTER TWO
Various materials and factors have been tested for their effect on bone graft incorporation and 
bone formation using the bone conduction chamber. However, biomaterials often have to be 
crushed to fit in this small chamber. Since cellular responses to biomaterials are influenced by 
the size and shape of particles, research concerning the evaluation of biomaterials is limited by 
the dimensions of this bone chamber. In chapter 2 we developed and tested three new large bone 
chambers, based on the bone conduction chamber model, in order to be able to investigate the 
in vivo influences of biomaterials and growth factors on tissue and bone ingrowth. Empty cham-
bers were used as a test to evaluate the in vivo tissue and bone ingrowth. The results showed 
that one of the enlarged models performed most similar to the bone conduction chamber. This 
new bone chamber offers new possibilities for studies of bone tissue reactions to various bio-
materials.
CHAPTER THREE
Bone impaction grafting with a cemented prosthesis is a biological attractive technique to treat 
bone stock defects around failed total hip prosthesis, with proven long term clinical results. Al-
though the technique on the acetabular side has been well described by the original promoters, 
a dispute has been raised about the pros and cons of rinsing the allograft bone chips. Both rins-
ing before and before and after impaction are used. However, rinsing before impaction or before 
and after impaction might have quite different effects on the incorporation of the grafts. Rins-
ing the grafts again after impaction might have a negative effect on bone formation if growth 
factors released by the impaction process are washed away. In chapter 3 we studied if TGF-β and 
BMPs are released from the mineralized matrix by impaction, and if these released growth fac-
tors induce osteogenic differentiation in human mesenchymal stem cells (hMSCs). The results 
showed that abundant TGF-β was present in the fluid released during impaction. No BMPs could 
be detected. Osteogenic differentiation of hMSCs was inhibited by the fluid. No detrimental 
biological effects of rinsing morselized impacted bone grafts prior to cementation were found. 
However, there are no in-vivo data to support whether rinsing after impaction is good for the 
incorporation process or not.
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CHAPTER FOUR
Gamma irradiation has been widely used for sterilization of bone allografts. However, gamma 
irradiation alters proteins. This is favorable when it reduces immunogenicity, but is undesirable 
when osteoinductive proteins are damaged. Although the effect of gamma irradiation on BMPs 
has been studied, the effect of gamma irradiation on the incorporation process of morselized 
bone chips remains unclear. Therefore, the effects of sterilization by gamma irradiation on the 
incorporation of impacted morselized allografts were investigated in chapter 4. The results showed 
that the incorporation process proceeded in a similar way in unprocessed, rinsed, and both 
rinsed and irradiated bone grafts. We concluded that sterilization with gamma irradiation does 
not influence the incorporation of impacted rinsed allografts.
CHAPTER FIVE
Bone morphogenetic proteins have the potential to improve clinical outcome after revision sur-
gery by improving graft incorporation and implant fixation. However, a major concern in using 
growth factors in impaction grafting is the potential stimulation of the osteoclastic lineage. A 
solution would be using an osteoconductive material resistant to resorption and providing ini-
tial stability after reconstruction. In chapter 5 we determined whether OP-1 would promote the 
incorporation of morselized allografts and tricalcium phosphate/hydroxyapatite (TCP/HA) into 
host bone, whether bone formation would be preceded by an initial process of accelerated re-
sorption, and whether the response to OP-1 would be dose-related. The results showed that the 
incorporation process of impacted morselized allografts and impacted TCP/HA granules was not 
promoted by OP-1. No signs of accelerated resorption preceding bone formation were observed. 
Remarkably, an increase in OP-1 dose resulted in a reduction of fibrous tissue formation and 
OP-1 did not promote bone formation. Within impacted bone chips, the migration of cells into 
the impacted allograft is compromised and vascularization is delayed for several weeks. The col-
lagen carrier might have additionally delayed bone and fibrous tissue ingrowth into the impacted 
graft material by filling up the space between the impacted graft material. Using higher doses 
of the OP-1 device, more collagen carrier material was impacted between the graft material, 
filling up the space between the impacted material and thereby delaying tissue ingrowth and 
remodeling.
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CHAPTER SIX
In chapter 6 was analyzed whether the decrease in fibrous tissue formation observed in chapter 5 
represented a final loss or just a delay, and if the decrease can be overcome and ultimately result 
in a better late ingrowth. The results revealed evidence of bone graft incorporation which pro-
ceeded in a similar way in both allografts and TCP/HA, with and without the addition of OP-1. 
No difference in bone ingrowth was found between OP-1 groups and their controls. The addition 
of OP-1 resulted in more fibrous tissue in the impacted allograft. We concluded that the previous 
observed delay in fibrous tissue ingrowth can be overcome only partly.
CHAPTER SEVEN
Data presented in chapter 5 and 6 demonstrated the difficulty of applying a biological enhancer of 
bone healing, such as an osteoinductive growth factor, in a situation where the access to blood 
supply and stem cells are limited and bone healing is not optimal. In chapter 7 we developed 
and evaluated a carrier based delivery system with a localized sustained release. Heparin was 
covalently attached to a collagen coated TCP/HA granules and loaded with BMP-7. The results 
showed that TCP/HA granules coated with collagen in the presence of heparin exhibited a local-
ized sustained release of BMP-7. BMP-7 was released more rapidly from the uncoated TCP/HA 
granules and the TCP/HA granules coated with collagen only. This delivery system could probably 
also be applied to deliver dual or multiple growth factors that have affinities for heparin such as 
VEGF, BMPs and PDGF, which could synergistically enhance osteogenesis by increasing vascular-
ity. The delivery system presented in this study may provide a powerful tool for bone regenera-
tion. However, before advocating this it should be evaluated in-vivo first.
CHAPTER EIGHT
One of the more promising groups of synthetic graft materials for augmenting acute fracture 
healing are the calcium phosphate cements. Recently it has been suggested that they might also 
compete with the PMMA bone cements and the apatite coatings for fixation of metal endopros-
theses in orthopaedics and oral implantology. In chapter 8, the physicochemical and biological 
properties of a new developed calcium phosphate cement (CPC) were investigated. The novel 
calcium phosphate cement was compared with two other commercially available CPCs. XRD 
and FTIR indicate that the cements convert to carbonated hydroxyapatite and remain stable 
over time. Histological and histomorphometrical analyses did not show any significant differ-
ences between the three implanted cements. The results indicate that the investigated cement is 
biocompatible, osteoconductive, and seems to be both biologically save and effective as a bone 
void filler.
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VALIDITY AND RELIABILITY OF BONE CHAMBERS
Many animal models have been used to study bone repair. Our group has used bone chambers 
in vivo to create models where we have tried to change a single factor at a time. This factor can 
be modified and studied under standardized conditions. As an outcome variable, we used the 
distance of new bone ingrowth into a bony material or bone substitute. Various ways of treating 
a graft, like irradiation, rinsing, or adding growth factors, have helped us to increase or reduce 
the ingrowth. An osteoconductive material can be inserted into the chamber, and tissue from 
the marrow cavity and/or cortical bone can grow in through the ingrowth openings at the bot-
tom. The interior of the chamber is stress-shielded and no deformations occur. This protects and 
deprives ingrowing vessels and tissues of mechanical stimulation. This means that any biologic 
effect that requires participation of a physical load, which bone remodeling presumably does, 
cannot be adequately studied under these artificial unloaded conditions. However, the bone 
chamber models with their limitations have been used so extensively that we feel they are valid 
for detecting the effects of bone substitutes and signaling molecules that arise under unloaded 
conditions. It has been suggested that bone chambers can be regarded as bone cultures in vivo. 
In our view, bone chambers should be interpreted at that level in the hierarchy of experimental 
models. However, extrapolation of results of studies with bone chambers to clinical recommen-
dations should be made carefully, because factors like vascularity and composition of the host 
bone bed, its interaction with the bone graft, loading conditions, and surrounding tissues are 
not included in these studies.
CLOSING REMARKS AND FUTURE PERSPECTIVES
Total hip arthroplasty (THA) remains one of the most successful procedures performed by any 
surgeon, as measured by quality adjusted life years with more than 90% clinical success rate 
at 10 years. Each year in the US there are over 200,000 THAs performed at a yearly cost of ap-
proximately $ 5 billion. With the demographics of an ageing population, this number is set to 
rise by as much as 174% to roughly 550,000 by 2030. At the opposite end of the age spectrum, 
the combination of younger and more active patients, with higher expectations and surgeons 
prepared to perform surgery on these patients, further increased the growing demand for THA 
surgery. These younger patients are likely to live longer and place higher demands on their joint 
replacements, which further increases the likelihood of revision surgery. In consequence, revision 
hip surgery has increased by 100% due to implant failure since 1991, and estimates from the 
American Academy of Orthopedic Surgeons (AAOS) show that this number is expected to double 
by the year 2026. Moreover, there are a number of issues surrounding revision hip arthroplasty, 
including high costs of revision operations, higher complication rate, longer operative time, 
significant blood loss in comparison with primary procedures, and outcomes are often inferior 
to the primary operation.
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The causes for many of these difficulties are the extensive bone loss associated with loose im-
plants requiring revision surgery. When an implant fails, bone is lost through a combination of 
stress shielding, osteolysis, instability and/or infection. Several techniques are available for deal-
ing with bone loss and bone defects in hip revision surgery. With primary THAs and subsequent 
revision THAs being performed on younger patients, restoring rather than replacing bone stock 
will be the option of first choice. Of the many methods of reconstruction available, only two 
have the aim to restore the bone stock, namely bone impaction grafting and the use of structural 
allograft. In this thesis was focused on bone impaction grafting.
The objective of bone impaction grafting is to achieve stability of an implant with the use of im-
pacted, morselized bone and subsequently to allow the restoration of living bone stock by bone 
ingrowth. This is an attractive option, and the aim of restoring the bone stock to a condition 
close to what was present during the primary arthroplasty may be achievable. There is, however, 
a delicate balance between the mechanical demands of achieving initial stability and the biology 
of long-term incorporation. During incorporation, the mechanical and biological properties of 
the reconstruction change with the progress of the process, which might disturb this balance. As 
the graft used in bone impaction grafting plays such an important mechanical role when initially 
implanted, it is important that the initial stability achieved through impaction is not compro-
mised by stimulation of early graft resorption.
Recently, with demand outweighing the limited supply and increasing concerns regarding trans-
mission of pathogens associated with the use of allograft, interest in synthetic materials has 
increased significantly. A prerequisite of these materials is that they must be able to endure the 
forces applied during the impaction procedure. Synthetic materials must initially also provide 
sufficient mechanical support for the prosthesis. Thereafter, the material is required to provide a 
framework onto which the host bone and vascular network can regenerate and heal. These syn-
thetic materials are resorbed or degraded at various rates, altering the mechanical properties of 
these materials with time. Although the initial mechanical stability may be improved with the use 
of these materials, the biological aspects of the graft incorporation have not been fully studied 
yet. A denser synthetic graft, which may be the result of crushing of the synthetic material due 
to impaction, has been shown to reduce cement penetration. This will lead to reduced ingrowth 
with a higher chance of long-term failure. A further concern is the possibility of third body wear 
of the articulating surfaces by the synthetic particles.
Although impaction is mechanically beneficial, it has been shown to be detrimental to bone 
ingrowth and remodeling. This has led to widespread interest in graft additives and, in particu-
lar, the application of bone morphogenetic proteins (BMPs). Growth factor enhanced allograft 
incorporation could improve clinical outcome after revision surgery by accelerating new bone 
formation and thereby improving implant stability. However, BMPs not only stimulate new bone 
formation but also simultaneously stimulate osteoclastic activity. Therefore, BMPs might be par-
ticular useful in hip revision surgery as a promoter of bone formation in combination with a slow 
resorbing synthetic graft material, which provides initial stability. Maintenance of growth factors 
at the site of implantation and delivery of an optimal dose by an appropriate carrier material dur-
ing the incorporation process are essential for successful application of growth factors.
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A possible exciting way to improve both the biological and mechanical aspects of allograft in 
bone impaction grafting for revision hip surgery is the expanding emerging discipline of tissue 
engineering. However, for stem cells to play a role in bone impaction grafting it is necessary first 
to determine if, when combined with allograft or synthetic graft, these cells could survive the 
impaction process.
Areas of particular interest for the future of bone impaction grafting include the potential use of 
stem cells, and scaffolds containing multiple growth factors, resulting in sustained and control-
led release over time, providing greater control of the delicate balance between initial stability 
and long-term incorporation. The current drive in tissue engineering and regenerative medicine 
energizes the further development of the bone impaction grafting technique, in particular the 
development of composites that provide enhanced biological, mechanical, and hopefully ulti-
mately, improved clinical outcome for patients requiring revision hip surgery.
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CHAPTER TEN 
SAMENVATTING, AFSLUITENDE 
OPMERKINGEN EN TOEKOMSTIG 
ONDERZOEK 
HOOFDSTUK EEN
De totale heupvervanging (THV) is één van meest succesvolle medische ingrepen. Het succes van 
de THV in combinatie met de toegenomen mogelijkheden binnen de heupchirurgie, heeft geleid 
tot een uitbreiding van de indicaties voor deze ingreep. Toch kunnen implantaten na verloop 
van tijd falen. De belangrijkste reden voor het falen van heupprothesen is aseptische loslating. 
Het falen van prothesen maakt een revisieoperatie noodzakelijk. Eén van grootste uitdagingen 
binnen de revisiechirurgie is het omgaan met botdefecten die worden aangetroffen tijdens een 
revisieoperatie. Botdefecten kunnen ontstaan door het loslatingproces zelf, maar kunnen wor-
den verergerd door het botverlies dat optreedt bij het verwijderen van een gefaalde prothese. 
“Bone impaction grafting” in combinatie met het plaatsen van een gecementeerde prothese 
is een succesvolle techniek gebleken om met deze botdefecten om te gaan, zowel bij primaire 
heupvervangingen met botverlies als bij patiënten die een revisieoperatie moeten ondergaan. 
De klinische resultaten zijn goed en ondersteunen het verdere gebruik en de ontwikkeling van 
deze techniek. Het succes van de “bone impaction grafting” techniek berust op het bereiken van 
een adequate initiële stabiliteit, gevolgd door een biologische ingroei en remodellering van het 
bottransplantaat op de langere termijn. Het behandelen van bottransplantaten om één van deze 
factoren, mechanisch dan wel biologisch, te verbeteren kan nadelige gevolgen hebben voor de 
ander. De meest optimale productie- en behandelingstechnieken van de bottransplantaten om 
een mechanisch stabiele reconstructie te creëren welke biologisch incorporeert en remodelleert 
is nog niet gevonden. In hoofdstuk 1 wordt een overzicht gegeven van de huidige status van het 
wetenschappelijke onderzoek naar de “bone impaction grafting” techniek. In dit hoofdstuk ko-
men relevante onderwerpen, zoals materialen, preparatie- en behandelingstechnieken, impactie, 
cementering, alternatieve materialen en groeifactoren aan bod.
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HOOFDSTUK TWEE
In de “bone conduction chamber” zijn effecten van verschillende materialen en factoren op de 
incorporatie van bottransplantaten en botformatie onderzocht. Wanneer biomaterialen worden 
getest, moeten deze vaak fijngestampt worden om in deze kleine botkamer te passen. Aange-
zien de reactie van cellen op biomaterialen wordt beïnvloed door de omvang en vorm van de 
partikels wordt het onderzoek naar biomaterialen beperkt door de afmetingen van deze botka-
mer. In hoofdstuk 2 hebben we drie nieuwe typen grote botkamers ontwikkeld en getest om de 
in-vivo invloeden van biomaterialen en groeifactoren op bot- en weefselingroei te kunnen be-
studeren. De drie nieuw ontwikkelde botkamertypen zijn gebaseerd op de kleinere “bone con-
duction chamber”. Kamers zonder inhoud werden gebruikt om de in-vivo bot- en weefselingroei 
te onderzoeken. De resultaten laten zien dat één van de drie nieuwe typen botkamers bot- en 
weefselingroei vertoonde vergelijkbaar met de “bone conduction chamber”. Deze nieuwe bot-
kamer biedt mogelijkheden om de reactie van botweefsel op verschillende biomaterialen te 
bestuderen, zonder deze biomaterialen fijn te hoeven stampen.
HOOFDSTUK DRIE
De “bone impaction grafting” techniek is een biologisch aantrekkelijke techniek om botdefecten 
rond gefaalde heupprothesen te behandelen. Hoewel de operatietechniek aan de acetabulaire 
zijde goed beschreven is door de oorspronkelijke bedenkers van de techniek, is er toch een 
discussie ontstaan over de voor- en nadelen van het spoelen van bottransplantaten. Zowel het 
spoelen van bottransplantaten vóór impactie als het spoelen vóór én na impactie worden in de 
(klinische) praktijk gebruikt. Echter, spoelen vóór of spoelen vóór én na impactie van de bot-
transplantaten zou verschillende effecten kunnen hebben op de incorporatie van deze transplan-
taten. Het nogmaals spoelen van de transplantaten na impactie zou een negatief effect op de 
botformatie kunnen hebben wanneer de groeifactoren, afgegeven tijdens de impactieprocedure, 
weggespoeld zouden worden. In hoofdstuk 3 werd onderzocht of transformerende groeifactor-
bèta (TGF-β ) en bot morfogenetische proteïnen (BMPs) vrijkomen uit de gemineraliseerde matrix 
tijdens de impactieprocedure. De resultaten laten zien dat er overvloedig TGF-β aanwezig was 
in de vloeistof die vrijkwam tijdens impactie. In deze vloeistof konden geen BMPs worden aan-
getoond. De osteogene differentiatie van humane mesenchymale stamcellen werd geremd door 
de vloeistof. Er werden geen nadelige biologische effecten van het spoelen van geïmpacteerde 
bottransplantaten gevonden. Echter, er zijn geen in-vivo data beschikbaar die ondersteunen of 
nogmaals spoelen na impactie het incorporatie proces stimuleert of niet.
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HOOFDSTUK VIER
Gammastraling wordt veel gebruikt voor de sterilisatie van bottransplantaten. Echter gamma 
straling verandert de structuur van eiwitten. Dit heeft een gunstig effect wanneer de immunoge-
niciteit verminderd wordt, maar is juist nadelig wanneer osteoinductieve eiwitten, die de ingroei 
van bot bevorderen, beschadigd worden. Hoewel het effect van gammastraling op BMPs bestu-
deerd is, blijft het effect van gammastraling op het incorporatieproces van bottransplantaten 
onduidelijk. In hoofdstuk 4 is het effect van gammastraling op de incorporatie van geïmpacteerde 
bottransplantaten bestudeerd. Het incorporatieproces verliep op een soortgelijke manier in on-
behandelde transplantaten, gespoelde transplantaten en gespoelde en vervolgens bestraalde 
transplantaten. We concluderen dat bestralen met gammastraling de incorporatie van geïmpac-
teerde bottransplantaten niet beïnvloedt.
HOOFDSTUK VIJF
BMPs hebben theoretisch de potentie om klinische resultaten na revisiechirurgie te verbeteren, 
door het incorporatieproces te versnellen en de fixatie van de prothese te verbeteren. Echter, 
BMPs kunnen ook osteoclasten stimuleren. Een oplossing zou zijn om deze BMPs in combi-
natie met een langzaam resorberend osteoconductief materiaal, dat tevens initiële stabiliteit 
biedt,  te gebruiken. In hoofdstuk 5 werd onderzocht of osteogeen proteïne-1 (OP-1 = BMP-7) het 
incorporatieproces van geïmpacteerde bottransplantaten en geïmpacteerde tricalciumfosfaat/
hydroxyapatiet (TCP/HA) korrels versneld. Tevens werd onderzocht of botformatie voorafgegaan 
wordt door een proces van versnelde resorptie en of de respons op OP-1 dosis gerelateerd is. 
Het incorporatieproces van geïmpacteerde bottransplantaten en geïmpacteerde TCP/HA korrels 
werd niet versneld door OP-1. Er werden geen tekenen van versnelde botresorptie voorafgaand 
aan botformatie gevonden. Opvallend was dat een toename in de OP-1 dosis resulteerde in een 
afname van de ingroei van fibreus weefsel en dat er geen versnelde botformatie werd gevon-
den. In geïmpacteerde bottransplantaten is de migratie van cellen beperkt en de vascularisatie 
meerdere weken vertraagd. In deze studie zou het collageen dragermateriaal van OP-1 voor 
een extra vertraging in bot- en weefselingroei kunnen hebben gezorgd door het opvullen van 
de ruimte tussen de geïmpacteerde bottransplantaten waardoor de ingroei van weefsels extra 
vertraagd werd.
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HOOFDSTUK ZES
In hoofdstuk 6 werd onderzocht of de in hoofdstuk 5 beschreven reductie van fibreus weefselingroei 
een definitief verminderde ingroei oplevert of dat het een slechts een vertraging van de ingroei 
tot gevolg heeft. Verder werd onderzocht of een mogelijke vertraging van de ingroei ingehaald 
zou kunnen worden en uiteindelijk zou kunnen resulteren in een betere ingroei op de lange 
termijn. De incorporatie van geïmpacteerde bottransplantaten en geïmpacteerde TCP/HA korrels 
verliep op soortgelijke wijze, zowel met als zonder toevoeging van OP-1. Er werd geen verschil 
gevonden in botingroei tussen OP-1 groepen en hun controle groepen. Het toevoegen van OP-1 
leidde wel tot meer fibreus weefselingroei in de geïmpacteerde bottransplantaten. We kunnen 
concluderen dat de in hoofdstuk 5 geobserveerde vertraging in fibreus weefselingroei slechts ge-
deeltelijk kan worden ingehaald.
HOOFDSTUK ZEVEN
De resultaten gepresenteerd in de hoofdstukken 5 en 6 laten de moeilijkheid zien van het toepas-
sen van een biologische stimulatie van botgenezing in een situatie waarin de bloedvoorziening 
beperkt is, en stamcellen verminderd aanwezig zijn. In hoofdstuk 7 wordt de ontwikkeling en 
evaluatie van een op een dragermateriaal gebaseerd afgiftesysteem met een lokale, langdurige 
afgifte van een groeifactor beschreven. Heparine werd covalent gebonden aan met collageen 
gecoate TCP/HA korrels en vervolgens geladen met BMP-7. TCP/HA korrels gecoat met collageen 
in de aanwezigheid van heparine lieten een lokale, langdurige afgifte van BMP-7 zien. BMP-7 
werd aanzienlijk sneller afgegeven door de niet gecoate TCP/HA korrels en de TCP/HA korrels die 
alleen met collageen waren gecoat. Het beschreven afgiftesysteem kan mogelijk ook gebruikt 
worden voor de afgifte van twee of meer groeifactoren die affiniteit hebben voor heparine, 
zoals VEGF, BMPs en PDGF, zodat deze synergistisch osteogenese kunnen stimuleren door een 
toename van vascularisatie. Het afgiftesysteem beschreven in deze studie zou een krachtig ge-
reedschap kunnen vormen voor botregeneratie. Echter, het afgiftesysteem moet om dit aan te 
tonen eerst in-vivo worden getest.
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HOOFDSTUK ACHT
Eén van de veelbelovende synthetische materialen om fracturen te verstevigen en te herstellen 
zijn de calciumfosfaatcementen (CPCs). Recentelijk is zelfs gesuggereerd dat deze materialen 
zouden kunnen concurreren met PMMA botcementen en apatietcoatings die gebruikt worden 
voor de fixatie van metalen implantaten. In hoofdstuk 8 werden de fysico-chemische en biologi-
sche eigenschappen van een nieuw ontwikkeld CPC onderzocht. Het nieuw ontwikkelde cement 
werd vergeleken met twee commercieel beschikbare CPCs. Met Röntgendiffractie (XRD) en Fou-
rier getransformeerde infraroodspectroscopie (FTIR) werd aangetoond dat alle drie de cementen 
converteren naar gecarboneerd hydroxyapatiet en stabiel blijven in de tijd. Histologische en 
histomorfometrische analyse lieten geen verschillen zien tussen de drie geteste cementen. Het 
nieuw ontwikkelde cement is biocompatibel, osteoconductief en lijkt biologisch veilig en effec-
tief als botdefectvuller.
VALIDITEIT EN BETROUWBAARHEID VAN BOTKAMERS
Er zijn veel verschillende diermodellen gebruikt om botherstel te bestuderen. Onze groep heeft 
botkamermodellen gebruikt waarin we geprobeerd hebben steeds één enkele factor per keer 
te veranderen. Deze factor kan aangepast en bestudeerd worden onder standaard condities. 
Als uitkomstmaat gebruiken we de afstand waarover nieuw bot ingroeit in de bottransplanta-
ten of de botvervangende materialen. Verschillende manieren van transplantaatbehandeling, 
zoals bestralen, spoelen of toevoegen van groeifactoren, hebben ons geholpen de ingroei van 
nieuw bot te vergroten of juist te verminderen. Een osteoconductief materiaal kan in de botka-
mer worden geplaatst waarna weefsel vanuit de mergholte en/of het omliggende corticale bot 
door de ingroeiopeningen onderin de kamer kan ingroeien. De binnenzijde van de botkamer is 
“stress shielded” en er treden geen deformaties op. Dit beschermt en depriveert ingroeiende 
bloedvaten en weefsels van mechanische stimulatie. Dit betekent dat elk biologisch proces dat 
deelname vereist van belasting, wat bij botremodellering het geval is, niet adequaat bestudeerd 
kan worden onder deze artificiële onbelaste condities. Echter, de botkamermodellen met hun 
beperkingen zijn zo intensief gebruikt dat we denken dat ze valide zijn om effecten te detecte-
ren van verschillende botvervangende materialen en signaleringsmoleculen die ontstaan onder 
onbelaste condities. Botkamers kunnen gezien worden als botculturen in-vivo. In hiërarchie van 
experimentele modellen moeten de botkamers dan ook geïnterpreteerd worden op dat niveau. 
Het extrapoleren van resultaten van studies met botkamers naar klinische aanbevelingen moet 
daarom met enige voorzichtigheid worden gedaan. Factoren zoals bloedvoorziening, samenstel-
ling van het botbed, interactie van het botbed met het transplantaat, belastingscondities en 
omliggende weefsels maken immers geen deel uit van deze studies.
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AFSLUITENDE OPMERKINGEN EN TOEKOMSTIG ONDERZOEK
De totale heupvervanging blijft één van de meest succesvolle medische ingrepen, gezien de 
overleving van de totale heupprothese met meer dan 90% na 10 jaar postoperatief. In de Ver-
enigde Staten worden ieder jaar meer dan 200.000 heupvervangende operaties verricht met 
ruim $5 miljard aan jaarlijkse kosten. Met het bevolkingsbeeld van een toenemende vergrijzing 
wordt een stijging verwacht van 174% naar een aantal van 550.000 heupvervangende operaties 
in 2030. Aan de andere kant van het leeftijdspectrum zorgt de combinatie van jonge, actieve 
patiënten en chirurgen die bereid zijn om deze jonge patiënten te opereren voor een verdere 
toename van de totale heupvervangende operaties. Deze jonge patiënten hebben een hogere 
levensverwachting en stellen hogere eisen aan hun prothesen wat de waarschijnlijkheid van 
een revisieoperatie in de toekomst doet toenemen. Mede hierdoor is, als gevolg van het falen 
van prothesecomponenten, het aantal revisie heupvervangingen toegenomen met 100% sinds 
1991. Schattingen van de American Academy of Orthopaedic Surgeons (AAOS) laten zien dat dit 
aantal waarschijnlijk opnieuw zal zijn verdubbeld in 2026.
Er zijn een aantal issues rondom de revisie totale heupvervangingen, waaronder de hoge kosten 
van een revisieoperatie, de hogere kans op complicaties, de langere operatieduur, het grotere 
bloedverlies in vergelijking met primaire ingrepen en de vaak mindere klinische resultaten in 
vergelijking met de resultaten bij een primaire totale heupvervanging. De oorzaak van veel van 
deze problemen is het omvangrijke botverlies wat optreedt rondom falende prothesecompo-
nenten. Wanneer een implantaat faalt, treedt botverlies op door een combinatie van “stress 
shielding”, osteolyse, instabiliteit en/of infectie. Verschillende technieken zijn beschikbaar om 
met botverlies en botdefecten bij heup revisieoperaties om te gaan. Tijdens primaire totale heup-
vervangingen en eventueel latere revisieoperaties bij jongere patiënten heeft het herstellen van 
het botbed, eerder dan het vervangen van het botbed, de voorkeur. Van de vele beschikbare 
reconstructiemethoden hebben er slechts twee het doel het botbed te herstellen, namelijk de 
“bone impaction grafting” techniek en het gebruik van structurele allologe bottransplantaten. 
In dit proefschrift ligt de focus op de “bone impaction grafting” techniek. Het doel van de 
“bone impaction grafting” techniek is het bereiken van stabiliteit van de prothese met behulp 
van geïmpacteerde bottransplantaten en vervolgens het herstellen van het beschadigde botbed 
door middel van botingroei. Er is echter een delicate balans tussen de mechanische eisen van 
het bereiken van initiële stabiliteit en de biologische eisen voor incorporatie op de lange termijn. 
Tijdens het incorporatieproces veranderen de mechanische en biologische eigenschappen van de 
reconstructie, wat deze balans zou kunnen verstoren. Het is belangrijk dat de initiële stabiliteit 
die bereikt wordt door het impactieproces, niet gecompromitteerd wordt door een stimulus van 
vroege resorptie van het bottransplantaat.
Steeds vaker overschrijdt de vraag naar bottransplantaten de beperkte voorraad van deze trans-
plantaten. Bovendien is er een toenemende ongerustheid over de transmissie van pathogenen 
die kan optreden bij het gebruik van allologe bottransplantaten. De belangstelling voor synthe-
tische botvervangende materialen is hierdoor sterk toegenomen. Een eerste vereiste van deze 
botvervangende materialen is dat ze de krachten die tijdens de impactieprocedure uitgeoefend 
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worden, moeten kunnen weerstaan. Verder moeten de materialen een matrix leveren waarop 
bot en bloedvaten kunnen regenereren en herstellen. Deze synthetische materialen worden ge-
resorbeerd met verschillende snelheden, wat zorgt voor een verandering van de mechanische 
eigenschappen in de tijd. Hoewel de initiële mechanische stabiliteit verbeterd kan worden door 
het gebruik van deze materialen, zijn de biologische aspecten van de incorporatie van deze 
materialen nog niet volledig bestudeerd. Een meer compact synthetisch transplantaat als gevolg 
van het verpoederen van een synthetisch materiaal door impactie, reduceert cementpenetratie 
en kan leiden tot een gereduceerde ingroei en een hogere faalkans van de reconstructie op 
de lange termijn. Een belangrijk punt van zorg is de mogelijkheid van het optreden van zoge-
naamde “third body wear”, een proces waarbij synthetische partikels tussen de articulerende 
gewrichtsoppervlakken komen en daar slijtage veroorzaken.
Vanuit mechanisch oogpunt gezien is het impacteren van bot voordelig, maar voor de boting-
roei en remodellering is het juist nadelig. Dit heeft geleid tot een grote belangstelling voor 
transplantaatadditieven, met het gebruik van osteoinductieve groeifactoren, zoals BMPs, in het 
bijzonder. Incorporatie van allologe bottransplantaten met behulp van groeifactoren, zou de 
klinische resultaten na revisiechirurgie kunnen verbeteren door de botformatie te versnellen en 
daardoor de initiële stabiliteit van het implantaat te verbeteren. Echter, BMPs stimuleren niet 
alleen botformatie maar kunnen tegelijkertijd ook de activiteit van osteoclaststen stimuleren. 
BMPs zouden daarom bijzonder geschikt kunnen zijn voor gebruik in de heup revisiechirurgie om 
botformatie te versnellen, waarbij een langzaam resorberend synthetisch transplantatiemateriaal 
de initiële stabiliteit waarborgt. Behoud van groeifactoren op de plaats van implantatie en de 
afgifte van een optimale dosis door een geschikt dragermateriaal tijdens het incorporatieproces 
zijn essentieel voor het succesvol toepassen van groeifactoren.
Een veelbelovende manier om zowel de biologische als de mechanische aspecten van transplan-
taten in de “bone impaction grafting” techniek te verbeteren, zou kunnen voortkomen uit de 
zich sterk ontwikkelende discipline van de tissue engineering. Echter, voordat stamcellen een rol 
kunnen spelen in de “bone impaction grafting” techniek is het eerst noodzakelijk om vast te 
stellen of deze cellen, gecombineerd met bottransplantaten of synthetische botvervangers, het 
impactieproces kunnen overleven.
Bijzondere aandachtsgebieden voor de toekomst van de “bone impaction grafting” techniek zijn 
het gebruik van stamcellen en het gebruik van matrices die meerdere groeifactoren bevatten. 
Door middel van een langdurige en gecontroleerde afgifte van deze groeifactoren zou controle 
over de delicate balans tussen initiële stabiliteit en incorporatie op de lange termijn verkregen 
kunnen worden.
De huidige drive in tissue engineering en regeneratieve geneeskunde stimuleert de verdere ont-
wikkeling van de “bone impaction grafting” techniek. De ontwikkeling van synthetische materi-
alen met verbeterde biologische en mechanische eigenschappen staat bijzonder in de belangstel-
ling. Uiteindelijk moet dit in de toekomst leiden tot een beter klinisch resultaat voor patiënten 
die een revisie totale heupvervanging moeten ondergaan.
bone_impaction_grafting_02.indd   137 21.04.2008   13:04:42 Uhr
bone_impaction_grafting_02.indd   138 21.04.2008   13:04:42 Uhr
139
CHAPTER ELEVEN 
ACKNOWLEDGEMENTS 
“Goed, dit doen we dus voorlopig even niet meer.”
Onderzoek doen is leuk, een beetje data vinden, er wat mee spelen, wat verstandige dingen 
zeggen over de uitkomsten en daar dan eens lekker over discussiëren. Het gaat bijna allemaal 
vanzelf…
Pieter, onwijs bedankt voor alles! Je hebt me altijd vrijgelaten in m’n doen en laten en me veel 
vertrouwen gegeven. Te pas en te onpas kon ik bij je binnen komen vallen. Ik vind het prachtig 
dat je begin januari al kunt roepen: “‘t Kon wel eens de laatste mooie dag van het jaar zijn”, en 
er gewoon een middagje tussenuit piept. Je enthousiasme en energie werken erg aanstekelijk. 
Ik vind het fijn dat je m’n promotor bent en ik ben blij dat ik weer terug ben op het lab. Oh ja, 
bedankt voor het perfectioneren van m’n “trucje”.
Wim, ook jij hebt een belangrijk aandeel in het hele gebeuren. Bedankt voor je super relaxte ma-
nier van begeleiden. Regelmatig kwam je even binnenlopen om te vragen hoe het ervoor stond. 
Je belangstelling op zowel het persoonlijke als op het onderzoeksvlak heb ik altijd geweldig 
prettig gevonden. Ik heb vaak hard moeten lachen om je mooie verhalen en “slechte” grappen 
tijdens de operaties op het CDL. Ook bedankt dat je me duidelijk hebt gemaakt dat je het jezelf 
een stuk gemakkelijker kunt maken door je aan te passen aan bepaalde dingen, in plaats van je 
ertegen te blijven verzetten.
John Jansen, Rob Nelissen en Thijs Merkx, de professoren van de Manuscriptcommissie, bedankt 
voor het snelle beoordelen van mijn manuscript.
Per, thanks for your razor sharp comments and questions. I really enjoyed working with you!
Ester, bedankt dat je me kennis hebt laten maken met humane stamcellen. Vanaf nul (of mis-
schien wel van ver daaronder) heb je geprobeerd me in te wijden in de “geheimen” van de cel-
kweek. Ik vind het erg knap dat je altijd zo enthousiast kon blijven, ondanks dat daar vaak weinig 
reden toe was. Het gebeuren rondom het epjesmysterie zal ik niet snel vergeten.
bone_impaction_grafting_02.indd   139 21.04.2008   13:04:42 Uhr
140
Paul, wat mooi dat een idee, dat tijdens een avondje bowlen ontstaat, ‘t tot een hoofdstuk in dit 
boek heeft geschopt. Bedankt voor al het biochemische goochelwerk dat je hebt verricht. 
Joop, jij bent iemand met wie ik het geweldig mooi samenwerken vind. De dingen niet moeilijker 
maken dan ze zijn (ook niet makkelijker trouwens) en gewoon lekker zeggen waar ’t op staat. Je 
uitspraak: “Dat is fout, het geeft niet maar het is wel fout”, is ook gewoon nog eens helemaal 
waar. Bedankt!
Peter, José, Lobke, Willeke, Toin, bedankt voor de prettige samenwerking.
Leon, het vakmanschap en de snelheid waarmee jij fixeert, snijdt, zaagt, kleurt, fotografeert en 
archiveert zijn bijna niet te geloven. Super!
Willem, er zijn maar weinig mensen die kunnen wat jij kunt. Ongelofelijk wat jij de afgelopen 
jaren allemaal hebt gefabriceerd. Ook al stond het zweet je op het voorhoofd, een klein expe-
rimentje kon er altijd wel even tussendoor. Bedankt! Ik verdenk je ervan onmisbaar te zijn voor 
het lab.
René, als ik eens ergens niet zélf een programmaatje voor wist te vinden op internet, wist jij het 
wel in no-time te schrijven. Dank je voor je snelle programmeerwerk!
Alex, Connie, Conrad, Frans, Jeroen, Henny, Ton en Wilma, geweldig hoe jullie met dieren om-
gaan! Bedankt voor de goede zorgen voor de konijnen en de geiten. En euh, voor mij... Ik heb 
’t bij jullie altijd reuze goed naar m’n zin gehad.
Nico, ook al hebben we onderzoekstechnisch zo goed als niet samengewerkt, ik heb je belang-
stelling tijdens vergaderingen en de gesprekken tijdens congressen en autoritjes altijd erg prettig 
gevonden.
Ineke, bedankt voor alle kleine regeldingen.
Dennis, Esther, Luc en René, het was me een bijzonder genoegen de afgelopen jaren bij jullie op 
de kamer te hebben doorgebracht. Bedankt!
Alle (ex)collega’s en stagiaires op het ORL, Chantal, Chris, Daan, Erwin, Harry, Huub, Jan, Jantien, 
Jasper, Jorrit, Maarten, Marco, Maria, Marieke, Marieke, Marloes, Maud, Michele, Miranda, 
Natasja, Navin, Sanne, Stefan, Sylvain en Tony, bedankt!
Chris, Lars, Maarten, Robert en Walter, bedankt dat jullie m’n vrienden zijn!
bone_impaction_grafting_02.indd   140 21.04.2008   13:04:42 Uhr
141
Christian, je hebt intussen bijna net zoveel uren in dit boek zitten als ik. Het is echt super mooi 
geworden!
Harald en Huub, het voelt goed om jullie op zo’n dag naast me te hebben. Ik heb veel van jullie 
geleerd over hoe hard werken en maximaal genieten toch samen kunnen gaan (en soms ook 
iets minder…).
Harald, ik ben blij je als vriend te hebben! Bedankt dat je, die keren dat ik iets minder enthousiast 
ben, me toch iedere keer weer op sleeptouw neemt! “Wijntje dan maar…?”
Huub, je bent een wereldvent! Fijn dat ik bij je terecht kon, toen dat even nodig was… Ik ben blij 
dat je mijn paranimf wilt zijn. Oh ja, natuurlijk ook bedankt voor de avonturen op het CDL en de 
mooie tijden op congressen. Je eindeloze voorraad sterke verhalen is indrukwekkend.
Jorien en Thierry, bedankt voor jullie belangstelling en gezelligheid!
Pa en ma, fijn dat jullie me altijd m’n ding hebben laten doen en me daar ook nog eens in steun-
den. Onwijs bedankt voor alles!
Karen, bedankt dat je er voor me bent!
bone_impaction_grafting_02.indd   141 21.04.2008   13:04:42 Uhr
142
bone_impaction_grafting_02.indd   142 21.04.2008   13:04:42 Uhr
143
CHAPTER TWELVE 
ABOUT THE AUTHOR 
Gerjon Hannink was born in Zwolle, the Netherlands, on the 25th of April 1977. He studied Physi-
cal Therapy at the Hogeschool Enschede, the Netherlands, between 1995 and 1999. In 2002, 
he graduated cum laude from the Catholic University Nijmegen, the Netherlands with a master’s 
degree in Biomedical Health Sciences (major in Human Movement Sciences). His subsequent PhD 
appointment at the Orthopaedic Research Lab, Department of Orthopaedics, Radboud Univer-
sity Nijmegen Medical Centre, the Netherlands, has resulted in several publications, a number 
of presentations at national and international conferences, and ultimately this thesis. In 2007, 
he won the Mario Boni Award in recognition of the best scientific paper presented at the EORS 
2006 in Bologna, Italy. Gerjon is currently working as a post doctoral research fellow at the 
Orthopaedic Research Lab, Department of Orthopaedics, Radboud University Nijmegen Medical 
Centre, the Netherlands.
bone_impaction_grafting_02.indd   143 21.04.2008   13:04:42 Uhr
bone_impaction_grafting_02.indd   144 21.04.2008   13:04:42 Uhr
